

Long-term effects of continuing adjuvant tamoxifen to  
after diagnosis of oestrogen receptor-positive breast ca

Lancet, The

381, 805-816

DOI: [10.1016/s0140-6736\(12\)61963-1](https://doi.org/10.1016/s0140-6736(12)61963-1)

Citation Report

#	ARTICLE	IF	CITATIONS
1	The Adolescent and Young Adult With Cancer: State of the Artâ€”Epithelial Cancer. <i>Current Oncology Reports</i> , 2013, 15, 287-295.	1.8	14
2	Luminal breast cancer: from biology to treatment. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 494-506.	12.5	183
4	Tamoxifen therapy for patients with breast cancer â€” Authors' reply. <i>Lancet, The</i> , 2013, 381, 2078-2079.	6.3	3
5	Decade of â€”Normalâ€” Mammography Reportsâ€”The Happygram. <i>Journal of the American College of Radiology</i> , 2013, 10, 903-908.	0.9	40
6	Cognitive Effects of Cancer and Its Treatments at the Intersection of Aging: What Do We Know; What Do We Need to Know?. <i>Seminars in Oncology</i> , 2013, 40, 709-725.	0.8	119
7	Management of breast cancer in very young women. <i>Breast</i> , 2013, 22, S176-S179.	0.9	56
8	Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. <i>Annals of Oncology</i> , 2013, 24, 2206-2223.	0.6	2,805
9	SEOM Clinical Guidelines for the systemic treatment of early breast cancer 2013. <i>Clinical and Translational Oncology</i> , 2013, 15, 1011-1017.	1.2	8
10	Prostate Cancer Screening: Biases and the Need for Consensus. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1522-1524.	3.0	11
11	Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer. <i>Breast</i> , 2013, 22, S165-S170.	0.9	23
12	Tamoxifen selects for breast cancer cells with mammosphere forming capacity and increased growth rate. <i>Breast Cancer Research and Treatment</i> , 2013, 142, 537-548.	1.1	32
13	Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. <i>Breast Cancer Research</i> , 2013, 15, R92.	2.2	320
14	Serum concentrations of tamoxifen and its metabolites increase with age during steady-state treatment. <i>Breast Cancer Research and Treatment</i> , 2013, 141, 243-248.	1.1	42
16	Factors associated with compliance to adjuvant hormone therapy in Black and White women with breast cancer. <i>SpringerPlus</i> , 2013, 2, 356.	1.2	19
17	Five or more years of adjuvant endocrine therapy in breast cancer: a meta-analysis of published randomised trials. <i>Breast Cancer Research and Treatment</i> , 2013, 140, 233-240.	1.1	44
19	A relative ordering-based predictor for tamoxifen-treated estrogen receptor-positive breast cancer patients: multi-laboratory cohort validation. <i>Breast Cancer Research and Treatment</i> , 2013, 142, 505-514.	1.1	17
20	Utility of GnRH-Agonists for Fertility Preservation in Women with Operable Breast Cancer: Is It Protective?. <i>Current Breast Cancer Reports</i> , 2013, 5, 302-308.	0.5	24
21	Impact of SERM adherence on treatment effect: International Breast Cancer Study Group Trials 13-93 and 14-93. <i>Breast Cancer Research and Treatment</i> , 2013, 142, 455-459.	1.1	19

#	ARTICLE	IF	CITATIONS
22	Tamoxifen therapy for patients with breast cancer. <i>Lancet, The</i> , 2013, 381, 2077-2078.	6.3	2
24	Increased expression of miR-126 and miR-10a predict prolonged relapse-free time of primary oestrogen receptor-positive breast cancer following tamoxifen treatment. <i>European Journal of Cancer</i> , 2013, 49, 3598-3608.	1.3	72
25	Special Considerations in Early-stage Breast Cancer Patients and Survivors. <i>Obstetrics and Gynecology Clinics of North America</i> , 2013, 40, 573-582.	0.7	2
26	Duration of adjuvant trastuzumab: shorter beats longer. <i>Lancet, The</i> , 2013, 382, 1010-1011.	6.3	5
27	Extended adjuvant endocrine therapy in hormone-receptor positive breast cancer. <i>Breast</i> , 2013, 22, S171-S175.	0.9	24
28	Role of Ki67 in predicting resistance to adjuvant tamoxifen in postmenopausal breast cancer patients. <i>Journal of the Egyptian National Cancer Institute</i> , 2013, 25, 181-191.	0.6	12
29	Tamoxifen therapy for patients with breast cancer. <i>Lancet, The</i> , 2013, 381, 2077.	6.3	4
30	Tamoxifen therapy for patients with breast cancer. <i>Lancet, The</i> , 2013, 381, 2078.	6.3	2
32	Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment. <i>European Journal of Cancer, Supplement</i> , 2013, 11, 3-22.	2.2	6
33	Is It Me Or Is It Hot In Here? A Plea For More Research Into Hot Flashes. <i>Clinical Oncology</i> , 2013, 25, 681-683.	0.6	7
34	Postmenopausal women with hormone receptor-positive breast cancer: Balancing benefit and toxicity from aromatase inhibitors. <i>Breast</i> , 2013, 22, S180-S183.	0.9	19
35	Tamoxifen“when more might be better. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 125-126.	12.5	3
36	Impact of metabolizing enzymes on drug response of endocrine therapy in breast cancer. <i>Expert Review of Molecular Diagnostics</i> , 2013, 13, 349-365.	1.5	22
37	Pharmacogenomics of breast cancer therapy: An update. , 2013, 139, 1-11.		36
38	Synthesis of Mixed (<i>E</i>,<i>Z</i>)-, (<i>E</i>)-, and (<i>Z</i>)-Norendoxifen with Dual Aromatase Inhibitory and Estrogen Receptor Modulatory Activities. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 4611-4618.	2.9	44
39	Sex Hormone Receptors in Breast Cancer. <i>Vitamins and Hormones</i> , 2013, 93, 99-133.	0.7	10
40	Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2013, 24, vi7-vi23.	0.6	400
41	Adjuvant Endocrine Therapy for the Surgeon: Options, Side Effects, and their Management. <i>Annals of Surgical Oncology</i> , 2013, 20, 3188-3193.	0.7	8

#	ARTICLE	IF	CITATIONS
43	AACR Cancer Progress Report 2013. <i>Clinical Cancer Research</i> , 2013, 19, S1-S98.	3.2	55
44	Metastasis Dormancy in Estrogen Receptor-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 6389-6397.	3.2	199
45	Ductal Carcinoma In Situ: A Rose by Any Other Name. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1521-1522.	3.0	13
46	Overview of diagnostic/targeted treatment combinations in personalized medicine for breast cancer patients. <i>Pharmacogenomics and Personalized Medicine</i> , 2013, 7, 1.	0.4	10
47	Do We Need Another Selective Estrogen Receptor Modulator for the Adjuvant Treatment of Breast Cancer?. <i>Current Oncology</i> , 2013, 20, 191-192.	0.9	0
48	Breast Cancer Index Identifies Early-Stage Estrogen Receptor-Positive Breast Cancer Patients at Risk for Early- and Late-Distant Recurrence. <i>Clinical Cancer Research</i> , 2013, 19, 4196-4205.	3.2	184
49	Breast Cancer. <i>JAMA Surgery</i> , 2013, 148, 971.	2.2	138
50	Prospective Observational Study of Breast Cancer Treatment Outcomes for UK Women Aged 18-40 Years at Diagnosis: The POSH Study. <i>Journal of the National Cancer Institute</i> , 2013, 105, 978-988.	3.0	156
51	From High-Throughput Microarray-Based Screening to Clinical Application: The Development of a Second Generation Multigene Test for Breast Cancer Prognosis. <i>Microarrays (Basel, Switzerland)</i> , 2013, 2, 243-264.	1.4	5
52	Fracture Risk in Older, Long-Term Survivors of Early-Stage Breast Cancer. <i>Journal of the American Geriatrics Society</i> , 2013, 61, 888-895.	1.3	14
53	Factors Predicting Late Recurrence for Estrogen Receptor-Positive Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1504-1511.	3.0	200
54	Genomic Profiling in Luminal Breast Cancer. <i>Breast Care</i> , 2013, 8, 414-422.	0.8	11
56	An unmet need: tailoring extended adjuvant endocrine therapy. <i>British Journal of Cancer</i> , 2013, 109, 2951-2953.	2.9	3
57	Suitable trial designs and cohorts for preventive breast cancer agents. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 677-687.	12.5	5
58	A nested case-control study of adjuvant hormonal therapy persistence and compliance, and early breast cancer recurrence in women with stage III breast cancer. <i>British Journal of Cancer</i> , 2013, 109, 1513-1521.	2.9	56
59	The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients. <i>British Journal of Cancer</i> , 2013, 109, 2959-2964.	2.9	288
60	Tamoxifen Benefits and CYP2D6 Testing in Women With Hormone Receptor-Positive Breast Cancer. <i>Clinical Journal of Oncology Nursing</i> , 2013, 17, 174-179.	0.3	8
61	Use of Medications to Reduce Risk for Primary Breast Cancer: A Systematic Review for the U.S. Preventive Services Task Force. <i>Annals of Internal Medicine</i> , 2013, 158, 604.	2.0	150

#	ARTICLE	IF	CITATIONS
62	Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer. <i>Oncology</i> , 2013, 85, 100-110.	0.9	8,974
65	New oral anticoagulant drugs: real-world data. <i>Personalized Medicine</i> , 2013, 10, 419-422.	0.8	3
66	Long-term efficacy and safety of exemestane in the treatment of breast cancer. <i>Patient Preference and Adherence</i> , 2013, 7, 245.	0.8	14
67	Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers. <i>Breast Cancer Research</i> , 2013, 15, R86.	2.2	44
68	Scientific rationale for postmenopause delay in the use of conjugated equine estrogens among postmenopausal women that causes reduction in breast cancer incidence and mortality. <i>Menopause</i> , 2013, 20, 372-382.	0.8	34
69	AGO Recommendations for Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2013. <i>Breast Care</i> , 2013, 8, 174-180.	0.8	7
70	CYP2D6 Genotype and Tamoxifen Response for Breast Cancer: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2013, 8, e76648.	1.1	43
71	Unique Features of Young Age Breast Cancer and Its Management. <i>Journal of Breast Cancer</i> , 2014, 17, 301.	0.8	92
72	Current Approaches and Challenges in Monitoring Treatment Responses in Breast Cancer. <i>Journal of Cancer</i> , 2014, 5, 58-68.	1.2	89
73	Major clinical research advances in gynecologic cancer in 2013. <i>Journal of Gynecologic Oncology</i> , 2014, 25, 236.	1.0	30
74	Novel drugs that target the estrogen-related receptor alpha: their therapeutic potential in breast cancer. <i>Cancer Management and Research</i> , 2014, 6, 225.	0.9	60
75	Use of hormonal therapy in senior breast cancer patients treated with or without radiotherapy. <i>Current Oncology</i> , 2014, 21, 105.	0.9	6
76	Considerations for payers in managing hormone receptor-positive advanced breast cancer. <i>ClinicoEconomics and Outcomes Research</i> , 2014, 6, 331.	0.7	2
77	Endocrine Therapy for Breast Cancer. <i>The Ewha Medical Journal</i> , 2014, 37, 83.	0.1	2
78	The Optimal Duration and Selection of Adjuvant Endocrine Therapy for Breast Cancer: How Long Is Enough?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , e16-e24.	1.8	9
79	Contralateral Breast Cancer Adjacent to a Fibroadenoma: Report of a Case. <i>Journal of Nippon Medical School</i> , 2014, 81, 168-172.	0.3	4
80	Endocrine Therapy Toxicity: Management Options. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , e25-e30.	1.8	26
81	Role of Hormones in Cancer Prevention. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , 34-40.	1.8	17

#	ARTICLE	IF	CITATIONS
82	Personalized Cancer Therapy. , 2014, , 671-824.		1
83	Sex Hormones and Related Compounds, Including Hormonal Contraceptives. Side Effects of Drugs Annual, 2014, 36, 615-634.	0.6	1
85	Intraoperative Radiation Therapy: A Critical Analysis of the ELIOT and TARGIT Trials. Part 1â€”ELIOT. Annals of Surgical Oncology, 2014, 21, 3787-3792.	0.7	43
86	Tamoxifen-DNA adduct formation in monkey and human reproductive organs. Carcinogenesis, 2014, 35, 1172-1176.	1.3	9
87	Breast cancer in young women: its biological and clinical uniqueness and needs of comprehensive care. Breast Cancer, 2014, 21, 641-642.	1.3	2
89	The Effect of Tamoxifen on Expression of ER, PR, Cerb-B2, and ki-67 in C3H Mice Spontaneous Breast Cancer Model and The Relation with Chemotherapeutic Effect. Cell Biochemistry and Biophysics, 2014, 70, 1875-1879.	0.9	2
90	The role of maintenance strategies in breast cancer. Memo - Magazine of European Medical Oncology, 2014, 7, 152-156.	0.3	1
91	IL-6 secreted by cancer-associated fibroblasts induces tamoxifen resistance in luminal breast cancer. Oncogene, 2014, , .	2.6	49
92	Pharmacological Relevance of Endoxifen in a Laboratory Simulation of Breast Cancer in Postmenopausal Patients. Journal of the National Cancer Institute, 2014, 106, .	3.0	17
93	Should We Embrace or Ablate Our Urge to (Ovarian) Suppress?. Journal of Clinical Oncology, 2014, 32, 3920-3922.	0.8	5
94	A hard pill to swallow: a qualitative study of women's experiences of adjuvant endocrine therapy for breast cancer. BMJ Open, 2014, 4, e005285-e005285.	0.8	59
95	Committee Opinion No. 601. Obstetrics and Gynecology, 2014, 123, 1394-1397.	1.2	105
99	Estimates of Young Breast Cancer Survivors at Risk for Infertility in the U.S.. Oncologist, 2014, 19, 814-822.	1.9	46
100	Strategies to overcome endocrine therapy resistance in hormone receptor-positive advanced breast cancer. Clinical Investigation, 2014, 4, 19-33.	0.0	9
101	More treatment options for women with hormone receptorâ€”positive breast cancer: Guideline update, studies lead to advances in care. Cancer, 2014, 120, 2939-2940.	2.0	1
102	Measuring persistence to hormonal therapy in patients with breast cancer: accounting for temporary treatment discontinuation. Pharmacoepidemiology and Drug Safety, 2014, 23, 882-889.	0.9	8
103	Improving Adherence to Oral Cancer Therapy in Clinical Practice. Pharmacotherapy, 2014, 34, 481-494.	1.2	67
104	Breast conserving therapy for DCISâ€”Does size matter?. Journal of Surgical Oncology, 2014, 110, 75-81.	0.8	12

#	ARTICLE	IF	CITATIONS
105	Managing Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer Who Progress on Endocrine Therapies with Inhibitors of the PI3K Pathway. <i>Breast Journal</i> , 2014, 20, 347-357.	0.4	3
106	Fertility issues in cancer survivorship. <i>Ca-A Cancer Journal for Clinicians</i> , 2014, 64, 118-134.	157.7	71
107	Researchers study implications of lung cancer screening. <i>Cancer</i> , 2014, 120, 2940-2941.	2.0	0
108	Linking Estrogen-Induced Apoptosis With Decreases in Mortality Following Long-term Adjuvant Tamoxifen Therapy. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju296-dju296.	3.0	34
109	Standard of Care and Controversies in the Adjuvant Endocrine Treatment of Hormone-Responsive Early Breast Cancer. <i>Breast Care</i> , 2014, 9, 283-286.	0.8	7
110	Developing a new generation of breast cancer clinical gene expression tests. <i>Breast Cancer Research</i> , 2014, 16, 103.	2.2	4
111	TheHOXB13:IL17BRbiomarker: prognostic for late recurrence and predictive for benefit from endocrine therapy. <i>Breast Cancer Management</i> , 2014, 3, 155-163.	0.2	0
114	Tamoxifen Toxicity in Cultured Retinal Pigment Epithelial Cells Is Mediated by Concurrent Regulated Cell Death Mechanisms. , 2014, 55, 4747.		39
115	Anastrozole versus tamoxifen as adjuvant therapy for Japanese postmenopausal patients with hormone-responsive breast cancer: efficacy results of long-term follow-up data from the N-SAS BC 03 trial. <i>Breast Cancer Research and Treatment</i> , 2014, 148, 337-343.	1.1	9
116	Estrogen independent gene expression defines clinically relevant subgroups of estrogen receptor positive breast cancer. <i>BMC Cancer</i> , 2014, 14, 871.	1.1	4
117	The renaissance of endocrine therapy in breast cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , 2014, 26, 41-47.	0.9	22
118	Tamoxifen as the first targeted long-term adjuvant therapy for breast cancer. <i>Endocrine-Related Cancer</i> , 2014, 21, R235-R246.	1.6	128
119	Adjuvant Therapy for Renal Cell Carcinoma: Past, Present, and Future. <i>Oncologist</i> , 2014, 19, 851-859.	1.9	57
120	The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 1298-1305.	3.2	182
121	No increased venous thromboembolism risk in Asian breast cancer patients receiving adjuvant tamoxifen. <i>Breast Cancer Research and Treatment</i> , 2014, 148, 135-142.	1.1	11
123	Hormone Responsive Cancers. , 2014, , 651-698.e14.		0
124	Evaluation of CYP2D6 Polymorphic Types and Their Effect on Tamoxifen Efficacy Among Turkish Tamoxifen Users with Breast Cancer. <i>UHOD - Uluslararası Hematoloji-Onkoloji Dergisi</i> , 2014, 24, 157-162.	0.1	1
125	Effects of switching from anastrozole to letrozole, due to reimbursement policy, on the outcome of breast cancer therapy. <i>Breast Cancer: Targets and Therapy</i> , 2014, 6, 145.	1.0	4

#	ARTICLE	IF	CITATIONS
126	Status of adjuvant endocrine therapy for breast cancer. <i>Breast Cancer Research</i> , 2014, 16, 206.	2.2	61
127	Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2 <sup>+</sup> breast cancer patients: results from the GEICAM 9906 trial. <i>Breast Cancer Research</i> , 2014, 16, R38.	2.2	133
128	Perspectives of Postmenopausal Breast Cancer Survivors on Adjuvant Endocrine Therapy-Related Symptoms. <i>Oncology Nursing Forum</i> , 2014, 41, 660-668.	0.5	27
129	Pathological Features and Prognosis of Lobular Carcinoma in Egyptian Breast Cancer Patients. <i>Women's Health</i> , 2014, 10, 511-518.	0.7	12
130	Fertility preservation and reproductive health in the pediatric, adolescent, and young adult female cancer patient. <i>Current Opinion in Obstetrics and Gynecology</i> , 2014, 26, 372-380.	0.9	23
131	Prediction of tamoxifen outcome by genetic variation of <i>CYP2D6</i> in postmenopausal women with early breast cancer. <i>British Journal of Clinical Pharmacology</i> , 2014, 77, 695-703.	1.1	42
132	Adjuvant Endocrine Therapy of Perimenopausal and Recently Postmenopausal Women With Hormone Receptor-Positive Breast Cancer. <i>Clinical Breast Cancer</i> , 2014, 14, 147-153.	1.1	17
133	Breast cancer. <i>Gynecologic Oncology</i> , 2014, 132, 264-267.	0.6	4
134	Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences. <i>Breast Cancer Research and Treatment</i> , 2014, 144, 321-329.	1.1	7
135	How Do I Follow Patients With Early Breast Cancer After Completing Adjuvant Therapy. <i>Current Treatment Options in Oncology</i> , 2014, 15, 63-78.	1.3	5
136	Invasive lobular carcinoma of the breast: long-term prognostic value of Ki67 and histological grade, alone and in combination with estrogen receptor. <i>SpringerPlus</i> , 2014, 3, 70.	1.2	14
137	Providers of follow-up care in a population-based sample of breast cancer survivors. <i>Breast Cancer Research and Treatment</i> , 2014, 144, 179-184.	1.1	13
138	The early discontinuation of adjuvant hormone therapy is associated with a poor prognosis in Japanese breast cancer patients. <i>Surgery Today</i> , 2014, 44, 1841-1846.	0.7	9
139	Precision treatment for cancer: Role of prognostic and predictive markers. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2014, 51, 30-45.	2.7	25
140	Mechanisms of tumor escape from immune system: Role of mesenchymal stromal cells. <i>Immunology Letters</i> , 2014, 159, 55-72.	1.1	120
141	First international consensus guidelines for breast cancer in young women (BCY1). <i>Breast</i> , 2014, 23, 209-220.	0.9	135
142	Current and Evolving Approaches to Individualizing Estrogen Receptor-Based Therapy for Menopausal Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 733-747.	1.8	22
143	Detection of Cancer DNA in Plasma of Patients with Early-Stage Breast Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 2643-2650.	3.2	341



#	ARTICLE	IF	CITATIONS
144	The failure of cancer chemoprevention. <i>Carcinogenesis</i> , 2014, 35, 974-982.	1.3	64
145	Cardiotoxicity of systemic agents used in breast cancer. <i>Breast</i> , 2014, 23, 317-328.	0.9	49
147	Inhibition of c-Src blocks oestrogen-induced apoptosis and restores oestrogen-stimulated growth in long-term oestrogen-deprived breast cancer cells. <i>European Journal of Cancer</i> , 2014, 50, 457-468.	1.3	45
148	Genomics, drug approval, and optimal treatment duration. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 71-72.	12.5	5
150	A review on the role of l-carnitine in the management of tamoxifen side effects in treated women with breast cancer. <i>Tumor Biology</i> , 2014, 35, 2845-2855.	0.8	10
151	The Optimal Duration of Adjuvant Endocrine Therapy for Early Stage Breast Cancer—With What Drugs and for How Long?. <i>Current Oncology Reports</i> , 2014, 16, 358.	1.8	9
152	Evaluation of Endometrial Thickness and Bone Mineral Density Based on CYP2D6 Polymorphisms in Turkish Breast Cancer Patients Receiving Tamoxifen Treatment. <i>Pharmacology</i> , 2014, 94, 183-189.	0.9	10
153	Tamoxifen-associated skin reactions in breast cancer patients: from case report to literature review. <i>Breast Cancer Research and Treatment</i> , 2014, 148, 1-5.	1.1	13
154	Biology of breast cancer in young women. <i>Breast Cancer Research</i> , 2014, 16, 427.	2.2	296
155	Time dependence of biomarkers: non-proportional effects of immunohistochemical panels predicting relapse risk in early breast cancer. <i>British Journal of Cancer</i> , 2014, 111, 2242-2247.	2.9	14
156	Adjuvant Endocrine Therapy for Women With Hormone Receptor—Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. <i>Journal of Clinical Oncology</i> , 2014, 32, 2255-2269.	0.8	661
157	Simulation with cells <i>in vitro</i> of tamoxifen treatment in premenopausal breast cancer patients with different CYP2D6 genotypes. <i>British Journal of Pharmacology</i> , 2014, 171, 5624-5635.	2.7	29
158	Prospective Study of Fertility Concerns and Preservation Strategies in Young Women With Breast Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 1151-1156.	0.8	313
159	Phase I clinical trial of nintedanib plus paclitaxel in early HER-2-negative breast cancer (CNIO-BR-01-2010/GEICAM-2010-10 study). <i>British Journal of Cancer</i> , 2014, 111, 1060-1064.	2.9	26
160	Aromatase inhibitors in the breast cancer clinic: focus on exemestane. <i>Endocrine-Related Cancer</i> , 2014, 21, R31-R49.	1.6	59
161	Intraoperative Radiation Therapy: A Critical Analysis of the ELIOT and TARGIT Trials. Part 2—TARGIT. <i>Annals of Surgical Oncology</i> , 2014, 21, 3793-3799.	0.7	53
162	The evolution of nonsteroidal antiestrogens to become selective estrogen receptor modulators. <i>Steroids</i> , 2014, 90, 3-12.	0.8	22
163	An update on the medical management of breast cancer. <i>BMJ</i> , 2014, 348, g3608-g3608.	3.0	54

#	ARTICLE	IF	CITATIONS
164	Adherence to Endocrine Therapy in Breast Cancer Adjuvant and Prevention Settings. <i>Cancer Prevention Research</i> , 2014, 7, 378-387.	0.7	147
165	Prise en charge du cancer du sein, avancées et perspectives. <i>Medecine Nucleaire</i> , 2014, 38, 299-302.	0.2	0
166	Fertility preservation in breast cancer patients. <i>Future Oncology</i> , 2014, 10, 1767-1777.	1.1	4
167	Psychosocial factors in adjuvant hormone therapy for breast cancer: an emerging context for adherence research. <i>Journal of Cancer Survivorship</i> , 2014, 8, 521-531.	1.5	45
168	Triple negative breast cancer in a poor resource setting in North-Western Tanzania: a preliminary study of 52 patients. <i>BMC Research Notes</i> , 2014, 7, 399.	0.6	14
169	Uridine prevents tamoxifen-induced liver lipid droplet accumulation. <i>BMC Pharmacology &amp; Toxicology</i> , 2014, 15, 27.	1.0	30
171	Haste makes waste: Are the data regarding TARGIT-A IORT ready for prime time?. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 221-222.	1.1	2
172	Differences in metastatic patterns in relation to time between primary surgery and first relapse from breast cancer suggest synchronized growth of dormant micrometastases. <i>Breast Cancer Research and Treatment</i> , 2014, 146, 627-636.	1.1	20
173	Selective estrogen-induced apoptosis in breast cancer. <i>Steroids</i> , 2014, 90, 60-70.	0.8	11
174	A molecular model for the mechanism of acquired tamoxifen resistance in breast cancer. <i>European Journal of Cancer</i> , 2014, 50, 2866-2876.	1.3	46
176	Cost-effectiveness analysis of extended adjuvant endocrine therapy in the treatment of post-menopausal women with hormone receptor positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014, 145, 267-279.	1.1	10
177	Late Recurrences in Early Breast Cancer: For Whom and How Long Is Endocrine Therapy Beneficial?. <i>Breast Care</i> , 2014, 9, 97-97.	0.8	12
178	Early discontinuation of endocrine therapy for breast cancer: who is at risk in clinical practice?. <i>SpringerPlus</i> , 2014, 3, 282.	1.2	36
179	Influence of the Length and Positioning of the Antiestrogenic Side Chain of Endoxifen and 4-Hydroxytamoxifen on Gene Activation and Growth of Estrogen Receptor Positive Cancer Cells. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 4569-4583.	2.9	18
180	Metformin enhances tamoxifen-mediated tumor growth inhibition in ER-positive breast carcinoma. <i>BMC Cancer</i> , 2014, 14, 172.	1.1	53
181	A case of invasive micropapillary carcinoma of the breast involving extensive lymph node metastasis. <i>World Journal of Surgical Oncology</i> , 2014, 12, 84.	0.8	7
182	Past, Present, and Future Challenges in Breast Cancer Treatment. <i>Journal of Clinical Oncology</i> , 2014, 32, 1979-1986.	0.8	180
183	Acquired resistance to selective estrogen receptor modulators (SERMs) in clinical practice (tamoxifen & raloxifene) by selection pressure in breast cancer cell populations. <i>Steroids</i> , 2014, 90, 44-52.	0.8	30

#	ARTICLE	IF	CITATIONS
184	Identification of gene regulation patterns underlying both oestrogen- and tamoxifen-stimulated cell growth through global gene expression profiling in breast cancer cells. <i>European Journal of Cancer</i> , 2014, 50, 2877-2886.	1.3	15
185	One year of adjuvant tamoxifen compared with chemotherapy and tamoxifen in postmenopausal patients with stage II breast cancer. <i>Breast Diseases</i> , 2014, 25, 176-178.	0.0	0
186	Use of SERMs for treatment in postmenopausal women. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2014, 142, 142-154.	1.2	119
187	Breast Cancer Cell Apoptosis with Phytoestrogens Is Dependent on an Estrogen-Deprived State. <i>Cancer Prevention Research</i> , 2014, 7, 939-949.	0.7	48
188	Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2014, 32, 129-160.	0.8	74
189	Clinico-pathology and prognosis of endometrial cancer in patients previously treated for breast cancer, with or without tamoxifen: A comparative study in 363 patients. <i>European Journal of Surgical Oncology</i> , 2014, 40, 1237-1244.	0.5	16
190	Extended Therapy With Letrozole and Ovarian Suppression in Premenopausal Patients With Breast Cancer After Tamoxifen. <i>Clinical Breast Cancer</i> , 2014, 14, 413-416.	1.1	16
192	Current treatment of early breast cancer: adjuvant and neoadjuvant therapy. <i>F1000Research</i> , 2014, 3, 198.	0.8	40
193	Main controversies in breast cancer. <i>World Journal of Clinical Oncology</i> , 2014, 5, 359.	0.9	27
194	Breast Cancer Version 3.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 542-590.	2.3	159
195	Survivorship: Tools for Transitioning Patients With Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1681-1687.	2.3	9
196	Association of Tamoxifen Use and Reduced Cardiovascular Events Among Asian Females With Breast Cancer. <i>Circulation Journal</i> , 2014, 78, 135-140.	0.7	19
197	AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2014. <i>Breast Care</i> , 2014, 9, 189-200.	0.8	9
198	Modern Therapeutic Concepts of Early Breast Cancer. <i>Breast Care</i> , 2014, 9, 85-85.	0.8	1
199	Outcomes of Adjuvant Endocrine Therapy and Hormone Receptor Status Change following Neoadjuvant Chemotherapy in Breast Cancer Patients. <i>International Journal of Biological Markers</i> , 2014, 29, 380-386.	0.7	1
200	Adjuvant hormonal therapy in young breast cancer patients. <i>Breast Cancer Management</i> , 2014, 3, 1-4.	0.2	2
202	The Impact of Access to Cancer Care on Adjuvant Endocrine Therapy Use Among Breast Cancer Survivors in Appalachia. <i>Value in Health</i> , 2015, 18, A215.	0.1	0
203	Big data: Are large prospective randomized trials obsolete in the future?. <i>Breast</i> , 2015, 24, S15-S18.	0.9	12

#	ARTICLE	IF	CITATIONS
204	Targeting glycolysis by 3-bromopyruvate improves tamoxifen cytotoxicity of breast cancer cell lines. <i>BMC Cancer</i> , 2015, 15, 838.	1.1	30
205	Application status of tamoxifen in endocrine therapy for early breast cancer. <i>Experimental and Therapeutic Medicine</i> , 2015, 9, 2207-2212.	0.8	5
206	The Modern Landscape of Endocrine Therapy for Premenopausal Women with Breast Cancer. <i>Breast Care</i> , 2015, 10, 312-315.	0.8	10
207	Breast Cancer Risk Reduction, Version 2.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 880-915.	2.3	52
208	Targeting Breast Cancer Metastasis. <i>Breast Cancer: Basic and Clinical Research</i> , 2015, 9s1, BCBCR.S25460.	0.6	145
209	Breast Cancer: Conventional Diagnosis and Treatment Modalities and Recent Patents and Technologies. <i>Breast Cancer: Basic and Clinical Research</i> , 2015, 9s2, BCBCR.S29420.	0.6	172
210	SEOM clinical guidelines in early-stage breast cancer 2015. <i>Clinical and Translational Oncology</i> , 2015, 17, 939-945.	1.2	18
211	Tamoxifen retinopathy: a case report. <i>SpringerPlus</i> , 2015, 4, 501.	1.2	14
212	Boronic prodrug of 4-hydroxytamoxifen is more efficacious than tamoxifen with enhanced bioavailability independent of CYP2D6 status. <i>BMC Cancer</i> , 2015, 15, 625.	1.1	32
213	Racial/Ethnic and Socioeconomic Disparities in Endocrine Therapy Adherence in Breast Cancer: A Systematic Review. <i>American Journal of Public Health</i> , 2015, 105, e4-e15.	1.5	102
214	Exemestane for breast cancer risk reduction. <i>Breast Cancer Management</i> , 2015, 4, 159-164.	0.2	0
215	Managing premature menopause and sexual dysfunction. <i>Current Opinion in Supportive and Palliative Care</i> , 2015, 9, 294-300.	0.5	22
216	Risk of Gastric and Colorectal Cancer After Tamoxifen Use for Breast Cancer. <i>Journal of Clinical Gastroenterology</i> , 2015, 49, 666-674.	1.1	11
217	<i>CCR</i> 20th Anniversary Commentary: Gene-Expression Signature in Breast Cancer—Where Did It Start and Where Are We Now?. <i>Clinical Cancer Research</i> , 2015, 21, 4743-4746.	3.2	23
218	Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. <i>The Cochrane Library</i> , 2015, , CD007245.	1.5	39
219	Better contralateral breast cancer risk estimation and alternative options to contralateral prophylactic mastectomy. <i>International Journal of Women's Health</i> , 2015, 7, 181.	1.1	18
220	Clinical utility of exemestane in the treatment of&nbsp;breast cancer&nbsp;. <i>International Journal of Women's Health</i> , 2015, 7, 551.	1.1	13
221	Mechanistic Progress of Estrogen-induced Apoptosis in Estrogen-deprived Breast Cancer Cells. <i>Journal of Cell Science &amp; Therapy</i> , 2015, 06, .	0.3	0

#	ARTICLE	IF	CITATIONS
222	Bone Health in Adults Treated with Endocrine Therapy for Early Breast or Prostate Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e567-e574.	1.8	13
223	The Role of MicroRNAs as Predictors of Response to Tamoxifen Treatment in Breast Cancer Patients. International Journal of Molecular Sciences, 2015, 16, 24243-24275.	1.8	51
224	Management of cancer of the breast. , 0, , 262-292.		1
225	Adjuvant Aromatase Inhibitor Therapy in Early Breast Cancer: What Factors Lead Patients to Discontinue Treatment?. Tumori, 2015, 101, 469-473.	0.6	36
226	Breast cancer: news in diagnosis and treatment. Revista Da Associação Médica Brasileira, 2015, 61, 543-552.	0.3	7
227	Tamoxifen with ovarian function suppression versus tamoxifen alone as an adjuvant treatment for premenopausal breast cancer: a meta-analysis of&nbsp;published randomized controlled trials. OncoTargets and Therapy, 2015, 8, 1433.	1.0	19
228	Onco&frac14;Contraception for Women Diagnosed with Breast Cancer. Oncology Issues, 2015, 30, 36-42.	0.0	0
229	Selective estrogen receptor modulators used for postmenopausal women. , 0, , 142-148.		0
230	High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer. Oncotarget, 2015, 6, 33972-33981.	0.8	159
231	Managing breast cancer in younger women: challenges and solutions. Breast Cancer: Targets and Therapy, 2016, 8, 1.	1.0	20
232	Current medical treatment of estrogen receptor-positive breast cancer. World Journal of Biological Chemistry, 2015, 6, 231.	1.7	144
233	Endocrine Therapy in Breast Cancer: The Neoadjuvant, Adjuvant, and Metastatic Approach. Seminars in Oncology Nursing, 2015, 31, 146-155.	0.7	41
234	Management of urogenital atrophy in breast cancer patients: a systematic review of available evidence from randomized trials. Breast Cancer Research and Treatment, 2015, 152, 1-8.	1.1	33
235	A snapshot of cancer in Chile: analytical frameworks for developing a cancer policy. Biological Research, 2015, 48, 10.	1.5	26
236	Challenges in the management of advanced, ER-positive, HER2-negative breast cancer. Nature Reviews Clinical Oncology, 2015, 12, 541-552.	12.5	121
237	Managing Breast Cancer in Young Women. , 2015, , 11-27.		0
238	Impact of Breast Cancer Treatment on Fertility. , 2015, , 29-43.		3
239	Pregnancy After Breast Cancer. , 2015, , 71-82.		1

#	ARTICLE	IF	CITATIONS
240	Tailored Tamoxifen Treatment for Breast Cancer Patients: A Perspective. <i>Clinical Breast Cancer</i> , 2015, 15, 241-244.	1.1	18
241	Extended adjuvant endocrine therapy in hormone-receptor positive early breast cancer: Current and future evidence. <i>Cancer Treatment Reviews</i> , 2015, 41, 271-276.	3.4	34
242	Polymorphism at 19q13.41 Predicts Breast Cancer Survival Specifically after Endocrine Therapy. <i>Clinical Cancer Research</i> , 2015, 21, 4086-4096.	3.2	12
243	Hormonal Therapy in Oncology: A Primer for the Radiologist. <i>American Journal of Roentgenology</i> , 2015, 204, W620-W630.	1.0	20
244	Personalized Therapy of Cancer. , 2015, , 199-381.		1
245	Breast Cancer in General Population. , 2015, , 331-351.		0
247	A comparison of letrozole and anastrozole followed by letrozole in breast cancer patients. <i>Breast Cancer: Targets and Therapy</i> , 2015, 7, 37.	1.0	1
248	Does patient education work in breast cancer? Final results from the global CARIATIDE study. <i>Future Oncology</i> , 2015, 11, 205-217.	1.1	23
249	Spectral Domain OCT Imaging Techniques in Tamoxifen Retinopathy. <i>Optometry and Vision Science</i> , 2015, 92, e55-e59.	0.6	8
250	Adjuvant Endocrine Therapy for Hormone Receptor-Positive Early Breast Cancer in Premenopausal Patient: Understanding the Data. <i>Current Breast Cancer Reports</i> , 2015, 7, 183-189.	0.5	0
251	The Introduction of Generic Aromatase Inhibitors and Treatment Adherence Among Medicare D Enrollees. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	40
252	New Insights Into Nonadherence With Adjuvant Endocrine Therapy Among Young Women With Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv245.	3.0	21
253	Effects of Tamoxifen and Other SERMs in the Endometrium and Follow-Up of Patients. , 2015, , 437-441.		0
254	Estrogen Receptor Expression in 21-Gene Recurrence Score Predicts Increased Late Recurrence for Estrogen-Positive/HER2-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 2763-2770.	3.2	36
255	Depression as a predictor of adherence to adjuvant endocrine therapy (AET) in women with breast cancer: a systematic review and meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2015, 152, 239-246.	1.1	111
256	Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 533-541.	1.1	31
257	To Treat or Not to Treat: The Use of Hormone Replacement Therapy in Patients With Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 4127-4128.	0.8	1
258	Management of breast cancer in very young women. <i>Breast</i> , 2015, 24, S154-S158.	0.9	79

#	ARTICLE	IF	CITATIONS
259	Cancer chemoprevention at the crossroads?. <i>Breast Cancer Management</i> , 2015, 4, 285-288.	0.2	0
260	Identification of multi-target effects of Huaier aqueous extract via microarray profiling in triple-negative breast cancer cells. <i>International Journal of Oncology</i> , 2015, 46, 2047-2056.	1.4	16
261	Breast Cancer in Young Women: Research Priorities. A Report of the Young Survival Coalition Research Think Tank Meeting. <i>Journal of Adolescent and Young Adult Oncology</i> , 2015, 4, 34-43.	0.7	13
262	Case 1-2015. <i>New England Journal of Medicine</i> , 2015, 372, 162-170.	13.9	2
263	Heterogeneity in hormone-receptor status and survival outcomes among women with synchronous and metachronous bilateral breast cancers. <i>Breast</i> , 2015, 24, 131-136.	0.9	21
264	Uses of anti-Müllerian hormone (AMH) measurement before and after cancer treatment in women. <i>Maturitas</i> , 2015, 80, 245-250.	1.0	60
265	Perfecting Breast-Cancer Treatment – Incremental Gains and Musculoskeletal Pains. <i>New England Journal of Medicine</i> , 2015, 372, 477-478.	13.9	14
266	Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure. <i>EMBO Reports</i> , 2015, 16, 280-296.	2.0	200
267	Current management of lesions associated with an increased risk of breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 227-238.	12.5	110
268	Markers for the identification of late breast cancer recurrence. <i>Breast Cancer Research</i> , 2015, 17, 10.	2.2	60
269	The new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer. <i>Endocrine-Related Cancer</i> , 2015, 22, R1-R31.	1.6	111
270	Adherence to adjuvant endocrine therapy: Is it a factor for ethnic differences in breast cancer outcomes in New Zealand?. <i>Breast</i> , 2015, 24, 62-67.	0.9	22
271	The future of breast cancer systemic therapy: the next 10 years. <i>Journal of Molecular Medicine</i> , 2015, 93, 119-125.	1.7	19
272	Germline oncopharmacogenetics, a promising field in cancer therapy. <i>Cellular Oncology (Dordrecht)</i> , 2015, 38, 65-89.	2.1	11
273	Factors influencing treatment adherence and discontinuation in women with breast cancer. <i>Breast Cancer Management</i> , 2015, 4, 25-31.	0.2	0
274	Identification of Subgroups of Early Breast Cancer Patients at High Risk of Nonadherence to Adjuvant Hormone Therapy: Results of an Italian Survey. <i>Clinical Breast Cancer</i> , 2015, 15, e131-e137.	1.1	27
275	Hormone Therapy for Breast Cancer in Men. <i>Clinical Breast Cancer</i> , 2015, 15, 245-250.	1.1	17
276	Adjuvant systemic therapy in breast cancer: quo vadis?. <i>Annals of Oncology</i> , 2015, 26, 1629-1634.	0.6	18

#	ARTICLE	IF	CITATIONS
278	Risk Factors for the Development of Uterine Cancer in Breast Cancer Survivors: An Army of Women Study. <i>Annals of Surgical Oncology</i> , 2015, 22, 1974-1979.	0.7	4
279	Unique Aspects of Caring for Young Breast Cancer Patients. <i>Current Oncology Reports</i> , 2015, 17, 1.	1.8	25
280	Treatment With Adjuvant Endocrine Therapy for Early-Stage Breast Cancer: Is It Forever?. <i>Journal of Clinical Oncology</i> , 2015, 33, 823-828.	0.8	12
281	Pharmacogenomics toward personalized tamoxifen therapy for breast cancer. <i>Pharmacogenomics</i> , 2015, 16, 287-296.	0.6	24
282	Molecular mechanisms of tamoxifen-associated endometrial cancer (Review). <i>Oncology Letters</i> , 2015, 9, 1495-1501.	0.8	102
283	Optimal Systemic Therapy for Early Breast Cancer in Women: A Clinical Practice Guideline. <i>Current Oncology</i> , 2015, 22, 67-81.	0.9	43
284	Cognitive effects of endocrine therapy for breast cancer: keep calm and carry on?. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 597-606.	12.5	51
285	The molecular, cellular and clinical consequences of targeting the estrogen receptor following estrogen deprivation therapy. <i>Molecular and Cellular Endocrinology</i> , 2015, 418, 245-263.	1.6	27
286	Clinical utility of the IHC4+C score in oestrogen receptor-positive early breast cancer: a prospective decision impact study. <i>British Journal of Cancer</i> , 2015, 113, 390-395.	2.9	41
287	Association of tamoxifen use and ovarian function in patients with invasive or pre-invasive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 153, 173-181.	1.1	17
288	Which Is the Appropriate Adjuvant Endocrine Therapy for Premenopausal Patients With Breast Cancer?. <i>Clinical Breast Cancer</i> , 2015, 15, 169-170.	1.1	0
289	Adjuvant Endocrine Therapy and Bone Health in Breast Cancer. <i>Current Osteoporosis Reports</i> , 2015, 13, 263-273.	1.5	3
290	Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. <i>Lancet, The</i> , 2015, 386, 1341-1352.	6.3	1,072
291	New Insights into Endocrine Therapy for Young Women with Breast Cancer. <i>Women's Health</i> , 2015, 11, 343-354.	0.7	3
292	Proven value of translational research with appropriate animal models to advance breast cancer treatment and save lives: the tamoxifen tale. <i>British Journal of Clinical Pharmacology</i> , 2015, 79, 254-267.	1.1	11
293	How individual participant data meta-analyses have influenced trial design, conduct, and analysis. <i>Journal of Clinical Epidemiology</i> , 2015, 68, 1325-1335.	2.4	60
294	Adjuvant Endocrine Therapy for Early Breast Cancer: A Systematic Review of the Evidence for the 2014 Cancer Care Ontario Systemic Therapy Guideline. <i>Current Oncology</i> , 2015, 22, 95-113.	0.9	37
295	Predictors of Discontinuation of Adjuvant Hormone Therapy in Patients With Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 2262-2269.	0.8	78



#	ARTICLE	IF	CITATIONS
296	Pregnancy following breast cancer using assisted reproduction and its effect on long-term outcome. <i>European Journal of Cancer</i> , 2015, 51, 1490-1496.	1.3	64
297	Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 2353-2360.	0.8	167
298	Changing Treatment Paradigms in Metastatic Breast Cancer. <i>JAMA Oncology</i> , 2015, 1, 528.	3.4	88
299	St. Gallen/Vienna 2015: A Brief Summary of the Consensus Discussion. <i>Breast Care</i> , 2015, 10, 124-130.	0.8	82
300	Biomarkers in Breast Cancer. <i>Advances in Clinical Chemistry</i> , 2015, 71, 1-23.	1.8	86
301	Outcome of Patients with Pregnancy during or after Breast Cancer: A Review of the Recent Literature. <i>Current Oncology</i> , 2015, 22, 8-18.	0.9	49
302	Fertility Preservation Success Subsequent to Concurrent Aromatase Inhibitor Treatment and Ovarian Stimulation in Women With Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 2424-2429.	0.8	178
303	Emotional Freedom Techniques (EFT) to reduce the side effects associated with tamoxifen and aromatase inhibitor use in women with breast cancer: A service evaluation. <i>European Journal of Integrative Medicine</i> , 2015, 7, 136-142.	0.8	12
304	Mechanisms of aromatase inhibitor resistance. <i>Nature Reviews Cancer</i> , 2015, 15, 261-275.	12.8	319
305	Timing of Adjuvant Surgical Oophorectomy in the Menstrual Cycle and Disease-Free and Overall Survival in Premenopausal Women With Operable Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv064.	3.0	16
307	Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. <i>Breast Diseases</i> , 2015, 26, 86-88.	0.0	3
308	Radiotherapy for elderly patients with low-risk breast cancer. <i>Lancet Oncology</i> , The, 2015, 16, e196-e197.	5.1	3
309	Breast Cancer Under Age 40: a Different Approach. <i>Current Treatment Options in Oncology</i> , 2015, 16, 16.	1.3	67
310	Pregnancy after breast cancer: Are young patients willing to participate in clinical studies?. <i>Breast</i> , 2015, 24, 201-207.	0.9	97
311	TFF3 is a valuable predictive biomarker of endocrine response in metastatic breast cancer. <i>Endocrine-Related Cancer</i> , 2015, 22, 465-479.	1.6	43
312	Mechanisms of endocrine resistance in breast cancer: an overview of the proposed roles of noncoding RNA. <i>Breast Cancer Research</i> , 2015, 17, 40.	2.2	148
313	Using a Sequence of Estrogen Response Elements as a DNA Aptamer for Estrogen Receptors <i>In Vitro</i> . <i>Nucleic Acid Therapeutics</i> , 2015, 25, 152-161.	2.0	6
314	Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. <i>Annals of Oncology</i> , 2015, 26, 1533-1546.	0.6	1,449

#	ARTICLE	IF	CITATIONS
315	Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen. <i>Clinical Pharmacokinetics</i> , 2015, 54, 797-810.	1.6	51
316	The Outpatient Breast Clinic. , 2015, , .		2
317	Resistance to Aromatase Inhibitors in Breast Cancer. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2015, , .	0.1	4
318	Patient pathway for breast cancer: turning points and future aspirations. <i>Future Oncology</i> , 2015, 11, 1059-1070.	1.1	2
319	Determining the indications for post mastectomy radiotherapy: moving from 20th century clinical staging to 21st century biological criteria. <i>Annals of Oncology</i> , 2015, 26, 1043-1044.	0.6	13
320	Textbook of Personalized Medicine. , 2015, , .		27
321	Metastasis prevention by targeting the dormant niche. <i>Nature Reviews Cancer</i> , 2015, 15, 238-247.	12.8	279
322	Revisiting the estrogen receptor pathway and its role in endocrine therapy for postmenopausal women with estrogen receptor-positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 150, 231-242.	1.1	35
324	Estrogen Receptor Mutations Found in Breast Cancer Metastases Integrated With the Molecular Pharmacology of Selective ER Modulators. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv075.	3.0	35
325	Tamoxifen (Selective Estrogen-Receptor Modulators) and Aromatase Inhibitors as Potential Perioperative Thrombotic Risk Factors in Free Flap Breast Reconstruction. <i>Plastic and Reconstructive Surgery</i> , 2015, 135, 670e-679e.	0.7	33
326	Patients'™ satisfaction in early breast cancer treatment: Change in treatment over time and impact of HER2-targeted therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 94, 270-278.	2.0	5
327	Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. <i>New England Journal of Medicine</i> , 2015, 373, 2005-2014.	13.9	1,146
328	Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2015, 26, v8-v30.	0.6	1,168
329	Nuclear Receptors: From Structure to the Clinic. , 2015, , .		3
330	Breast Cancer After Use of Estrogen Plus Progestin and Estrogen Alone. <i>JAMA Oncology</i> , 2015, 1, 296.	3.4	177
331	Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analyses. <i>Lancet Neurology</i> , The, 2015, 14, 1171-1181.	4.9	124
332	Challenges and Potential for Ovarian Preservation with SERMs1. <i>Biology of Reproduction</i> , 2015, 92, 133.	1.2	6
333	Sub-centimeter HER2-Positive Breast Cancer: How Small Is Too Small to Treat?. <i>Seminars in Oncology</i> , 2015, 42, e67-e79.	0.8	0

#	ARTICLE	IF	CITATIONS
334	Clinical and molecular complexity of breast cancer metastases. <i>Seminars in Cancer Biology</i> , 2015, 35, 85-95.	4.3	118
335	Statistical controversies in clinical research: long-term follow-up of clinical trials in cancer. <i>Annals of Oncology</i> , 2015, 26, 2363-2366.	0.6	18
337	Biological markers of invasive breast cancer. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, hv153.	0.6	23
338	Adjuvant endocrine therapy in pre- versus postmenopausal patients with steroid hormone receptor-positive breast cancer: results from a large population-based cohort of a cancer registry. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 2229-2240.	1.2	11
339	The Actual Role of Receptors as Cancer Markers, Biochemical and Clinical Aspects: Receptors in Breast Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2015, 867, 327-337.	0.8	13
340	Adherence to Adjuvant Endocrine Therapy for Breast Cancer: Importance in Women with Low Income. <i>Journal of Women's Health</i> , 2015, 24, 403-408.	1.5	13
341	Navigating the Challenges of Endocrine Treatments in Premenopausal Women with ER-Positive Early Breast Cancer. <i>Drugs</i> , 2015, 75, 1311-1321.	4.9	5
342	Postmenopausal breast cancer: a best endocrine strategy?. <i>Lancet, The</i> , 2015, 386, 1317-1319.	6.3	8
343	Progress in adjuvant chemotherapy for breast cancer: an overview. <i>BMC Medicine</i> , 2015, 13, 195.	2.3	241
344	More Options for Fertility Preservation for Patients With Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 2413-2415.	0.8	2
345	Picking the optimal endocrine adjuvant treatment for pre-menopausal women. <i>Breast</i> , 2015, 24, S11-S14.	0.9	6
346	St. Gallen endocrine response classes predict recurrence rates over time. <i>Breast</i> , 2015, 24, 705-712.	0.9	5
347	Impact of Fertility Concerns on Tamoxifen Initiation and Persistence. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv202.	3.0	120
348	Uterine Cancer. , 2015, , .		3
349	Update of the Phase III trial â€˜GRETAâ€™ of surgery and tamoxifen versus tamoxifen alone for early breast cancer in elderly women. <i>Future Oncology</i> , 2015, 11, 933-941.	1.1	14
350	Clinical utility of genetic signatures in selecting adjuvant treatment: Risk stratification for early vs. late recurrences. <i>Breast</i> , 2015, 24, S6-S10.	0.9	13
351	Adjuvant endocrine therapy for postmenopausal women: Type and duration. <i>Breast</i> , 2015, 24, S126-S128.	0.9	5
352	Time-varying effect and long-term survival analysis in breast cancer patients treated with neoadjuvant chemotherapy. <i>British Journal of Cancer</i> , 2015, 113, 30-36.	2.9	25

#	ARTICLE	IF	CITATIONS
353	Comparative metabolic study between two selective estrogen receptor modulators, toremifene and tamoxifen, in human liver microsomes. <i>Drug Metabolism and Pharmacokinetics</i> , 2015, 30, 325-333.	1.1	9
354	Breast Cancer Management Updates: Young and Older, Pregnant, or Male. <i>Annals of Surgical Oncology</i> , 2015, 22, 3219-3224.	0.7	8
355	Selective Estrogen Receptor Modulators (SERMs) and Selective Androgen Receptor Modulators (SARMs). , 2015, , 205-227.		0
356	Adjuvant endocrine therapy for premenopausal women with hormone-responsive breast cancer. <i>Breast</i> , 2015, 24, S120-S125.	0.9	15
357	Comparison of Adjuvant Radiation Therapy Alone Versus Radiation Therapy and Endocrine Therapy in Elderly Women With Early-Stage, Hormone Receptor-Positive Breast Cancer Treated With Breast-Conserving Surgery. <i>Clinical Breast Cancer</i> , 2015, 15, 381-389.	1.1	19
358	Metastasis to the Cervix Uteri 15 Years After Treatment of Lobular Carcinoma of the Breast. <i>Seminars in Oncology</i> , 2015, 42, e81-e94.	0.8	7
359	Benefit/risk for adjuvant breast cancer therapy with tamoxifen or aromatase inhibitor use by age, and race/ethnicity. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 609-616.	1.1	18
360	Advances in Cancer Biomarkers. <i>Advances in Experimental Medicine and Biology</i> , 2015, , .	0.8	14
361	The UZ Leuven Policy for Extended Adjuvant Anti-estrogen Therapy in Women With Early Estrogen Receptor-Positive Breast Cancer. <i>Current Treatment Options in Oncology</i> , 2015, 16, 31.	1.3	0
362	3-month triptorelin in premenopausal patients with hormone receptor-positive early breast cancer: a commentary and a retrospective experience. <i>Future Oncology</i> , 2015, 11, 3109-3112.	1.1	0
363	Comparison of Breast Cancer Recurrence and Outcome Patterns Between Patients Treated From 1986 to 1992 and From 2004 to 2008. <i>Journal of Clinical Oncology</i> , 2015, 33, 65-73.	0.8	131
364	Bilateral parotid gland metastases from carcinoma of the breast that presented 25 years after initial treatment. <i>British Journal of Oral and Maxillofacial Surgery</i> , 2015, 53, 94-96.	0.4	7
365	Selective estrogen receptor modulators (SERMs): A review of clinical data. <i>Maturitas</i> , 2015, 80, 52-57.	1.0	75
366	Expression levels of SF3B3 correlate with prognosis and endocrine resistance in estrogen receptor-positive breast cancer. <i>Modern Pathology</i> , 2015, 28, 677-685.	2.9	28
367	Breast Diseases. , 2015, , .		7
368	Genetic variants of kinase suppressors of Ras (KSR1) to predict survival in patients with ER±-positive advanced breast cancer. <i>Pharmacogenomics Journal</i> , 2015, 15, 235-240.	0.9	2
369	Meaningful prevention of breast cancer metastasis: candidate therapeutics, preclinical validation, and clinical trial concerns. <i>Journal of Molecular Medicine</i> , 2015, 93, 13-29.	1.7	15
370	Breast cancer therapy planning "a novel support concept for a sequential decision making problem. <i>Health Care Management Science</i> , 2015, 18, 389-405.	1.5	3

#	ARTICLE	IF	CITATIONS
371	Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer. <i>Pharmacogenomics Journal</i> , 2015, 15, 84-94.	0.9	148
372	Informing women with breast cancer about endocrine therapy: effects on knowledge and adherence. <i>Psycho-Oncology</i> , 2015, 24, 130-137.	1.0	57
373	Persistence and discontinuation of adjuvant endocrine therapy in women with breast cancer. <i>Breast Cancer</i> , 2016, 23, 128-133.	1.3	24
374	MiR-4653-3p and its target gene FRS2 are prognostic biomarkers for hormone receptor positive breast cancer patients receiving tamoxifen as adjuvant endocrine therapy. <i>Oncotarget</i> , 2016, 7, 61166-61182.	0.8	18
375	Oncology providers' perspectives on endocrine therapy prescribing and management. <i>Patient Preference and Adherence</i> , 2016, Volume 10, 2007-2019.	0.8	20
376	Heterogeneity of leukemia-initiating capacity of chronic myelogenous leukemia stem cells. <i>Journal of Clinical Investigation</i> , 2016, 126, 975-991.	3.9	44
377	Targeted therapies with companion diagnostics in the management of breast cancer: current perspectives. <i>Pharmacogenomics and Personalized Medicine</i> , 2016, 9, 7.	0.4	20
378	HormonothÃ©rapie adjuvante dans le cancer du sein. , 2016, , 95-107.		0
379	Recent advances in the medical treatment of breast cancer. <i>F1000Research</i> , 2016, 5, 2786.	0.8	10
380	Challenges in Treating Premenopausal Women with Endocrine-Sensitive Breast Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, 23-32.	1.8	20
381	Impact of Molecular Subtype Conversion of Breast Cancers after Neoadjuvant Chemotherapy on Clinical Outcome. <i>Cancer Research and Treatment</i> , 2016, 48, 133-141.	1.3	35
382	How Do We Best Ensure That Rosebuds Are Gathered?. <i>Journal of Oncology Practice</i> , 2016, 12, 1157-1159.	2.5	0
383	When to Treat, With What, and for How Long: That Is the Question!. <i>Journal of Oncology Practice</i> , 2016, 12, 1160-1162.	2.5	0
384	Breast Cancer Profile among Patients with a History of Chemoprevention. <i>International Journal of Breast Cancer</i> , 2016, 2016, 1-5.	0.6	0
386	Breast Cancer-Specific Mortality Pattern and Its Changing Feature According to Estrogen Receptor Status in Two Time Periods. <i>PLoS ONE</i> , 2016, 11, e0157322.	1.1	5
387	Influences on quality of prescribing in breast cancer patients. <i>NursePrescribing</i> , 2016, 14, 502-506.	0.1	0
388	Embryo Cryopreservation in Breast Cancer Patients. , 2016, , 39-52.		0
389	Anticancer drugs during pregnancy. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 795-804.	0.6	15

#	ARTICLE	IF	CITATIONS
390	Sticking to It: Improving Outcomes by Increasing Adherence. <i>Journal of Clinical Oncology</i> , 2016, 34, 2440-2442.	0.8	16
391	Multigene and Drug Interaction Approach for Tamoxifen Metabolite Patterns Reveals Possible Involvement of CYP2C9, CYP2C19, and <i>ABCB1</i> . <i>Journal of Clinical Pharmacology</i> , 2016, 56, 1570-1581.	1.0	17
392	Significance of Ovarian Function Suppression in Endocrine Therapy for Breast Cancer in Pre-Menopausal Women. <i>Geburtshilfe Und Frauenheilkunde</i> , 2016, 76, 516-524.	0.8	5
393	Update in treatment of early breast cancer in post-menopausal women. <i>Expert Review of Endocrinology and Metabolism</i> , 2016, 11, 243-252.	1.2	0
394	Breast Cancer Survivorship. , 2016, , .		3
395	Factors associated with late recurrence after completion of 5-year adjuvant tamoxifen in estrogen receptor positive breast cancer. <i>BMC Cancer</i> , 2016, 16, 430.	1.1	15
396	Hormone Receptors in Breast Cancer. , 2016, , 45-58.		0
398	Finding Influential Genes Using Gene Expression Data and Boolean Models of Metabolic Networks. , 2016, , .		2
399	Predicting Risk of Disease Recurrence. , 2016, , 15-30.		0
400	Cancer in the elderly. , 2016, , 537-563.		0
401	Extended adjuvant endocrine therapy in hormone-receptor-positive early breast cancer. <i>Current Opinion in Oncology</i> , 2016, 28, 455-460.	1.1	9
402	Adjuvant Treatment for Older Women with Invasive Breast Cancer. <i>Women's Health</i> , 2016, 12, 129-146.	0.7	13
403	Mammographic Density as a Biosensor of Tamoxifen Effectiveness in Adjuvant Endocrine Treatment of Breast Cancer: Opportunities and Implications. <i>Journal of Clinical Oncology</i> , 2016, 34, 2093-2097.	0.8	22
404	AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and <i>ESR1</i> -Mutant Breast Tumors in Preclinical Models. <i>Cancer Research</i> , 2016, 76, 3307-3318.	0.4	151
405	Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity. <i>Oncologist</i> , 2016, 21, 795-803.	1.9	42
406	A Review of Local and Systemic Therapy in Breast Cancer. , 2016, , 731-764.		0
407	Behavioral Interventions to Enhance Adherence to Hormone Therapy in Breast Cancer Survivors: A Systematic Literature Review. <i>Clinical Breast Cancer</i> , 2016, 16, 247-255.e3.	1.1	55
408	Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence. <i>Journal of Clinical Oncology</i> , 2016, 34, 2452-2459.	0.8	178

#	ARTICLE	IF	CITATIONS
409	Prognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (<i>ESR1</i>) on Predicting Late Distant Recurrence Risk in Estrogen Receptor-Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-28 and B-14. <i>Journal of Clinical Oncology</i> , 2016, 34, 2350-2358.	0.8	71
410	The tipping point: Tamoxifen toxicity, central serous chorioretinopathy, and the role of estrogen and its receptors. <i>American Journal of Ophthalmology Case Reports</i> , 2016, 3, 8-13.	0.4	11
411	Intrinsic Subtypes of Primary Breast Cancer - Gene Expression Analysis. <i>Oncology Research and Treatment</i> , 2016, 39, 102-110.	0.8	18
412	Treatment Modification in Young Breast Cancer Patients. <i>Oncology Research and Treatment</i> , 2016, 39, 122-128.	0.8	1
413	Vaginal Health During Breast Cancer Treatment. <i>Current Oncology Reports</i> , 2016, 18, 32.	1.8	20
414	Cardiovascular Disease After Aromatase Inhibitor Use. <i>JAMA Oncology</i> , 2016, 2, 1590.	3.4	74
415	Psychosocial factors related to non-persistence with adjuvant endocrine therapy among women with breast cancer: the Breast Cancer Quality of Care Study (BQUAL). <i>Breast Cancer Research and Treatment</i> , 2016, 157, 133-143.	1.1	51
416	Analysis of factors affecting endocrine therapy resistance in breast cancer. <i>Oncology Letters</i> , 2016, 11, 379-384.	0.8	6
417	Pattern of relapse after breast conserving therapy, a study of 1519 early breast cancer patients treated in the Central Region of Denmark 2000-2009. <i>Acta Oncologica</i> , 2016, 55, 964-969.	0.8	13
418	Cardiovascular surveillance in breast cancer treatment: A more individualized approach is needed. <i>Maturitas</i> , 2016, 89, 58-62.	1.0	12
419	Are SOFT and TEXT results practice changing and how?. <i>Breast</i> , 2016, 27, 122-125.	0.9	14
420	Two Years of Adjuvant Tamoxifen Provides a Survival Benefit Compared With No Systemic Treatment in Premenopausal Patients With Primary Breast Cancer: Long-Term Follow-Up (> 25 years) of the Phase III SBII:2pre Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 2232-2238.	0.8	30
421	Renforcer l'observance de l'hormonothérapie. <i>Actualites Pharmaceutiques</i> , 2016, 55, 33-34.	0.0	3
423	Persistence to 5-year hormonal breast cancer therapy: a French national population-based study. <i>British Journal of Cancer</i> , 2016, 115, 912-919.	2.9	20
424	Reply to D.C. Sgroi et al, T. Sanft et al, M.S. Copur et al, and M.P. Goetz et al. <i>Journal of Clinical Oncology</i> , 2016, 34, 3946-3948.	0.8	3
426	Special considerations in the evaluation and management of breast cancer in men11This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.. <i>Current Problems in Cancer</i> , 2016, 40, 163-171.	1.0	9
427	Oncofertility Knowledge, Attitudes, and Practices of Canadian Breast Surgeons. <i>Annals of Surgical Oncology</i> , 2016, 23, 3850-3859.	0.7	16
429	A Raloxifene Withdrawal Response. <i>Integrative Cancer Therapies</i> , 2016, 15, 242-244.	0.8	1

#	ARTICLE	IF	CITATIONS
430	Endometrial cancer risk in postmenopausal breast cancer patients treated with tamoxifen or aromatase inhibitors. <i>Expert Review of Endocrinology and Metabolism</i> , 2016, 11, 425-432.	1.2	1
431	The modulation of estrogen-induced apoptosis as an interpretation of the women's health initiative trials. <i>Expert Review of Endocrinology and Metabolism</i> , 2016, 11, 81-86.	1.2	10
432	Biomarker assessment and molecular testing for prognostication in breast cancer. <i>Histopathology</i> , 2016, 68, 70-85.	1.6	53
433	Issues Affecting the Loco-regional and Systemic Management of Patients with Invasive Lobular Carcinoma of the Breast. <i>Breast Journal</i> , 2016, 22, 45-53.	0.4	14
434	Biomarkers for Early-Stage Breast Cancer: Clinical Utility for Extended Adjuvant Treatment Decisions. <i>Journal of Clinical Oncology</i> , 2016, 34, 3941-3942.	0.8	4
435	Factors that predict recurrence later than 5 years after initial treatment in operable breast cancer. <i>World Journal of Surgical Oncology</i> , 2016, 14, 223.	0.8	53
436	Is it best to expect the worst? Influence of patients' side-effect expectations on endocrine treatment outcome in a 2-year prospective clinical cohort study. <i>Annals of Oncology</i> , 2016, 27, 1909-1915.	0.6	72
437	Endocrine Therapy in Premenopausal Hormone Receptor-Positive Breast Cancer. <i>Journal of Oncology Practice</i> , 2016, 12, 1148-1156.	2.5	7
438	Endocrine treatment in breast cancer: Cure, resistance and beyond. <i>Cancer Treatment Reviews</i> , 2016, 50, 68-81.	3.4	114
439	Prediction of ovarian function in premenopausal breast cancer patients with amenorrhoea after chemotherapy: a simple clinical score. <i>SpringerPlus</i> , 2016, 5, 1052.	1.2	3
440	In situ thermosensitive Tamoxifen citrate loaded hydrogels: An effective tool in breast cancer loco-regional therapy. <i>Journal of Drug Delivery Science and Technology</i> , 2016, 35, 155-164.	1.4	24
442	The adherence and tolerance of adjuvant endocrine therapy in geriatric breast cancer patients. <i>Journal of Cancer Research and Practice</i> , 2016, 3, 69-72.	0.2	2
443	Terapia antiestrogénica en los cánceres de mama. <i>EMC - Ginecología-Obstetricia</i> , 2016, 52, 1-7.	0.0	0
444	Postoperative hormonal therapy prevents recovery of neurological damage after surgery in patients with breast cancer. <i>Scientific Reports</i> , 2016, 6, 34671.	1.6	2
445	The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer. <i>Science Advances</i> , 2016, 2, e1601737.	4.7	175
448	Caring for breast cancer survivors in primary care. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2016, 29, 16-22.	0.1	0
449	CE. <i>American Journal of Nursing</i> , 2016, 116, 28-36.	0.2	0
450	Identifying biomarkers to select patients with early breast cancer suitable for extended adjuvant endocrine therapy. <i>Current Opinion in Oncology</i> , 2016, 28, 461-468.	1.1	4



#	ARTICLE	IF	CITATIONS
451	Systemic Therapies for Nonmetastatic Breast Cancer: The Role of Neoadjuvant and Adjuvant Chemotherapy and the Use of Endocrine Therapy. <i>Clinical Obstetrics and Gynecology</i> , 2016, 59, 756-771.	0.6	2
453	Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. <i>New England Journal of Medicine</i> , 2016, 375, 209-219.	13.9	507
454	Fertility in Women of Reproductive Age After Breast Cancer Treatment: Practice Patterns and Outcomes. <i>Annals of Surgical Oncology</i> , 2016, 23, 3175-3181.	0.7	35
455	Effect of Temporary Ovarian Suppression on Chemotherapy-Induced Amenorrhea, Pregnancy, and Outcome. <i>JAMA Oncology</i> , 2016, 2, 1089.	3.4	2
456	News on the medical treatment of young women with early-stage HER2-negative breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1643-1655.	0.9	8
457	The impact of adjuvant endocrine therapy in early breast cancer on quality-of-life: an overview of prospective trials. <i>Expert Review of Quality of Life in Cancer Care</i> , 2016, 1, 111-120.	0.6	2
458	Inhibition of breast cancer with transdermal tamoxifen-encapsulated lipoplex. <i>Journal of Nanobiotechnology</i> , 2016, 14, 11.	4.2	36
459	The association between the duration of fluoropyrimidine-based adjuvant chemotherapy and survival in stage II or III gastric cancer. <i>World Journal of Surgical Oncology</i> , 2016, 14, 102.	0.8	4
460	Die gegenwärtige Landschaft der endokrinen Therapie für prämenopausale Frauen mit Brustkrebs. <i>Karger Kompass Onkologie</i> , 2016, 3, 14-18.	0.0	0
462	Les traitements adjuvants des cancers du sein : dernières avancées et perspectives pour des cancers très diffusifs. <i>Oncologie</i> , 2016, 18, 120-127.	0.2	1
463	Weight gain during adjuvant endocrine treatment for early-stage breast cancer: What is the evidence?. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 203-217.	1.1	31
464	The Role of mTOR Inhibitors in Breast Cancer. , 2016, , 67-92.		0
465	Hormonal therapy for cancer. <i>Medicine</i> , 2016, 44, 30-33.	0.2	21
466	Characterizing and quantifying the effects of breast cancer therapy using mathematical modeling. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 303-311.	1.1	2
467	Extracellular vesicles in breast cancer drug resistance and their clinical application. <i>Tumor Biology</i> , 2016, 37, 2849-2861.	0.8	19
470	Endocrine therapy in premenopausal women with breast cancer: a critical appraisal of current evidence. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 211-218.	1.1	11
471	Induction and subcellular redistribution of progesterone receptor A and B by tamoxifen in the hypothalamic ventromedial neurons of young adult female Wistar rats. <i>Molecular and Cellular Endocrinology</i> , 2016, 420, 1-10.	1.6	7
472	The Impact of Endocrine Therapy on Cognitive Functions of Breast Cancer Patients: A Systematic Review. <i>Clinical Drug Investigation</i> , 2016, 36, 109-118.	1.1	35

#	ARTICLE	IF	CITATIONS
473	Advances in Medical Management of Early Stage and Advanced Breast Cancer: 2015. Seminars in Radiation Oncology, 2016, 26, 59-70.	1.0	11
474	Prognostic and Predictive Biomarkers of Endocrine Responsiveness for Estrogen Receptor Positive Breast Cancer. Advances in Experimental Medicine and Biology, 2016, 882, 125-154.	0.8	29
476	Principles of a risk evaluation and mitigation strategy (REMS) for breast cancer patients receiving potentially cardiotoxic adjuvant treatments. Expert Opinion on Drug Safety, 2016, 15, 911-923.	1.0	7
477	Emerging therapeutic targets in metastatic progression: A focus on breast cancer. , 2016, 161, 79-96.		53
478	Targeting dormant micrometastases: rationale, evidence to date and clinical implications. Therapeutic Advances in Medical Oncology, 2016, 8, 126-137.	1.4	23
479	Adjuvant treatment for breast cancer. Surgery, 2016, 34, 43-46.	0.1	2
480	Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial. Annals of Oncology, 2016, 27, 806-812.	0.6	21
481	Patterns in target-directed breast cancer research. SpringerPlus, 2016, 5, 109.	1.2	1
482	Aromatase inhibitors alone or sequentially combined with tamoxifen in postmenopausal early breast cancer compared with tamoxifen or placebo – Meta-analyses on efficacy and adverse events based on randomized clinical trials. Breast, 2016, 26, 106-114.	0.9	56
483	Sisyphean Efforts: Establishing the Correct Risk-Benefit Balance for Adjuvant Therapies. Journal of Clinical Oncology, 2016, 34, 895-897.	0.8	0
485	Clinical Diagnosis and Management of Breast Cancer. Journal of Nuclear Medicine, 2016, 57, 9S-16S.	2.8	314
486	Second international consensus guidelines for breast cancer in young women (BCY2). Breast, 2016, 26, 87-99.	0.9	142
487	Time to Surgery and Breast Cancer Survival in the United States. JAMA Oncology, 2016, 2, 330.	3.4	418
488	Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer. Breast Cancer, 2016, 23, 830-843.	1.3	36
489	The Japanese Breast Cancer Society Clinical Practice Guideline for systemic treatment of breast cancer, 2015 edition. Breast Cancer, 2016, 23, 329-342.	1.3	49
490	Risk of Recurrence or Contralateral Breast Cancer More than 5 Years After Diagnosis of Hormone Receptor-Positive Early-Stage Breast Cancer. Clinical Breast Cancer, 2016, 16, 284-290.	1.1	2
491	Macrophage migration inhibitory factor promotes breast cancer metastasis via activation of HMGB1/TLR4/NF kappa B axis. Cancer Letters, 2016, 375, 245-255.	3.2	86
492	Activated Caspase 3 Expression in Remnant Disease After Neoadjuvant Chemotherapy May Predict Outcomes of Breast Cancer Patients. Annals of Surgical Oncology, 2016, 23, 2235-2241.	0.7	10

#	ARTICLE	IF	CITATIONS
493	Is Estradiol Monitoring Necessary in Women Receiving Ovarian Suppression for Breast Cancer?. <i>Journal of Clinical Oncology</i> , 2016, 34, 1573-1579.	0.8	15
494	Perceptions, Attributions, and Emotions Toward Endocrine Therapy in Young Women with Breast Cancer. <i>Journal of Adolescent and Young Adult Oncology</i> , 2016, 5, 16-23.	0.7	26
495	Improvements in breast cancer survival between 1995 and 2012 in Denmark: The importance of earlier diagnosis and adjuvant treatment. <i>Acta Oncologica</i> , 2016, 55, 24-35.	0.8	33
496	Recommendations from the EGAPP Working Group: does the use of Oncotype DX tumor gene expression profiling to guide treatment decisions improve outcomes in patients with breast cancer?. <i>Genetics in Medicine</i> , 2016, 18, 770-779.	1.1	12
497	The impact of treatment compliance on fracture risk in women with breast cancer treated with aromatase inhibitors in the United Kingdom. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 151-157.	1.1	32
498	Cancer of the Breast: An Overview. , 2016, , 147-209.		0
499	New insights on the role of luteinizing hormone releasing hormone agonists in premenopausal early breast cancer patients. <i>Cancer Treatment Reviews</i> , 2016, 42, 18-23.	3.4	11
500	Long-term use of tamoxifen reduces the risk of dementia: a nationwide population-based cohort study. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2016, 109, 103-109.	0.2	30
501	Breast Cancer Chemoprevention: A Network Meta-Analysis of Randomized Controlled Trials. <i>Journal of the National Cancer Institute</i> , 2016, 108, .	3.0	34
502	Prognostic impact of a single-nucleotide polymorphism near the CTSO gene in hormone receptor-positive breast cancer patients. <i>International Journal of Clinical Oncology</i> , 2016, 21, 539-547.	1.0	9
503	Joint symptoms and health-related quality of life in postmenopausal women with breast cancer who completed 5 years of anastrozole. <i>Supportive Care in Cancer</i> , 2016, 24, 683-689.	1.0	11
504	Identification of patients with hormone receptor-positive breast cancer who need adjuvant tamoxifen therapy for more than 5 years. <i>Journal of the Formosan Medical Association</i> , 2016, 115, 249-256.	0.8	3
505	Endocrine therapy adherence: a cross-sectional study of factors affecting adherence and discontinuation of therapy. <i>Irish Journal of Medical Science</i> , 2016, 185, 383-392.	0.8	14
506	Coping with cancer-related cognitive dysfunction: a scoping review of the literature. <i>Disability and Rehabilitation</i> , 2016, 38, 400-408.	0.9	19
507	Which patient- and physician-related factors are associated with guideline adherent initiation of adjuvant endocrine therapy? Results of the prospective multi-centre cohort study BRENDA II. <i>Breast Cancer</i> , 2017, 24, 281-287.	1.3	4
508	Combination of metformin with chemotherapeutic drugs via different molecular mechanisms. <i>Cancer Treatment Reviews</i> , 2017, 54, 24-33.	3.4	76
509	Gravidez após neoplasia da mama: relato de caso. <i>Reproducao E Climaterio</i> , 2017, 32, 145-147.	0.1	0
510	Tumor characteristics and survival outcomes of women with tamoxifen-related uterine carcinosarcoma. <i>Gynecologic Oncology</i> , 2017, 144, 329-335.	0.6	20

#	ARTICLE	IF	CITATIONS
511	Has the Time Come to Stop Surgical Staging of the Axilla for All Women Age 70 Years or Older with Hormone Receptor-Positive Breast Cancer?. <i>Annals of Surgical Oncology</i> , 2017, 24, 614-617.	0.7	35
512	Long noncoding RNAs (lncRNAs) in triple negative breast cancer. <i>Journal of Cellular Physiology</i> , 2017, 232, 3226-3233.	2.0	27
513	Extended adjuvant endocrine therapy – A standard to all or some?. <i>Breast</i> , 2017, 32, 112-118.	0.9	12
514	Prevalence of preterm, low birthweight, and small for gestational age delivery after breast cancer diagnosis: a population-based study. <i>Breast Cancer Research</i> , 2017, 19, 11.	2.2	27
515	First report on molecular breast cancer subtypes and their clinico-pathological characteristics in Eastern Morocco: series of 2260 cases. <i>BMC Women's Health</i> , 2017, 17, 3.	0.8	30
516	Identifying High-Risk Women for Endometrial Cancer Prevention Strategies: Proposal of an Endometrial Cancer Risk Prediction Model. <i>Cancer Prevention Research</i> , 2017, 10, 1-13.	0.7	68
517	Novel Selective Estrogen Receptor Downregulators (SERDs) Developed against Treatment-Resistant Breast Cancer. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 1325-1342.	2.9	68
518	Ovarian ablation for premenopausal breast cancer: A review of treatment considerations and the impact of premature menopause. <i>Cancer Treatment Reviews</i> , 2017, 55, 26-35.	3.4	19
519	Is the neutrophil-to-lymphocyte ratio prognostic of survival outcomes in gynecologic cancers? A systematic review and meta-analysis. <i>Gynecologic Oncology</i> , 2017, 145, 584-594.	0.6	85
520	Ovarian Function Suppression in Premenopausal Women with Early-Stage Breast Cancer. <i>Current Treatment Options in Oncology</i> , 2017, 18, 4.	1.3	17
521	Evolution of Cancer Stem-like Cells in Endocrine-Resistant Metastatic Breast Cancers Is Mediated by Stromal Microvesicles. <i>Cancer Research</i> , 2017, 77, 1927-1941.	0.4	112
522	Real-world impact of non-breast cancer-specific death on overall survival in resectable breast cancer. <i>Cancer</i> , 2017, 123, 2432-2443.	2.0	25
524	Opportunities and challenges of long term anti-estrogenic adjuvant therapy: treatment forever or intermittently?. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 297-310.	1.1	3
525	Galangin potentiates human breast cancer to apoptosis induced by TRAIL through activating AMPK. <i>Biomedicine and Pharmacotherapy</i> , 2017, 89, 845-856.	2.5	38
526	Management Strategies for Sexual Health After Breast Cancer Diagnosis. , 2017, , 303-322.		0
527	Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM). <i>European Journal of Cancer</i> , 2017, 75, 284-298.	1.3	363
528	Identification of miRNAs as biomarkers for acquired endocrine resistance in breast cancer. <i>Molecular and Cellular Endocrinology</i> , 2017, 456, 76-86.	1.6	35
529	Breast Cancer Outcomes After Diagnosis of Hormone-positive Breast Cancer and Subsequent Pregnancy in the Tamoxifen Era. <i>Clinical Breast Cancer</i> , 2017, 17, e185-e189.	1.1	16

#	ARTICLE	IF	CITATIONS
530	Extended Adjuvant Endocrine Therapy in Breast Cancer: Evidence and Update - A Review. Breast Journal, 2017, 23, 694-705.	0.4	12
531	Computer-aided Diagnosis-generated Kinetic Features of Breast Cancer at Preoperative MR Imaging: Association with Disease-free Survival of Patients with Primary Operable Invasive Breast Cancer. Radiology, 2017, 284, 45-54.	3.6	40
532	Extended Endocrine Therapy: Is 5 Years Enough?. Current Oncology Reports, 2017, 19, 16.	1.8	5
534	Anordrin Eliminates Tamoxifen Side Effects without Changing Its Antitumor Activity. Scientific Reports, 2017, 7, 43940.	1.6	10
535	Tamoxifen Decreases Mortality, but How?. Journal of Clinical Oncology, 2017, 35, 379-379.	0.8	1
536	Embryonic transcription factor SOX9 drives breast cancer endocrine resistance. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E4482-E4491.	3.3	83
537	Therapeutic escalation â€“ De-escalation: Data from 15,508 early breast cancer treated with upfront surgery and sentinel lymph node biopsy (SLNB). Breast, 2017, 34, 24-33.	0.9	7
539	10 vs 5 years of adjuvant tamoxifen: exclusion of 1/402 centres in ATLAS. Lancet, The, 2017, 389, 1884.	6.3	4
541	Adjuvant Endocrine Therapy in Breast Cancer: Evolving Paradigms in Premenopausal Women. Current Treatment Options in Oncology, 2017, 18, 28.	1.3	11
542	A Way Forward for Cancer Chemoprevention: Think Local. Cancer Prevention Research, 2017, 10, 14-35.	0.7	19
543	Extended adjuvant endocrine therapy in early breast cancer: a meta-analysis of published randomized trials. Medical Oncology, 2017, 34, 131.	1.2	14
544	Treatment Decisions and Adherence to Adjuvant Endocrine Therapy in Breast Cancer. Current Breast Cancer Reports, 2017, 9, 100-110.	0.5	14
545	Gynecological Cancer as a Second Malignancy in Patients With Breast Cancer. International Journal of Gynecological Cancer, 2017, 27, 1298-1304.	1.2	8
546	Diagnosis and Pre-management Workup of Endometrial Carcinoma. , 2017, , 41-53.		0
547	Acquired Tamoxifen Resistance in MCF-7 Breast Cancer Cells Requires Hyperactivation of eIF4F-Mediated Translation. Hormones and Cancer, 2017, 8, 219-229.	4.9	14
548	Vaginal Atrophy in Breast Cancer Survivors: Attitude and Approaches Among Oncologists. Clinical Breast Cancer, 2017, 17, 611-617.	1.1	59
550	Adjuvant endocrine therapy for premenopausal women: type and duration. Breast, 2017, 32, S19.	0.9	0
551	Adjuvant endocrine therapy for postmenopausal women with ER positive breast cancer: tailoring therapy based on tumors and patients. Breast, 2017, 32, S19-S20.	0.9	0

#	ARTICLE	IF	CITATIONS
552	Are There Breast Cancer Patients with Node-Negative Small Tumours, Who Do Not Benefit from Adjuvant Systemic Therapy?. <i>Oncology</i> , 2017, 92, 317-324.	0.9	7
553	Utilization of gynecologic services in women with breast cancer receiving hormonal therapy. <i>American Journal of Obstetrics and Gynecology</i> , 2017, 217, 59.e1-59.e12.	0.7	8
554	Expression of oxysterol pathway genes in oestrogen- $\alpha$ positive breast carcinomas. <i>Clinical Endocrinology</i> , 2017, 86, 852-861.	1.2	4
556	Current Concepts in Endometrial Cancer. , 2017, , .		2
557	Neoadjuvant endocrine therapy " moving forward as a standard of care?. <i>Breast</i> , 2017, 32, S18-S19.	0.9	0
558	MED1 may explain the interaction between receptor tyrosine kinases and ER $\pm$ 66 in the complicated network of Tamoxifen resistance. <i>European Journal of Pharmacology</i> , 2017, 804, 78-81.	1.7	9
559	Pathologic diagnosis of breast cancer patients: evolution of the traditional clinical-pathologic paradigm toward "precision" cancer therapy. <i>Biotechnic and Histochemistry</i> , 2017, 92, 175-200.	0.7	10
560	Factors related to the experience of menopausal symptoms in women prescribed tamoxifen. <i>Journal of Psychosomatic Obstetrics and Gynaecology</i> , 2017, 38, 226-235.	1.1	44
561	An Antiestrogenic Activity Score for tamoxifen and its metabolites is associated with breast cancer outcome. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 567-574.	1.1	18
562	Family-building After Breast Cancer: Considering the Effect on Adherence to Adjuvant Endocrine Therapy. <i>Clinical Breast Cancer</i> , 2017, 17, 165-170.	1.1	12
563	The Relationship Between Tamoxifen-associated Nonalcoholic Fatty Liver Disease and the Prognosis of Patients With Early-stage Breast Cancer. <i>Clinical Breast Cancer</i> , 2017, 17, 195-203.	1.1	14
564	Second Opinions From Medical Oncologists for Early-Stage Breast Cancer. <i>JAMA Oncology</i> , 2017, 3, 391.	3.4	22
565	Surveillance of women with a personal history of breast cancer by tumour subtype. <i>Clinical Radiology</i> , 2017, 72, 266.e1-266.e6.	0.5	1
566	Cytochrome P-450 2D6 ( <i>CYP2D6</i> ) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity. <i>American Journal of Epidemiology</i> , 2017, 185, 75-85.	1.6	30
567	Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials. <i>Annals of Oncology</i> , 2017, 28, 487-496.	0.6	141
568	Significant Effect of Polymorphisms in <i>CYP2D6</i> on Response to Tamoxifen Therapy for Breast Cancer: A Prospective Multicenter Study. <i>Clinical Cancer Research</i> , 2017, 23, 2019-2026.	3.2	33
569	Management of hot flashes in women with breast cancer receiving ovarian function suppression. <i>Cancer Treatment Reviews</i> , 2017, 52, 82-90.	3.4	34
570	Effects of Electroporation on Tamoxifen Delivery in Estrogen Receptor Positive (ER+) Human Breast Carcinoma Cells. <i>Cell Biochemistry and Biophysics</i> , 2017, 75, 103-109.	0.9	4

#	ARTICLE	IF	CITATIONS
571	Use of 21-gene recurrence score assay to individualize adjuvant chemotherapy recommendations in ER+/HER2 <sup>+</sup> node positive breast cancer—A National Cancer Database study. <i>Npj Breast Cancer</i> , 2017, 3, 41.	2.3	18
572	Extended Adjuvant Aromatase Inhibitor Therapy in Post-Menopausal Women. <i>Current Breast Cancer Reports</i> , 2017, 9, 236-241.	0.5	4
573	Recurrence dynamics of breast cancer according to baseline body mass index. <i>European Journal of Cancer</i> , 2017, 87, 10-20.	1.3	35
574	Trends and predictions to 2020 in breast cancer mortality in Europe. <i>Breast</i> , 2017, 36, 89-95.	0.9	186
575	Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1502-1511.	5.1	119
576	CIP2A expression predicts recurrences of tamoxifen-treated breast cancer. <i>Tumor Biology</i> , 2017, 39, 101042831772206.	0.8	2
577	ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3). <i>Breast</i> , 2017, 35, 203-217.	0.9	203
578	Medical ovariectomy in menopausal breast cancer patients with high testosterone levels: a further step toward tailored therapy. <i>Endocrine-Related Cancer</i> , 2017, 24, C21-C29.	1.6	3
579	Preservaci3n de la fertilidad femenina. <i>EMC - GinecologÃa-Obstetricia</i> , 2017, 53, 1-15.	0.0	1
580	An Update on Randomized Clinical Trials in Breast Cancer. <i>Surgical Oncology Clinics of North America</i> , 2017, 26, 587-620.	0.6	7
581	Deconstructing Decisions to Initiate, Maintain, or Discontinue Adjuvant Endocrine Therapy in Breast Cancer Survivors: A Mixed-Methods Study. <i>Oncology Nursing Forum</i> , 2017, 44, E101-E110.	0.5	38
582	Understanding tamoxifen adherence in women with breast cancer: A qualitative study. <i>British Journal of Health Psychology</i> , 2017, 22, 978-997.	1.9	88
583	Increased risk of SSEs in bone-only metastatic breast cancer patients treated with zoledronic acid. <i>Journal of Bone Oncology</i> , 2017, 8, 18-22.	1.0	9
584	Identification of plasma biomarkers for distinguishing bipolar depression from major depressive disorder by iTRAQ-coupled LC-MS/MS and bioinformatics analysis. <i>Psychoneuroendocrinology</i> , 2017, 86, 17-24.	1.3	51
585	A Novel Breast Cancer Index for Prediction of Distant Recurrence in HR+ Early-Stage Breast Cancer with One to Three Positive Nodes. <i>Clinical Cancer Research</i> , 2017, 23, 7217-7224.	3.2	27
586	Efficacy of extended adjuvant therapy with aromatase inhibitors in early breast cancer among common clinicopathologically-defined subgroups: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2017, 60, 53-59.	3.4	21
587	Aromatase Inhibitors for the adjuvant treatment of breast cancer in postmenopausal women. <i>The Cochrane Library</i> , 0, , .	1.5	0
588	Flexible small molecular anti-estrogens with N,N-dialkylated-2,5-diethoxy-4-morpholinoaniline scaffold targets multiple estrogen receptor conformations. <i>Cell Cycle</i> , 2017, 16, 1465-1477.	1.3	3

#	ARTICLE	IF	CITATIONS
590	Application of pharmacometrics and quantitative systems pharmacology to cancer therapy: The example of luminal a breast cancer. <i>Pharmacological Research</i> , 2017, 124, 20-33.	3.1	13
591	Provider perspectives on barriers and facilitators to adjuvant endocrine therapy-related symptom management. <i>Supportive Care in Cancer</i> , 2017, 25, 3723-3731.	1.0	7
592	De-escalating and escalating systemic therapy of early breast cancer. <i>Breast</i> , 2017, 34, S5-S9.	0.9	3
593	Prognostic assessment and systemic treatments of invasive local relapses of hormone receptor-positive breast cancer. <i>Breast</i> , 2017, 35, 162-168.	0.9	2
594	Luteinizing hormone releasing hormones analogs in combination with tamoxifen for the adjuvant treatment of premenopausal women with hormone receptor positive breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1357-1362.	0.9	5
595	Managing Menopausal Symptoms and Associated Clinical Issues in Breast Cancer Survivors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 3647-3661.	1.8	89
597	Evaluating the Role of Extended Aromatase Inhibitor Therapy in Early Hormone-Positive Breast Cancer. <i>Current Breast Cancer Reports</i> , 2017, 9, 183-187.	0.5	1
598	Costs and Benefits of Extended Endocrine Strategies for Premenopausal Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 1015-1021.	2.3	9
599	Identifying Biomarkers to Select Patients with Early Breast Cancer Suitable for Extended Adjuvant Endocrine Therapy. <i>Breast Care</i> , 2017, 12, 146-151.	0.8	8
600	Extended Adjuvant Endocrine Therapy in Hormone Receptor-Positive Early Breast Cancer. <i>Breast Care</i> , 2017, 12, 138-144.	0.8	2
603	Navigation through inter- and intratumoral heterogeneity of endocrine resistance mechanisms in breast cancer: A potential role for Liquid Biopsies?. <i>Tumor Biology</i> , 2017, 39, 101042831773151.	0.8	20
604	20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. <i>New England Journal of Medicine</i> , 2017, 377, 1836-1846.	13.9	1,052
605	Endocrine Therapies in the Adjuvant and Advanced Disease Settings. , 2017, , 557-568.		0
606	Targeting progesterone metabolism in breast cancer with l-proline derived new 14-azasteroids. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 4452-4463.	1.4	10
607	Stimulation of the ovaries in women with breast cancer undergoing fertility preservation: Alternative versus standard stimulation protocols; the study protocol of the STIM-trial. <i>Contemporary Clinical Trials</i> , 2017, 61, 96-100.	0.8	13
608	Adjuvant ovarian suppression for resected breast cancer: 2017 critical assessment. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 1-13.	1.1	7
609	Breast cancer subtype and stage are prognostic of time from breast cancer diagnosis to brain metastasis development. <i>Journal of Neuro-Oncology</i> , 2017, 134, 453-463.	1.4	16
610	Impact of adjuvant anti-estrogen therapies (tamoxifen and aromatase inhibitors) on perioperative outcomes of breast reconstruction. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2017, 70, 1495-1504.	0.5	23



#	ARTICLE	IF	CITATIONS
611	Breast cancer milestones 2007â€“2016. Memo - Magazine of European Medical Oncology, 2017, 10, 27-32.	0.3	0
614	Adjuvant endocrine therapy for premenopausal women: Type and duration. Breast, 2017, 34, S108-S111.	0.9	5
615	Highlights of the San Antonio Breast Cancer Symposium 2016. Future Oncology, 2017, 13, 1291-1295.	1.1	0
616	Current advances in endocrine therapy options for premenopausal women with hormone receptor positive breast cancer. Gynecologic Oncology, 2017, 147, 153-157.	0.6	9
617	Cold atmospheric plasma restores tamoxifen sensitivity in resistant MCF-7 breast cancer cell. Free Radical Biology and Medicine, 2017, 110, 280-290.	1.3	49
618	Vaginal Estrogens and Aromatase Inhibitors. JAMA Oncology, 2017, 3, 305.	3.4	4
619	Tamoxifen resistance and metastasis of human breast cancer cells were mediated by the membrane-associated estrogen receptor ER- $\alpha$ 36 signaling in vitro. Cell Biology and Toxicology, 2017, 33, 183-195.	2.4	28
620	Breast cancer. Lancet, The, 2017, 389, 1134-1150.	6.3	1,568
621	Breast Cancer Before 40. Pediatric Oncology, 2017, , 177-202.	0.5	1
622	Switching between endocrine therapies for primary breast cancer: Frequency and timing in Australian clinical practice. Asia-Pacific Journal of Clinical Oncology, 2017, 13, e161-e170.	0.7	5
623	Cardiotoxicity of Aromatase Inhibitors in Breast Cancer Patients. Clinical Breast Cancer, 2017, 17, 11-17.	1.1	60
624	Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index. Clinical Breast Cancer, 2017, 17, 41-47.	1.1	23
625	Long-term Adjuvant Tamoxifen Therapy and Decreases in Contralateral Breast Cancer. JAMA Oncology, 2017, 3, 163.	3.4	4
626	Tamoxifen and amphetamine abuse: Are there therapeutic possibilities?. Journal of Chemical Neuroanatomy, 2017, 83-84, 50-58.	1.0	15
627	Impact of tamoxifen therapy on fertility in breast cancer survivors. Fertility and Sterility, 2017, 107, 243-252.e5.	0.5	54
628	Identify high risk estrogen receptor-positive breast cancer patients for extended endocrine therapy. Breast, 2017, 31, 173-180.	0.9	4
629	Clinical evidence supporting genomic tests in early breast cancer: Do all genomic tests provide the same information?. European Journal of Surgical Oncology, 2017, 43, 909-920.	0.5	34
630	Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer. Breast Cancer, 2017, 24, 473-482.	1.3	19

#	ARTICLE	IF	CITATIONS
631	Psychometric properties of the Beliefs about Medicine Questionnaireâ€™s adjuvant endocrine therapy (BMQ-AET) for women taking AETs following early-stage breast cancer. <i>Health Psychology Open</i> , 2017, 4, 205510291774046.	0.7	10
632	Optimal duration of adjuvant endocrine therapy: how to apply the newest data. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 679-692.	1.4	10
635	Tamoxifen Pharmacovigilance: Implications for Safe Use in the Future. <i>The Consultant Pharmacist</i> , 2017, 32, 535-546.	0.4	2
636	Hormone Therapy in Breast Cancer: Where do We Stand?. <i>Journal of Brain Tumors &amp; Neurooncology</i> , 2017, 06, .	0.1	0
637	The sexual lives of breast cancer patients: Coping with changes associated with treatment. <i>Clinical Nursing Studies</i> , 2017, 6, 61.	0.1	1
638	ER-positive breast cancer patients with more than three positive nodes or grade 3 tumors are at high risk of late recurrence after 5-year adjuvant endocrine therapy. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 4859-4867.	1.0	11
639	Nationwide Case-Control Study Examining the Association between Tamoxifen Use and Alzheimerâ€™s Disease in Aged Women with Breast Cancer in Taiwan. <i>Frontiers in Pharmacology</i> , 2017, 8, 612.	1.6	24
640	Pharmacogenomics Guided-Personalization of Warfarin and Tamoxifen. <i>Journal of Personalized Medicine</i> , 2017, 7, 20.	1.1	12
641	Alternative Splicing in Breast Cancer and the Potential Development of Therapeutic Tools. <i>Genes</i> , 2017, 8, 217.	1.0	24
642	Nomegestrol Acetate Suppresses Human Endometrial Cancer RL95-2 Cells Proliferation In Vitro and In Vivo Possibly Related to Upregulating Expression of SUFU and Wnt7a. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1337.	1.8	15
644	Self-Assembling RADA16-I Peptide Hydrogel Scaffold Loaded with Tamoxifen for Breast Reconstruction. <i>BioMed Research International</i> , 2017, 2017, 1-10.	0.9	13
645	Temporal influence of endocrine therapy with tamoxifen and chemotherapy on nutritional risk and obesity in breast cancer patients. <i>BMC Cancer</i> , 2017, 17, 578.	1.1	7
646	Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up. <i>Breast Cancer Research</i> , 2017, 19, 120.	2.2	93
647	Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients. <i>Breast Cancer Research</i> , 2017, 19, 125.	2.2	58
649	NCCN Guidelines Insights: Breast Cancer, Version 1.2017. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 433-451.	2.3	317
650	Endocrine Therapy in Older Women with Early-Stage Hormone Sensitive Breast Cancer. <i>Journal of Gerontology &amp; Geriatric Research</i> , 2017, 06, .	0.1	0
651	Endometrial polyp surveillance in premenopausal breast cancer patients using tamoxifen. <i>Obstetrics and Gynecology Science</i> , 2017, 60, 26.	0.6	11
652	Managing Expectations in the Transition to Proof of Concept Studies. <i>Reviews on Recent Clinical Trials</i> , 2017, 12, 111-123.	0.4	1

#	ARTICLE	IF	CITATIONS
653	Endoxifen: The End, or Are We at the Beginning?. <i>Journal of Clinical Oncology</i> , 2017, 35, 3378-3379.	0.8	6
654	Long-Term Follow-Up of the Intergroup Exemestane Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 2507-2514.	0.8	22
655	Association Between Out-Of-Pocket Costs, Race/Ethnicity, and Adjuvant Endocrine Therapy Adherence Among Medicare Patients With Breast Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 86-95.	0.8	90
656	Standard and Genomic Tools for Decision Support in Breast Cancer Treatment. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 106-115.	1.8	6
657	Prognostic and Predictive Value of Low Estrogen Receptor Expression in Breast Cancer. <i>Current Oncology</i> , 2017, 24, 106-114.	0.9	28
658	Good adherence to adjuvant endocrine therapy in early breast cancer – a population-based study based on the Swedish Prescribed Drug Register. <i>Acta Oncologica</i> , 2018, 57, 935-940.	0.8	20
659	Tamoxifen Resistance Trumped and Oral Selective Estrogen Receptor Degraders Arrive. <i>Clinical Cancer Research</i> , 2018, 24, 3480-3482.	3.2	8
660	SULFATION PATHWAYS: Steroid sulphatase inhibition via aryl sulphamates: clinical progress, mechanism and future prospects. <i>Journal of Molecular Endocrinology</i> , 2018, 61, T233-T252.	1.1	55
661	Dosage-dependent reduction of macular pigment optical density in female breast cancer patients receiving tamoxifen adjuvant therapy. <i>Breast</i> , 2018, 39, 117-122.	0.9	4
662	Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOC 2006-05). <i>Journal of the National Cancer Institute</i> , 2018, 110, 40-48.	3.0	138
663	Fertility and pregnancy in cancer survivors. <i>Obstetric Medicine</i> , 2018, 11, 110-115.	0.5	13
664	Mammographic density changes following discontinuation of tamoxifen in premenopausal women with oestrogen receptor-positive breast cancer. <i>European Radiology</i> , 2018, 28, 3176-3184.	2.3	9
665	Polycomb complex protein BMI1 confers resistance to tamoxifen in estrogen receptor positive breast cancer. <i>Cancer Letters</i> , 2018, 426, 4-13.	3.2	24
666	Treatment decisions and the impact of adverse events before and during extended endocrine therapy in postmenopausal early breast cancer. <i>European Journal of Cancer</i> , 2018, 95, 59-67.	1.3	7
668	Interventions to improve endocrine therapy adherence in breast cancer survivors: what is the evidence?. <i>Journal of Cancer Survivorship</i> , 2018, 12, 348-356.	1.5	49
669	Endocrine therapy for cancer. <i>Surgery</i> , 2018, 36, 128-133.	0.1	1
670	Design, synthesis, anti-proliferative evaluation and docking studies of 1 <i>H</i> -1,2,3-triazole tethered ospemifene isatin conjugates as selective estrogen receptor modulators. <i>New Journal of Chemistry</i> , 2018, 42, 3703-3713.	1.4	25
671	Reactivation of cAMP Pathway by PDE4D Inhibition Represents a Novel Druggable Axis for Overcoming Tamoxifen Resistance in ER-positive Breast Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 1987-2001.	3.2	37

#	ARTICLE	IF	CITATIONS
672	Targeting of Steroid Hormone Receptor Function in Breast and Prostate Cancer. <i>Endocrinology</i> , 2018, , 765-785.	0.1	0
673	Fertility preservation in <i>BRCA</i>-mutated women: when and how?. <i>Future Oncology</i> , 2018, 14, 483-490.	1.1	17
674	Adjuvant Endocrine Therapy. <i>Cancer Treatment and Research</i> , 2018, 173, 15-29.	0.2	12
675	Adjuvant hormonal therapy for early breast cancer: an epidemiologic study of medication adherence. <i>Breast Cancer Research and Treatment</i> , 2018, 169, 153-162.	1.1	13
676	Breast Biomarker Immunocytochemistry. , 2018, , 197-206.e6.		1
677	Primary Prevention of Breast Cancer. , 2018, , 219-236.e3.		2
678	Steroid Receptors in Breast Cancer. , 2018, , 272-281.e2.		2
679	Therapeutic Strategies for Breast Cancer. , 2018, , 315-330.e7.		5
680	Adjuvant Endocrine Therapy. , 2018, , 736-751.e4.		2
681	Adjuvant and Neoadjuvant Systemic Therapies for Early-Stage Breast Cancer. , 2018, , 752-762.e4.		0
682	Oncofertility Options for Young Women With Breast Cancer. , 2018, , 773-777.e3.		0
683	Locally Advanced Breast Cancer. , 2018, , 819-831.e6.		3
684	Endocrine Therapy for Breast Cancer. , 2018, , 907-923.e6.		2
685	Bilateral Breast Cancer. , 2018, , 967-973.e2.		1
686	Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment. , 2018, 186, 1-24.		297
687	Adjuvant Endocrine Therapy. , 2018, , 427-438.		0
688	Adjuvant Molecular Therapies in Breast Cancer. , 2018, , 447-452.		0
689	Breast Cancer in Special Groups: Young Women with Early Breast Cancer. , 2018, , 487-498.		1

#	ARTICLE	IF	CITATIONS
690	Fertility Preservation in Women with Breast Cancer. , 2018, , 521-527.		0
691	Molecular Profiling of Breast Cancer and DCIS. , 2018, , 89-101.		0
692	Hormone receptor positive breast cancer: state of the art. Current Opinion in Obstetrics and Gynecology, 2018, 30, 51-54.	0.9	12
693	Adherence to Adjuvant Endocrine Therapy in Christchurch Women with Early Breast Cancer. Clinical Oncology, 2018, 30, e9-e15.	0.6	22
694	Theranostics of Triple-Negative Breast Cancer Based on Conjugated Polymer Nanoparticles. ACS Applied Materials & Interfaces, 2018, 10, 10634-10646.	4.0	72
695	Facilitating adherence to endocrine therapy in breast cancer: stability and predictive power of treatment expectations in a 2-year prospective study. Breast Cancer Research and Treatment, 2018, 168, 667-677.	1.1	26
696	Tamoxifen inhibits fibroblast proliferation and prevents epidural fibrosis by regulating the AKT pathway in rats. Biochemical and Biophysical Research Communications, 2018, 497, 937-942.	1.0	12
697	Aromatase inhibitors and the risk of colorectal cancer in postmenopausal women with breast cancer. Annals of Oncology, 2018, 29, 744-748.	0.6	10
698	Fertility preservation for medical reasons in girls and women: British fertility society policy and practice guideline. Human Fertility, 2018, 21, 3-26.	0.7	61
699	Searching for the IDEAL Duration of Adjuvant Endocrine Therapy. Journal of the National Cancer Institute, 2018, 110, 6-8.	3.0	5
700	A study on platinum(<sc>iv</sc>) species containing an estrogen receptor modulator to reverse tamoxifen resistance of breast cancer. Metallomics, 2018, 10, 346-359.	1.0	14
701	Fertility preservation in women harboring deleterious BRCA mutations: ready for prime time?. Human Reproduction, 2018, 33, 181-187.	0.4	44
702	Ultrasound assisted gene and photodynamic synergistic therapy with multifunctional FOXA1-siRNA loaded porphyrin microbubbles for enhancing therapeutic efficacy for breast cancer. Biomaterials, 2018, 173, 58-70.	5.7	46
703	Current Status of Extended Adjuvant Endocrine Therapy in Early Stage Breast Cancer. Current Treatment Options in Oncology, 2018, 19, 26.	1.3	44
704	Cardiovascular Risk in Breast Cancer Patients Receiving Estrogen or Progesterone Antagonists. Current Treatment Options in Cardiovascular Medicine, 2018, 20, 48.	0.4	3
705	Tamoxifen a pioneering drug: An update on the therapeutic potential of tamoxifen derivatives. European Journal of Medicinal Chemistry, 2018, 143, 515-531.	2.6	175
706	Evaluation of Reproductive Concerns and Biographical Impact of Breast Cancer in Young Patients. Breast Care, 2018, 13, 124-128.	0.8	4
707	A qualitative transcriptional signature to reclassify estrogen receptor status of breast cancer patients. Breast Cancer Research and Treatment, 2018, 170, 271-277.	1.1	8

#	ARTICLE	IF	CITATIONS
708	Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 310-320.	2.3	476
709	Risk-benefit perception of pregnancy among breast cancer survivors. European Journal of Cancer Care, 2018, 27, e12696.	0.7	16
710	Factors associated with intentional and unintentional non-adherence to adjuvant endocrine therapy following breast cancer. European Journal of Cancer Care, 2018, 27, e12601.	0.7	70
711	Understanding Breast Cancer Survivors' Beliefs and Concerns About Adjuvant Hormonal Therapy: Promoting Adherence. Journal of Cancer Education, 2018, 33, 436-439.	0.6	16
712	Breast Diseases. , 2018, , 320-352.e6.		2
713	Borderline ER-Positive Primary Breast Cancer Gains No Significant Survival Benefit From Endocrine Therapy: A Systematic Review and Meta-Analysis. Clinical Breast Cancer, 2018, 18, 1-8.	1.1	61
714	Adjuvant endocrine monotherapy for postmenopausal early breast cancer patients with hormone-receptor positive: a systemic review and network meta-analysis. Breast Cancer, 2018, 25, 8-16.	1.3	9
715	The clinical significance of QT prolongation associated with tamoxifen: A review of the literature. Journal of Oncology Pharmacy Practice, 2018, 24, 525-530.	0.5	10
716	Physical Activity and Survival in Women With Advanced Breast Cancer. Cancer Nursing, 2018, 41, E31-E38.	0.7	36
717	Effects of tamoxifen on neuronal morphology, connectivity and biochemistry of hypothalamic ventromedial neurons: Impact on the modulators of sexual behavior. Neurobiology of Disease, 2018, 109, 33-43.	2.1	5
718	Tamoxifen usage correlates with increased risk of Parkinson's disease in older women with breast cancer: a case-control study in Taiwan. European Journal of Clinical Pharmacology, 2018, 74, 99-107.	0.8	18
719	Translational opportunities for broad-spectrum natural phytochemicals and targeted agent combinations in breast cancer. International Journal of Cancer, 2018, 142, 658-670.	2.3	21
720	Changing Paradigms in the Management of Breast Cancer. , 2018, , .		1
721	Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis. Journal of the National Cancer Institute, 2018, 110, 31-39.	3.0	129
722	Breast Cancer Treatment in Young Women. , 2018, , 209-215.		0
723	Neurological Complications of Chemotherapy. , 2018, , 275-310.		1
724	A unifying biology of sex steroid-induced apoptosis in prostate and breast cancers. Endocrine-Related Cancer, 2018, 25, R83-R113.	1.6	21
725	Coactivation of Estrogen Receptor and IKK $\beta$ Induces a Dormant Metastatic Phenotype in ER-Positive Breast Cancer. Cancer Research, 2018, 78, 974-984.	0.4	34

#	ARTICLE	IF	CITATIONS
726	Forty years of landmark trials undertaken by the Danish Breast Cancer Cooperative Group (DBCG) nationwide or in international collaboration. <i>Acta Oncologica</i> , 2018, 57, 3-12.	0.8	14
727	Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990-2010. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 579-590.	1.1	104
728	Patient-reported factors associated with adherence to adjuvant endocrine therapy after breast cancer: an integrative review. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 615-633.	1.1	88
729	Rethinking Extended Adjuvant Antiestrogen Therapy to Increase Survivorship in Breast Cancer. <i>JAMA Oncology</i> , 2018, 4, 15.	3.4	24
730	First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer. <i>Oncologist</i> , 2018, 23, 297-305.	1.9	8
731	Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 127-138.	5.1	91
732	Letrozole may be a valuable maintenance treatment in high-grade serous ovarian cancer patients. <i>Gynecologic Oncology</i> , 2018, 148, 79-85.	0.6	29
733	The Association Between Out-of-Pocket Costs and Adherence to Adjuvant Endocrine Therapy Among Newly Diagnosed Breast Cancer Patients. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 708-715.	0.6	30
734	Factors associated with seeking western or Chinese medical treatment for fertility among women with breast cancer in Taiwan. <i>Journal of Traditional Chinese Medicine = Chung I Tsa Chih Ying Wen Pan / Sponsored By All-China Association of Traditional Chinese Medicine, Academy of Traditional Chinese Medicine</i> , 2018, 38, 904-910.	0.4	0
735	Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5. <i>Journal of Clinical Oncology</i> , 2018, 36, 1941-1948.	0.8	116
736	Evolving Landscape of US Food and Drug Administration Drug Approval in the Era of Precision Oncology: Finding the Right Balance Between Access and Safety. <i>Journal of Clinical Oncology</i> , 2018, 36, 1773-1776.	0.8	4
738	Advances in Fertility Preservation for Young Women With Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 27-37.	1.8	13
740	Extended duration of adjuvant aromatase inhibitor in breast cancer: a meta-analysis of randomized controlled trials. <i>Gland Surgery</i> , 2018, 7, 449-457.	0.5	10
741	Expression of the CD59 Glycoprotein Precursor is Upregulated in an Estrogen Receptor-alpha (ER- $\alpha$ )-Negative and a Tamoxifen-Resistant Breast Cancer Cell Line In Vitro. <i>Medical Science Monitor</i> , 2018, 24, 7883-7890.	0.5	2
743	16 Breast Cancer. , 2018, , .		0
744	Epigenetic and Pluripotency Aspects of Disseminated Cancer Cells During Minimal Residual Disease. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1100, 1-18.	0.8	3
745	MALAYSIAN MEDICINAL PLANTS™ POTENTIAL FOR BREAST CANCER THERAPY. <i>Asian Journal of Pharmaceutical and Clinical Research</i> , 2018, 11, 101.	0.3	4
746	Case 35-2018: A 68-Year-Old Woman with Back Pain and a Remote History of Breast Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 1946-1953.	13.9	4

#	ARTICLE	IF	CITATIONS
747	Improving adherence to endocrine hormonal therapy among breast cancer patients: Study protocol for a randomized controlled trial. <i>Contemporary Clinical Trials Communications</i> , 2018, 12, 109-115.	0.5	20
748	Obesity and outcome of post-menopausal women receiving adjuvant letrozole for breast cancer. <i>Ecancermedalscience</i> , 2018, 12, 821.	0.6	8
749	Rapamycin enhances the sensitivity of ER $\alpha$ -positive breast cancer cells to tamoxifen by upregulating p73 expression. <i>Oncology Reports</i> , 2018, 41, 455-464.	1.2	4
750	Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) – Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 1056-1088.	0.8	69
751	Impact of a medication therapy management service offered to patients in treatment of breast cancer. <i>Brazilian Journal of Pharmaceutical Sciences</i> , 2018, 54, .	1.2	8
752	Risk and prognostic factors for endometrial carcinoma after diagnosis of breast or Lynch-associated cancers – A population-based analysis. <i>Cancer Medicine</i> , 2018, 7, 6411-6422.	1.3	9
753	Development of a high performance liquid chromatography method with fluorescence detection for the routine quantification of tamoxifen, endoxifen, and 4-hydroxytamoxifen in plasma from breast cancer patients. <i>Biomedical Chromatography</i> , 2018, 33, e4462.	0.8	7
754	Endocrine Therapy for Breast Cancer: A Model of Hormonal Manipulation. <i>Oncology and Therapy</i> , 2018, 6, 141-156.	1.0	30
755	Evaluation of progressive hepatic histopathology in long-term tamoxifen therapy. <i>Pathology Research and Practice</i> , 2018, 214, 2115-2120.	1.0	10
756	Potential Mechanisms of Age Acceleration Caused by Estrogen Deprivation: Do Endocrine Therapies Carry the Same Risks?. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky035.	1.4	11
757	Lymph node metastasis and high serum CEA are important prognostic factors in hormone receptor positive and HER2 negative breast cancer. <i>Molecular and Clinical Oncology</i> , 2018, 9, 566-574.	0.4	6
759	Co-expression of nuclear P38 and hormone receptors is prognostic of good long-term clinical outcome in primary breast cancer and is linked to upregulation of DNA repair. <i>BMC Cancer</i> , 2018, 18, 1027.	1.1	3
760	The Value of Monitoring the Behavior of Circulating Tumor Cells at the End of Endocrine Therapy in Breast Cancer Patients. <i>Cancers</i> , 2018, 10, 407.	1.7	6
761	Is monitoring mean platelet volume necessary in breast cancer patients?. <i>Open Medicine (Poland)</i> , 2018, 13, 450-455.	0.6	3
762	Dormant tumour cells, their niches and the influence of immunity. <i>Nature Cell Biology</i> , 2018, 20, 1240-1249.	4.6	134
763	Clinical outcomes comparison of 10 years versus 5 years of adjuvant endocrine therapy in patients with early breast cancer. <i>BMC Cancer</i> , 2018, 18, 977.	1.1	19
764	The therapy is making me sick: how online portal communications between breast cancer patients and physicians indicate medication discontinuation. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2018, 25, 1444-1451.	2.2	19
765	Can We Use Survival Data from Cancer Registries to Learn about Disease Recurrence? The Case of Breast Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 1332-1341.	1.1	28



#	ARTICLE	IF	CITATIONS
766	Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer. <i>Breast Cancer Research</i> , 2018, 20, 103.	2.2	7
767	A contemporary review of male breast cancer: current evidence and unanswered questions. <i>Cancer and Metastasis Reviews</i> , 2018, 37, 599-614.	2.7	63
768	Managing side effects in adjuvant endocrine therapy for breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 1101-1112.	1.1	70
769	SET Overexpression is Associated with Worse Recurrence-Free Survival in Patients with Primary Breast Cancer Receiving Adjuvant Tamoxifen Treatment. <i>Journal of Clinical Medicine</i> , 2018, 7, 245.	1.0	15
770	Breast cancer in adolescents and young adults. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27397.	0.8	117
771	Does Hormone Therapy Use Increase Perioperative Complications in Abdominally Based Microsurgical Breast Reconstruction?. <i>Plastic and Reconstructive Surgery</i> , 2018, 141, 805e-813e.	0.7	11
772	Targeting of EGFR, VEGFR2, and Akt by Engineered Dual Drug Encapsulated Mesoporous Silica "Gold Nanoclusters Sensitizes Tamoxifen-Resistant Breast Cancer. <i>Molecular Pharmaceutics</i> , 2018, 15, 2698-2713.	2.3	29
773	Fulvestrant in management of hormone receptor-positive metastatic breast cancer. <i>Future Oncology</i> , 2018, 14, 1789-1800.	1.1	1
774	Association of Low-Fat Dietary Pattern With Breast Cancer Overall Survival. <i>JAMA Oncology</i> , 2018, 4, e181212.	3.4	62
775	Tamoxifen and CYP2D6: A Controversy in Pharmacogenetics. <i>Advances in Pharmacology</i> , 2018, 83, 65-91.	1.2	34
776	Long-Term Administration of Conjugated Estrogen and Bazedoxifene Decreased Murine Fecal $\beta$ -Glucuronidase Activity Without Impacting Overall Microbiome Community. <i>Scientific Reports</i> , 2018, 8, 8166.	1.6	40
777	Updates in the Evaluation and Management of Breast Cancer. <i>Mayo Clinic Proceedings</i> , 2018, 93, 794-807.	1.4	39
778	Breast cancer and ovarian tissue cryopreservation: Review of the literature. <i>Journal of Gynecology Obstetrics and Human Reproduction</i> , 2018, 47, 351-357.	0.6	11
779	Overview of Breast Cancer Therapy. <i>PET Clinics</i> , 2018, 13, 339-354.	1.5	279
780	Racial and geographic disparities in adherence and discontinuation to adjuvant endocrine therapy in Texas Medicaid-insured patients with breast cancer. <i>Medical Oncology</i> , 2018, 35, 113.	1.2	9
781	Hesperidin, piperine and bee venom synergistically potentiate the anticancer effect of tamoxifen against breast cancer cells. <i>Biomedicine and Pharmacotherapy</i> , 2018, 105, 1335-1343.	2.5	79
782	Durable response in a woman with recurrent low-grade endometrioid endometrial cancer and a germline BRCA2 mutation treated with a PARP inhibitor. <i>Gynecologic Oncology</i> , 2018, 150, 219-226.	0.6	17
783	Long-term effect of exemestane therapy on bone mineral density supported by bisphosphonates: Results of 5-year adjuvant treatment in postmenopausal women with early-stage breast cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, e238-e242.	0.7	3

#	ARTICLE	IF	CITATIONS
784	A dual role of miR-22 modulated by RelA/p65 in resensitizing fulvestrant-resistant breast cancer cells to fulvestrant by targeting FOXP1 and HDAC4 and constitutive acetylation of p53 at Lys382. <i>Oncogenesis</i> , 2018, 7, 54.	2.1	33
785	Vinorelbine-induced regression of a choroidal metastasis from primary breast carcinoma. <i>International Journal of Retina and Vitreous</i> , 2018, 4, 17.	0.9	2
786	Determinants of non-adherence to adjuvant endocrine treatment in women with breast cancer: the role of comorbidity. <i>Breast Cancer Research and Treatment</i> , 2018, 172, 167-177.	1.1	33
787	Co-inhibition of mTORC1, HDAC and ESR1± retards the growth of triple-negative breast cancer and suppresses cancer stem cells. <i>Cell Death and Disease</i> , 2018, 9, 815.	2.7	34
788	Effect of <i>CYP2C19</i> and <i>CYP2D6</i> genotype on tamoxifen treatment outcome indicates endogenous and exogenous interplay. <i>Pharmacogenomics</i> , 2018, 19, 1027-1037.	0.6	10
789	Distinct Characteristics and Metastatic Behaviors of Late Recurrence in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2-negative Breast Cancer: A Single Institute Experience of More Than 10 Years. <i>Clinical Breast Cancer</i> , 2018, 18, e1353-e1360.	1.1	7
790	Association of Circulating Tumor Cells With Late Recurrence of Estrogen Receptor-Positive Breast Cancer. <i>JAMA Oncology</i> , 2018, 4, 1700.	3.4	151
791	Rising Incidence of Breast Cancer in the Young Fertile Indian Population—a Reality Check. <i>Indian Journal of Surgical Oncology</i> , 2018, 9, 296-299.	0.3	7
792	Adjuvant endocrine therapy after breast cancer: a qualitative study of factors associated with adherence. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 291-300.	0.8	36
793	Optimal Control Analysis of a Mathematical Model for Breast Cancer. <i>Mathematical and Computational Applications</i> , 2018, 23, 21.	0.7	26
794	Circulating microRNAs in the early prediction of disease recurrence in primary breast cancer. <i>Breast Cancer Research</i> , 2018, 20, 72.	2.2	69
795	Should age impact breast cancer management in young women? Fine tuning of treatment guidelines. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591877692.	1.4	27
796	Optimal management of luminal breast cancer: how much endocrine therapy is long enough?. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591877743.	1.4	12
798	Meta-analysis of the cumulative risk of endometrial malignancy and systematic review of endometrial surveillance in extended tamoxifen therapy. <i>British Journal of Surgery</i> , 2018, 105, 1098-1106.	0.1	35
799	Cost-effectiveness of monitoring endoxifen levels in breast cancer patients adjuvantly treated with tamoxifen. <i>Breast Cancer Research and Treatment</i> , 2018, 172, 143-150.	1.1	12
800	Intimate estrogen receptor±/ligand relationships signal biological activity. <i>Toxicology</i> , 2018, 408, 80-87.	2.0	12
801	Small Simple Trials: A Strategy for Orthopaedic Randomized Trials. <i>Journal of Bone and Joint Surgery - Series A</i> , 2018, 100, e95.	1.4	0
802	Successful Targeted Therapies for Breast Cancer: the Worcester Foundation and Future Opportunities in Women's Health. <i>Endocrinology</i> , 2018, 159, 2980-2990.	1.4	17

#	ARTICLE	IF	CITATIONS
803	Assessment and management of bone health in women with oestrogen receptor- $\alpha$ -positive breast cancer receiving endocrine therapy: Position statement of the Endocrine Society of Australia, the Australian and New Zealand Bone & Mineral Society, the Australasian Menopause Society and the Clinical Oncology Society of Australia. <i>Clinical Endocrinology</i> , 2018, 89, 280-296.	1.2	24
804	Construction of a novel multi-gene assay (42-gene classifier) for prediction of late recurrence in ER-positive breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 33-41.	1.1	9
805	Tamoxifen-induced fatty liver disease in a Caucasian patient. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 243-244.	1.1	4
806	A suppressive role of guanine nucleotide-binding protein subunit beta-4 inhibited by DNA methylation in the growth of anti-estrogen resistant breast cancer cells. <i>BMC Cancer</i> , 2018, 18, 817.	1.1	19
807	Endocrine Therapy for Breast Cancer in the Primary Care Setting. <i>Current Oncology</i> , 2018, 25, 285-291.	0.9	40
808	In vitro cytotoxic and antiproliferative effects of usnic acid on hormone-dependent breast and prostate cancer cells. <i>Journal of Biochemical and Molecular Toxicology</i> , 2018, 32, e22208.	1.4	18
809	The benefits of adding metformin to tamoxifen to protect the endometrium- A randomized placebo-controlled trial. <i>Clinical Endocrinology</i> , 2018, 89, 605-612.	1.2	20
810	Considering the biology of late recurrences in selecting patients for extended endocrine therapy in breast cancer. <i>Cancer Treatment Reviews</i> , 2018, 70, 118-126.	3.4	13
811	The Evolving Role of Postmastectomy Radiation Therapy. <i>Surgical Clinics of North America</i> , 2018, 98, 801-817.	0.5	4
812	Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 122-137.	13.9	448
813	Hormonal Effects on Breast Density, Fibroglandular Tissue, and Background Parenchymal Enhancement. <i>Radiographics</i> , 2018, 38, 983-996.	1.4	36
814	Breast Cancer Survivorship: A Comprehensive Review of Long-Term Medical Issues and Lifestyle Recommendations. , 2015, 19, 48-79.		232
815	Optimizing adjuvant endocrine therapy for early ER+ breast cancer: An update for surgeons. <i>American Journal of Surgery</i> , 2019, 217, 152-155.	0.9	4
816	Challenges in Treating Estrogen Receptor-Positive Breast Cancer. , 0, , .		5
817	Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes. <i>Breast Cancer Research</i> , 2019, 21, 90.	2.2	81
818	Platelet-lymphocyte ratio as a potential prognostic factor in gynecologic cancers: a meta-analysis. <i>Archives of Gynecology and Obstetrics</i> , 2019, 300, 829-839.	0.8	16
819	A Review of Local and Systemic Therapy in Breast Cancer. , 2019, , 637-690.		0
820	Assessment and management of bone health in women with oestrogen receptor- $\alpha$ -positive breast cancer receiving endocrine therapy: position statement summary. <i>Medical Journal of Australia</i> , 2019, 211, 224-229.	0.8	11

#	ARTICLE	IF	CITATIONS
821	Pharmacogenomics, CYP2D6, and Tamoxifen: A Survey of the Reasons Sustaining European Clinical Practice Paradigms. <i>Medicina (Lithuania)</i> , 2019, 55, 344.	0.8	3
822	&lt;p&gt;Bisphosphonates and primary breast cancer risk: an updated systematic review and meta-analysis involving 963,995 women&lt;/p&gt;. <i>Clinical Epidemiology</i> , 2019, Volume 11, 593-603.	1.5	8
823	A prospective decision-impact study incorporating Breast Cancer Index into extended endocrine therapy decision-making. <i>Breast Cancer Management</i> , 2019, 8, BMT22.	0.2	8
824	Social Web and Health Research. , 2019, , .		7
825	Long-Term Use of Tamoxifen Is Associated With a Decreased Subsequent Meningioma Risk in Patients With Breast Cancer: A Nationwide Population-Based Cohort Study. <i>Frontiers in Pharmacology</i> , 2019, 10, 674.	1.6	11
826	The potential influence of breast cancer estrogen receptorsâ€™™ distribution on active DNA demethylation. <i>Wspolczesna Onkologia</i> , 2019, 23, 74-80.	0.7	2
827	Incidence of Late Relapses in Patients With HER2-Positive Breast Cancer Receiving Adjuvant Trastuzumab: Combined Analysis of NCCTG N9831 (Alliance) and NRG Oncology/NSABP B-31. <i>Journal of Clinical Oncology</i> , 2019, 37, 3425-3435.	0.8	51
828	Breast Cancer Stem Cells as Drivers of Tumor Chemoresistance, Dormancy and Relapse: New Challenges and Therapeutic Opportunities. <i>Cancers</i> , 2019, 11, 1569.	1.7	121
829	Prediction of Late Breast Cancer-Specific Mortality in Recurrence-Free Breast Cancer Survivors Treated for Five Years with Tamoxifen. <i>Journal of Breast Cancer</i> , 2019, 22, 387.	0.8	3
830	Toronto Workshop on Late Recurrence in Estrogen Receptorâ€™™Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz050.	1.4	15
832	Update Breast Cancer 2019 Part 4 â€™™ Diagnostic and Therapeutic Challenges of New, Personalised Therapies for Patients with Early Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 1079-1089.	0.8	18
833	Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifenâ€™™To Offer More? (aTTom) trial. <i>Annals of Oncology</i> , 2019, 30, 1776-1783.	0.6	108
834	Metastatic Latency, a Veiled Threat. <i>Frontiers in Immunology</i> , 2019, 10, 1836.	2.2	19
835	PD-L1 expression is a predictive biomarker for CIK cell-based immunotherapy in postoperative patients with breast cancer. , 2019, 7, 228.		26
836	Preventive drug therapy and contralateral breast cancer: summary of the evidence of clinical trials and observational studies. <i>Acta OncolÃ³gica</i> , 2019, 58, 1581-1593.	0.8	2
838	Activated zinc transporter ZIP7 as an indicator of anti-hormone resistance in breast cancer. <i>Metallomics</i> , 2019, 11, 1579-1592.	1.0	18
839	CDC20 expression in oestrogen receptor positive breast cancer predicts poor prognosis and lack of response to endocrine therapy. <i>Breast Cancer Research and Treatment</i> , 2019, 178, 535-544.	1.1	36
840	Assessment of Relative Utility of Underlying vs Contributory Causes of Death. <i>JAMA Network Open</i> , 2019, 2, e198024.	2.8	18

#	ARTICLE	IF	CITATIONS
841	Evaluating triptorelin as a treatment option for breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1809-1818.	0.9	3
842	Triple-Negative Breast Cancer: Current Understanding and Future Therapeutic Breakthrough Targeting Cancer Stemness. <i>Cancers</i> , 2019, 11, 1334.	1.7	150
843	ER $\alpha$ -targeted endocrine therapy, resistance and the role of GPER. <i>Steroids</i> , 2019, 152, 108493.	0.8	18
844	Breast Cancer Treatment. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 288.	3.8	2,785
845	Extended adjuvant therapy for early-stage breast cancer: Are there markers for its use?. <i>Breast Journal</i> , 2019, 25, 7-8.	0.4	0
846	The optimal duration of adjuvant endocrine therapy in early luminal breast cancer: A concise review. <i>Cancer Treatment Reviews</i> , 2019, 74, 29-34.	3.4	23
847	Emulsion-templated synthesis and in vitro characterizations of niosomes for improved therapeutic potential of hydrophobic anti-cancer drug: tamoxifen. <i>Journal of Nanoparticle Research</i> , 2019, 21, 1.	0.8	6
848	Double Trouble: Contralateral Breast Cancer Risk Management in the Modern Era. <i>Journal of the National Cancer Institute</i> , 2019, 111, 641-643.	3.0	2
849	Mission-oriented translational cancer research – health economics. <i>Molecular Oncology</i> , 2019, 13, 636-647.	2.1	9
850	Factors influencing the use of extended adjuvant endocrine therapy. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 181-189.	1.1	6
851	Decreasing secondary primary uterine cancer after breast cancer: A population-based analysis. <i>Gynecologic Oncology</i> , 2019, 154, 169-176.	0.6	8
852	Induction of cell cycle arrest and apoptosis by copper complex Cu(SBCM) <sub>2</sub> towards oestrogen-receptor positive MCF-7 breast cancer cells. <i>RSC Advances</i> , 2019, 9, 18359-18370.	1.7	31
853	Issues with Fertility in Young Women with Breast Cancer. <i>Current Oncology Reports</i> , 2019, 21, 58.	1.8	13
854	<i>Detarium microcarpum</i> , <i>Guiera senegalensis</i> , and <i>Cassia siamea</i> Induce Apoptosis and Cell Cycle Arrest and Inhibit Metastasis on MCF7 Breast Cancer Cells. <i>Evidence-based Complementary and Alternative Medicine</i> , 2019, 2019, 1-12.	0.5	11
855	Drug monitoring of tamoxifen metabolites predicts vaginal dryness and verifies a low discontinuation rate from the Norwegian Prescription Database. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 185-195.	1.1	17
856	Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2019, 30, 1194-1220.	0.6	1,241
857	Adjuvant Systemic Therapy in Breast Cancer. , 2019, , 179-194.		0
858	Multi-polar scripts: Techno-regulatory environments and the rise of precision oncology diagnostic tests. <i>Social Science and Medicine</i> , 2022, 304, 112317.	1.8	4

#	ARTICLE	IF	CITATIONS
859	Preexisting Commensal Dysbiosis Is a Host-Intrinsic Regulator of Tissue Inflammation and Tumor Cell Dissemination in Hormone Receptor-Positive Breast Cancer. <i>Cancer Research</i> , 2019, 79, 3662-3675.	0.4	118
860	Prediction of Distant Recurrence Using EndoPredict Among Women with ER+, HER2- Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only. <i>Clinical Cancer Research</i> , 2019, 25, 3865-3872.	3.2	54
861	Adjuvant therapeutic approaches of HER2-positive breast cancer with a focus on neratinib maleate. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 447-454.	1.1	8
862	Simulating Time-Dependent Patterns of Nonadherence by Patients With Breast Cancer to Adjuvant Oral Endocrine Therapy. <i>JCO Clinical Cancer Informatics</i> , 2019, 3, 1-9.	1.0	11
863	Efficacy of extended aromatase inhibitors for hormone-receptor-positive breast cancer: A literature-based meta-analysis of randomized trials. <i>Breast</i> , 2019, 46, 19-24.	0.9	16
864	Extended Adjuvant Therapy With Aromatase Inhibitors for Early Breast Cancer: A Meta-analysis of Randomized Controlled Trials. <i>Clinical Breast Cancer</i> , 2019, 19, e578-e588.	1.1	4
865	Beyond estrogen: advances in tissue selective estrogen complexes and selective estrogen receptor modulators. <i>Climacteric</i> , 2019, 22, 140-147.	1.1	36
866	Influence of adherence to adjuvant endocrine therapy on disease-free and overall survival: a population-based study in Catalonia, Spain. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 733-740.	1.1	32
867	Adjuvant treatment for breast cancer. <i>Surgery</i> , 2019, 37, 176-180.	0.1	0
868	Differential Involvement of Autophagy and Apoptosis in Response to Chemoendocrine and Endocrine Therapy in Breast Cancer: JBCRG-07TR. <i>International Journal of Molecular Sciences</i> , 2019, 20, 984.	1.8	16
869	Association between tamoxifen use and acute myocardial infarction in women with breast cancer. <i>Medicine (United States)</i> , 2019, 98, e13925.	0.4	6
870	Estrogens and breast cancer: Mechanisms involved in obesity-related development, growth and progression. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2019, 189, 161-170.	1.2	108
871	Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups. <i>Nature</i> , 2019, 567, 399-404.	13.7	239
872	Triptolide Suppresses Growth of Breast Cancer by Targeting HMGB1 <i>in Vitro</i> and <i>in Vivo</i> . <i>Biological and Pharmaceutical Bulletin</i> , 2019, 42, 892-899.	0.6	33
873	Prescription Refill Gap of Endocrine Treatment from Electronic Medical Records as a Prognostic Factor in Breast Cancer Patients. <i>Journal of Breast Cancer</i> , 2019, 22, 86.	0.8	9
874	SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 97-104.	0.8	159
875	Defining Risk of Late Recurrence in Early-Stage Estrogen Receptor-Positive Breast Cancer: Clinical Versus Molecular Tools. <i>Journal of Clinical Oncology</i> , 2019, 37, 1365-1369.	0.8	17
876	Therapeutic advances in hormone-dependent cancers: focus on prostate, breast and ovarian cancers. <i>Endocrine Connections</i> , 2019, 8, R10-R26.	0.8	33

#	ARTICLE	IF	CITATIONS
877	Effects of adjuvant tamoxifen over three decades on breast cancerâ€‘free and distant recurrenceâ€‘free interval among premenopausal women with oestrogen receptorâ€‘positive breast cancer randomised in the Swedish SBlI:2pre trial. <i>European Journal of Cancer</i> , 2019, 110, 53-61.	1.3	13
878	Mortality after breast cancer as a function of time since diagnosis by estrogen receptor status and age at diagnosis. <i>International Journal of Cancer</i> , 2019, 145, 3207-3217.	2.3	14
879	Increasing Adherence to Adjuvant Hormone Therapy Among Patients With Breast Cancer: A Smart Phone App-Based Pilot Study. <i>Cancer Control</i> , 2019, 26, 107327481988328.	0.7	23
880	Society for Translational Medicine consensus on postoperative management of EGFR-mutant lung cancer (2019 edition). <i>Translational Lung Cancer Research</i> , 2019, 8, 1163-1173.	1.3	34
881	Endocrine-responsive lobular carcinoma of the breast: features associated with risk of late distant recurrence. <i>Breast Cancer Research</i> , 2019, 21, 153.	2.2	10
882	Partner status moderates the relationships between sexual problems and self-efficacy for managing sexual problems and psychosocial quality-of-life for postmenopausal breast cancer survivors taking adjuvant endocrine therapy. <i>Menopause</i> , 2019, 26, 823-832.	0.8	15
883	Adjuvant endocrine therapy for premenopausal women: risk stratification, type and duration. <i>Breast</i> , 2019, 48, S85-S88.	0.9	1
884	The â€‘1-year-death number needed to treatâ€‘for comparing the impact of distinct interventions on patient outcomes. <i>Cmaj</i> , 2019, 191, E1242-E1249.	0.9	0
885	Diagnosis and Treatment of Breast Cancer in Young Women. <i>Current Treatment Options in Oncology</i> , 2019, 20, 86.	1.3	70
886	Detection of disseminated tumor cells in bone marrow predict late recurrences in operable breast cancer patients. <i>BMC Cancer</i> , 2019, 19, 1131.	1.1	33
887	Counseling young women with early breast cancer on fertility preservation. <i>Journal of Assisted Reproduction and Genetics</i> , 2019, 36, 2593-2604.	1.2	27
888	Event-free survival following early endometrial events in breast cancer patients treated with anti-hormonal therapy. <i>Medicine (United States)</i> , 2019, 98, e13976.	0.4	4
889	Reply. <i>Plastic and Reconstructive Surgery</i> , 2019, 143, 658e.	0.7	0
890	iRGD-guided tamoxifen polymersomes inhibit estrogen receptor transcriptional activity and decrease the number of breast cancer cells with self-renewing capacity. <i>Journal of Nanobiotechnology</i> , 2019, 17, 120.	4.2	19
891	The duration of endocrine therapy and breast cancer patientsâ€™ survival. <i>Medicine (United States)</i> , 2019, 98, e17746.	0.4	1
893	Does Hormone Therapy Use Increase Perioperative Complications in Abdominally Based Microsurgical Breast Reconstruction?. <i>Plastic and Reconstructive Surgery</i> , 2019, 143, 657e-658e.	0.7	1
895	CYP2D6-inhibiting medication use and inherited CYP2D6 variation in relation to adverse breast cancer outcomes after tamoxifen therapy. <i>Cancer Causes and Control</i> , 2019, 30, 103-112.	0.8	9
896	Examination of a paradox: recurrent metastatic breast cancer incidence decline without improved distant disease survival: 1990â€‘2011. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 505-514.	1.1	20

#	ARTICLE	IF	CITATIONS
897	Beyond 5 years: enduring risk of recurrence in oestrogen receptor-positive breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 296-311.	12.5	64
898	Prognostic factors predicting recurrence in invasive breast cancer: An analysis of radiological and clinicopathological factors. <i>Asian Journal of Surgery</i> , 2019, 42, 613-620.	0.2	10
899	Efficacy of anastrozole after tamoxifen in early breast cancer patients with chemotherapy-induced ovarian function failure. <i>International Journal of Cancer</i> , 2019, 145, 274-283.	2.3	7
900	Influences of adjuvant treatments in hormone receptor positive breast cancer on receptor conversion in recurrent breast cancer. <i>Archives of Gynecology and Obstetrics</i> , 2019, 299, 533-541.	0.8	4
901	The First Targeted Therapy to Treat Cancer: The Tamoxifen Tale. <i>Cancer Drug Discovery and Development</i> , 2019, , 151-188.	0.2	1
902	SEOM clinical guidelines in early stage breast cancer (2018). <i>Clinical and Translational Oncology</i> , 2019, 21, 18-30.	1.2	48
903	Providers' perspectives on adherence to hormonal therapy in breast cancer survivors. Is there a role for the digital health feedback system?. <i>Health and Technology</i> , 2019, 9, 175-184.	2.1	11
904	Multi-drug resistance protein 2 (MRP2) expression, adjuvant tamoxifen therapy, and risk of breast cancer recurrence: a Danish population-based nested case-control study. <i>Acta Oncologica</i> , 2019, 58, 168-174.	0.8	4
905	Impact of preexisting mental illness on breast cancer endocrine therapy adherence. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 197-208.	1.1	40
906	Sex hormones and stroke: Beyond estrogens. <i>Hormones and Behavior</i> , 2019, 111, 87-95.	1.0	30
907	Effects of Hormones. , 2019, , 145-172.		0
908	Dormancy in cancer. <i>Cancer Science</i> , 2019, 110, 474-480.	1.7	121
909	Letrozole-associated controlled ovarian hyperstimulation in breast cancer patients versus conventional controlled ovarian hyperstimulation in infertile patients: assessment of oocyte quality related biomarkers. <i>Reproductive Biology and Endocrinology</i> , 2019, 17, 3.	1.4	27
910	Targeting Cancer Cell Dormancy. <i>Trends in Pharmacological Sciences</i> , 2019, 40, 128-141.	4.0	224
911	Testing a behavioral intervention to improve adherence to adjuvant endocrine therapy (AET). <i>Contemporary Clinical Trials</i> , 2019, 76, 120-131.	0.8	12
912	MiRNA-27a sensitizes breast cancer cells to treatment with Selective Estrogen Receptor Modulators. <i>Breast</i> , 2019, 43, 31-38.	0.9	25
913	OFS plus AI or SERM vs. SERM alone in premenopausal women with hormone receptor-positive breast cancer: a prospective cohort study using the real-world database. <i>Breast Cancer</i> , 2019, 26, 339-348.	1.3	2
914	Applying the theory of planned behavior to examine adjuvant endocrine therapy adherence intentions. <i>Psycho-Oncology</i> , 2019, 28, 187-194.	1.0	16



#	ARTICLE	IF	CITATIONS
915	Age-related risk factors associated with primary contralateral breast cancer among younger women versus older women. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 657-665.	1.1	15
916	Hormonal Treatment of Breast Cancer. , 2019, , 646-655.		1
917	Tamoxifen use correlates with increased risk of hip fractures in older women with breast cancer: A caseâ€“control study in Taiwan. <i>Geriatrics and Gerontology International</i> , 2019, 19, 56-60.	0.7	7
918	Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG) Tj ETQq1 1 0.784314 rgBT /Overlock The, 2019, 20, 88-99.	5.1	108
919	Breast cancer metastasis to gynaecological organs: a clinicoâ€“pathological and molecular profiling study. <i>Journal of Pathology: Clinical Research</i> , 2019, 5, 25-39.	1.3	31
920	Is the high proportion of young age at breast cancer onset a unique feature of Asian breast cancer?. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 189-199.	1.1	27
921	Clinicopathologic features of hormoneâ€“receptorâ€“positive breast cancer patients with late recurrence. <i>Breast Journal</i> , 2019, 25, 9-15.	0.4	4
922	TAMOXIFEN RETINOPATHY DURING TREATMENT OF AN INOPERABLE DESMOID TUMOR. <i>Retinal Cases and Brief Reports</i> , 2020, 14, 268-270.	0.3	2
923	Adding Ovarian Suppression to Tamoxifen for Premenopausal Breast Cancer: A Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 434-443.	0.8	52
924	Factors associated with endometrial pathology during tamoxifen therapy in women with breast cancer: a retrospective analysis of 821 biopsies. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 125-130.	1.1	16
925	Factors associated with endocrine therapy adherence among post-menopausal women treated for early-stage breast cancer in Ontario, Canada. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 217-227.	1.1	16
926	Delayed adjuvant hormonal therapy and its impact on mortality in women with breast cancer. <i>Breast Journal</i> , 2020, 26, 952-959.	0.4	1
927	Efficacy and toxicity of extended aromatase inhibitors after adjuvant aromatase inhibitors-containing therapy for hormone-receptor-positive breast cancer: a literature-based meta-analysis of randomized trials. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 275-285.	1.1	26
929	Depomedroxyprogesterone acetate therapy for hot flashes in survivors of breast cancer: no unfavorable impact on recurrence and survival. <i>Supportive Care in Cancer</i> , 2020, 28, 2139-2143.	1.0	1
930	Prediction of late recurrence in patients with breast cancer: elevated neutrophil to lymphocyte ratio (NLR) at 5Â¥years after diagnosis and late recurrence. <i>Breast Cancer</i> , 2020, 27, 54-61.	1.3	28
931	Stabilization of MORC2 by estrogen and antiestrogens through GPER1- PRKACA-CMA pathway contributes to estrogen-induced proliferation and endocrine resistance of breast cancer cells. <i>Autophagy</i> , 2020, 16, 1061-1076.	4.3	32
932	Fertility Challenges and Solutions in Women with Cancer. , 2020, , .		0
933	CDK4/6 inhibitors in breast cancer â€“ from <i>in vitro</i> models to clinical trials. <i>Acta Oncologica</i> , 2020, 59, 219-232.	0.8	8

#	ARTICLE	IF	CITATIONS
934	The Effects of Adjuvant Tamoxifen Use on Macula Pigment Epithelium Optical Density, Visual Acuity and Retinal Thickness in Patients with Breast Cancer. <i>Current Eye Research</i> , 2020, 45, 623-628.	0.7	5
935	Fertility preservation before breast cancer treatment appears unlikely to affect disease-free survival at a median follow-up of 43 months after fertility preservation consultation. <i>Cancer</i> , 2020, 126, 487-495.	2.0	43
936	Targeting Phosphorylation of Y-Box Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 882-894.	1.9	27
937	Hormonal therapy for cancer. <i>Medicine</i> , 2020, 48, 103-107.	0.2	4
938	Downregulation of CXXC Finger Protein 4 Leads to a Tamoxifen-resistant Phenotype in Breast Cancer Cells Through Activation of the Wnt/ $\beta$ -catenin Pathway. <i>Translational Oncology</i> , 2020, 13, 423-440.	1.7	10
939	Outcomes for Patients with Residual Stage II/III Breast Cancer Following Neoadjuvant Chemotherapy (AFT-01). <i>Annals of Surgical Oncology</i> , 2020, 27, 637-644.	0.7	2
940	Effects of Previous Medication Regimen Factors and Bipolar and Psychotic Disorders on Breast Cancer Endocrine Therapy Adherence. <i>Clinical Breast Cancer</i> , 2020, 20, e261-e280.	1.1	1
941	Adherence and Persistence to Adjuvant Hormonal Therapy in Early-Stage Breast Cancer Patients: A Population-Based Retrospective Cohort Study in Israel. <i>Breast Care</i> , 2020, 15, 45-54.	0.8	13
942	Are large simple trials for dementia prevention possible?. <i>Age and Ageing</i> , 2020, 49, 154-160.	0.7	17
943	Window of opportunity treatment in breast cancer. <i>ANZ Journal of Surgery</i> , 2020, 90, 34-40.	0.3	2
944	Proactive visual and statistical analysis of genomic data in Epviz. <i>Bioinformatics</i> , 2020, 36, 2195-2201.	1.8	1
945	TAMOXIFEN-INDUCED CHORIORETINAL CHANGES. <i>Retina</i> , 2020, 40, 1185-1190.	1.0	11
946	CRISPR-Cas9 Genome-Wide Knockout Screen Identifies Mechanism of Selective Activity of Dehydrofalcarnin in Mesenchymal Stem-like Triple-Negative Breast Cancer Cells. <i>Journal of Natural Products</i> , 2020, 83, 3080-3092.	1.5	13
947	Time-Resolved Profiling Reveals ATF3 as a Novel Mediator of Endocrine Resistance in Breast Cancer. <i>Cancers</i> , 2020, 12, 2918.	1.7	10
948	Clinical practice to address tamoxifen nonadherence. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 675-682.	1.1	1
949	Nationwide survey of Japanese breast oncology and reproductive endocrinology departments about the impact of breast cancer treatment on fertility. <i>Journal of Obstetrics and Gynaecology Research</i> , 2020, 46, 2488-2496.	0.6	1
950	Landmark trials in the medical oncology management of early stage breast cancer. <i>Seminars in Oncology</i> , 2020, 47, 278-292.	0.8	6
951	Breast cancer in the young patient: review of therapy and treatment considerations. <i>Breast Cancer Management</i> , 2020, 9, BMT39.	0.2	0

#	ARTICLE	IF	CITATIONS
952	How to treat lobular cancer in the adjuvant setting?. <i>Current Opinion in Oncology</i> , 2020, 32, 561-567.	1.1	5
953	Extended Endocrine Therapy for Early-Stage Breast Cancer: How Do We Decide?. <i>Current Oncology Reports</i> , 2020, 22, 123.	1.8	6
954	Toxicity of extended adjuvant endocrine with aromatase inhibitors in patients with postmenopausal breast cancer: A Systemtic review and Meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 156, 103114.	2.0	15
955	Examining the language demands of informed consent documents in patient recruitment to cancer trials using tools from corpus and computational linguistics. <i>Health (United Kingdom)</i> , 2022, 26, 431-456.	0.9	10
956	Cancer progression and the invisible phase of metastatic colonization. <i>Nature Reviews Cancer</i> , 2020, 20, 681-694.	12.8	194
957	Management of hormone receptor-positive, HER2-negative early breast cancer. <i>Seminars in Oncology</i> , 2020, 47, 187-200.	0.8	24
958	Identifying oncogenic drivers associated with increased risk of late distant recurrence in postmenopausal, estrogen receptor-positive, HER2-negative early breast cancer: results from the BIG 1-98 study. <i>Annals of Oncology</i> , 2020, 31, 1359-1365.	0.6	5
959	Fertility under uncertainty: exploring differences in fertility-related concerns and psychosocial aspects between breast cancer survivors and non-cancer infertile women. <i>Breast Cancer</i> , 2020, 27, 1177-1186.	1.3	13
960	A prospective, randomized study of Toremifene vs. tamoxifen for the treatment of premenopausal breast cancer: safety and genital symptom analysis. <i>BMC Cancer</i> , 2020, 20, 663.	1.1	13
961	Adherence to adjuvant endocrine therapy among breast cancer survivors: a systematic review and meta-synthesis of the qualitative literature using grounded theory. <i>Supportive Care in Cancer</i> , 2020, 28, 5075-5084.	1.0	26
962	Womenâ€™s Cancer Rehabilitation: a Review of Functional Impairments and Interventions Among Breast and Gynecologic Cancer Survivors. <i>Current Physical Medicine and Rehabilitation Reports</i> , 2020, 8, 217-228.	0.3	1
963	Targeting dormant tumor cells to prevent cancer recurrence. <i>FEBS Journal</i> , 2021, 288, 6286-6303.	2.2	54
964	Oocyte Donation, Gestational Carriers, and Adoption for Breast Cancer Survivors. <i>Current Breast Cancer Reports</i> , 2020, 12, 361-366.	0.5	0
965	<p>Breast Cancer and Tamoxifen: A Nigerian Perspective to Effective Personalised Therapy</p>. <i>Breast Cancer: Targets and Therapy</i> , 2020, Volume 12, 123-130.	1.0	0
966	The crucial role of epigenetic regulation in breast cancer anti-estrogen resistance: Current findings and future perspectives. <i>Seminars in Cancer Biology</i> , 2022, 82, 35-59.	4.3	31
967	Tuning Cancer Fate: Tumor Microenvironment's Role in Cancer Stem Cell Quiescence and Reawakening. <i>Frontiers in Immunology</i> , 2020, 11, 2166.	2.2	60
968	Does Use of Neoadjuvant Chemotherapy Affect the Decision to Pursue Fertility Preservation Options in Young Women with Breast Cancer?. <i>Annals of Surgical Oncology</i> , 2020, 27, 4740-4749.	0.7	7
969	&lt;p&gt;Digital Image Analysis of Ki-67 Stained Tissue Microarrays and Recurrence in Tamoxifen-Treated Breast Cancer Patients&lt;/p&gt;. <i>Clinical Epidemiology</i> , 2020, Volume 12, 771-781.	1.5	5

#	ARTICLE	IF	CITATIONS
970	Overestimation of Late Distant Recurrences in High-Risk Patients With ER-Positive Breast Cancer: Validity and Accuracy of the CTS5 Risk Score in the TEAM and IDEAL Trials. <i>Journal of Clinical Oncology</i> , 2020, 38, 3273-3281.	0.8	20
971	Risk of fatty liver after long-term use of tamoxifen in patients with breast cancer. <i>PLoS ONE</i> , 2020, 15, e0236506.	1.1	18
972	Endocrine Therapy in Early Breast Cancer. <i>Breast Care</i> , 2020, 15, 337-346.	0.8	42
973	Genome-wide analysis of therapeutic response uncovers molecular pathways governing tamoxifen resistance in ER+ breast cancer. <i>EBioMedicine</i> , 2020, 61, 103047.	2.7	6
974	A new approach for cancer treatment: from specific induction of breast cancer to innovative gold-nanoparticle mediated thermal therapies. , 2020, , 269-298.		0
975	Validation of Clinical Treatment Score post-5 years (CTS5) risk stratification in premenopausal breast cancer patients and Ki-67 labelling index. <i>Scientific Reports</i> , 2020, 10, 16850.	1.6	9
976	Adjuvant treatment of early male breast cancer. <i>Current Opinion in Oncology</i> , 2020, 32, 594-602.	1.1	6
977	Endoxifen levels and metabolic phenotype-associated factors in Mexican Mestizo patients under tamoxifen treatment. <i>Pharmacogenomics</i> , 2020, 21, 929-943.	0.6	1
978	&lt;p&gt;Tamoxifen Induced Pachychoroid Pigment Epitheliopathy with Reversible Changes After Drug Discontinuation&lt;/p&gt;. <i>International Medical Case Reports Journal</i> , 2020, Volume 13, 285-289.	0.3	3
979	Evaluation of endocrine therapy and patients preferences in early breast cancer: results of Elena study. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 783-795.	1.1	3
981	Pregnancy in Breast Cancer Survivors. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1252, 165-174.	0.8	2
983	A review of clinical and emerging biomarkers for breast cancers: towards precision medicine for patients. <i>Journal of Radiotherapy in Practice</i> , 2020, , 1-14.	0.2	0
984	Transcription Factors in Cartilage Homeostasis and Osteoarthritis. <i>Biology</i> , 2020, 9, 290.	1.3	16
985	Tamoxifen and Endometrial Cancer: A Janus-Headed Drug. <i>Cancers</i> , 2020, 12, 2535.	1.7	42
986	Application of the ESMO-Magnitude of Clinical Benefit Scale (V.1.1) to the field of early breast cancer therapies. <i>ESMO Open</i> , 2020, 5, e000743.	2.0	7
987	Therapy Algorithms for the Diagnosis and Treatment of Patients with Early and Advanced Breast Cancer. <i>Breast Care</i> , 2020, 15, 608-618.	0.8	8
988	Current Status of Circulating Tumor Cells, Circulating Tumor DNA, and Exosomes in Breast Cancer Liquid Biopsies. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9457.	1.8	56
989	Impact of Breast Cancer Systemic Therapies on Fertility. <i>Current Breast Cancer Reports</i> , 2020, 12, 367-374.	0.5	2

#	ARTICLE	IF	CITATIONS
990	Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 2557-2570.	13.9	146
991	Development of a Prognostic Tool to Guide the Decision to Extend Adjuvant Aromatase Inhibitors for up to Ten Years in Postmenopausal Early Breast Cancer Patients. <i>Cancers</i> , 2020, 12, 3725.	1.7	3
992	Addressing Fertility: an Essential Aspect of Comprehensive Care for Young Patients with Breast Cancer. <i>Current Breast Cancer Reports</i> , 2020, 12, 381-390.	0.5	1
994	Estrogen Receptor Pathway Activity Score to Predict Clinical Response or Resistance to Neoadjuvant Endocrine Therapy in Primary Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 680-689.	1.9	44
995	Fertility in Breast Cancer Survivors in the Middle East: A Retrospective Study. <i>Breast</i> , 2020, 52, 58-63.	0.9	7
996	Breast cancer: are long-term and intermittent endocrine therapies equally effective?. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2041-2049.	1.2	7
997	Extended endocrine therapy in premenopausal breast cancer patients: Where are we now?. <i>Breast Journal</i> , 2020, 26, 2018-2020.	0.4	0
998	Adjuvant ovarian function suppression and tamoxifen in premenopausal breast cancer patients: A meta-analysis. <i>Current Problems in Cancer</i> , 2020, 44, 100592.	1.0	1
999	The European Portuguese version of the Reproductive Concerns After Cancer Scale (RCACS): A psychometric validation for young adult female cancer survivors. <i>European Journal of Oncology Nursing</i> , 2020, 47, 101781.	0.9	5
1000	Computer-Aided Ligand Discovery for Estrogen Receptor Alpha. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4193.	1.8	33
1001	Adjuvant endocrine treatment for estrogen receptor (ER)-positive/HER2-negative breast cancer. <i>Chinese Clinical Oncology</i> , 2020, 9, 33-33.	0.4	7
1002	Insights from a Long-Term Follow-Up Evaluation of Early Breast Cancer Outcomes by Tumor Subtype. <i>Oncology Research and Treatment</i> , 2020, 43, 362-371.	0.8	2
1003	Prevalence, incidence and risk factors of tamoxifen-related non-alcoholic fatty liver disease: A systematic review and meta-analysis. <i>Liver International</i> , 2020, 40, 1344-1355.	1.9	11
1004	Cancer Vaccines and Oncolytic Viruses Exert Profoundly Lower Side Effects in Cancer Patients than Other Systemic Therapies: A Comparative Analysis. <i>Biomedicines</i> , 2020, 8, 61.	1.4	36
1005	Novel Tamoxifen Nanof formulations for Improving Breast Cancer Treatment: Old Wine in New Bottles. <i>Molecules</i> , 2020, 25, 1182.	1.7	41
1006	Outcomes of ovarian stimulation and fertility preservation in breast cancer patients with different hormonal receptor profiles. <i>Journal of Assisted Reproduction and Genetics</i> , 2020, 37, 913-921.	1.2	10
1007	Adjuvant and neoadjuvant therapy for breast cancer. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 225-229.	0.6	96
1008	Adjuvant therapies after curative treatments for hepatocellular carcinoma: Current status and prospects. <i>Genes and Diseases</i> , 2020, 7, 359-369.	1.5	40

#	ARTICLE	IF	CITATIONS
1009	Informing Patients About Expected Outcomes: The Efficacy-Effectiveness Gap. <i>Journal of Clinical Oncology</i> , 2020, 38, 1651-1654.	0.8	50
1010	Validation of CTS5 model in large-scale breast cancer population and the impact of menopausal and HER2 status on its prognostic value. <i>Scientific Reports</i> , 2020, 10, 4660.	1.6	10
1011	The Legacy Effect in Treating Hypercholesterolemia. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2020, 25, 291-298.	1.0	4
1012	4. Supportivtherapie. , 2020, , 127-216.		0
1013	<i>CYP2D6</i> does not impact on breast cancer-free survival in Southeast Mexican patients under tamoxifen treatment. <i>Personalized Medicine</i> , 2020, 17, 261-270.	0.8	7
1014	Understanding ER+ Breast Cancer Dormancy Using Bioinspired Synthetic Matrices for Long-term 3D Culture and Insights into Late Recurrence. <i>Advanced Biology</i> , 2020, 4, e2000119.	3.0	17
1015	Hormones and thrombosis: risk across the reproductive years and beyond. <i>Translational Research</i> , 2020, 225, 9-19.	2.2	7
1016	Endocrine Risk Factors of Endometrial Cancer: Polycystic Ovary Syndrome, Oral Contraceptives, Infertility, Tamoxifen. <i>Cancers</i> , 2020, 12, 1766.	1.7	41
1017	The association between endocrine therapy use and dementia among post-menopausal women treated for early-stage breast cancer in Ontario, Canada. <i>Journal of Geriatric Oncology</i> , 2020, 11, 1132-1137.	0.5	7
1018	&lt;p&gt;ERÎ±36 as a Potential Therapeutic Target for Tamoxifen-Resistant Breast Cancer Cell Line Through EGFR/ERK Signaling Pathway&lt;/p&gt;. <i>Cancer Management and Research</i> , 2020, Volume 12, 265-275.	0.9	15
1020	Treatment times in breast cancer patients receiving neoadjuvant vs adjuvant chemotherapy: Is efficiency a benefit of preoperative chemotherapy?. <i>Cancer Medicine</i> , 2020, 9, 2742-2751.	1.3	11
1021	Case 7-2020: A 52-Year-Old Man with a Mass in the Left Breast. <i>New England Journal of Medicine</i> , 2020, 382, 856-864.	13.9	1
1022	Fertility in female cancer survivors: a systematic review and meta-analysis. <i>Reproductive BioMedicine Online</i> , 2020, 41, 96-112.	1.1	16
1023	Tamoxifen-related endocrine symptoms in Chinese patients with breast cancer. <i>Medicine (United Tj ETQq1 1 0.784314 rgBT 0/Overload</i>	0.4	0
1024	Management of Male Breast Cancer: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2020, 38, 1849-1863.	0.8	122
1025	Factors Associated with Endocrine Therapy Non-Adherence in Breast Cancer Survivors. <i>Psycho-Oncology</i> , 2020, 29, 647-654.	1.0	24
1026	Changes in bone mineral density during 5Âyears of adjuvant treatment in premenopausal breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2020, 180, 657-663.	1.1	3
1027	Extended endocrine therapy in early breast cancer: how long and who for?. <i>Future Oncology</i> , 2020, 16, 4327-4336.	1.1	5

#	ARTICLE	IF	CITATIONS
1028	Predicting, Preventing, and Managing Treatment-Related Complications in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1324-1335.e2.	2.4	72
1029	Breast cancer risk reduction: Notable achievements and remaining challenges. <i>Breast Journal</i> , 2020, 26, 86-91.	0.4	3
1030	Alleviation of Multidrug Resistance by Flavonoid and Non-Flavonoid Compounds in Breast, Lung, Colorectal and Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 401.	1.8	48
1031	Survivors of primary breast cancer 5 years after surgery: follow-up care, long-term problems, and treatment regrets. Results of the prospective BRENDA II-study. <i>Archives of Gynecology and Obstetrics</i> , 2020, 301, 761-767.	0.8	5
1032	ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4). <i>Annals of Oncology</i> , 2020, 31, 674-696.	0.6	172
1033	Risk Factors for Tamoxifen-Induced Ovarian Hyperstimulation in Breast Cancer Patients. <i>Clinical Breast Cancer</i> , 2020, 20, 408-412.	1.1	4
1034	Integrated Data Analysis of Six Clinical Studies Points Toward Model-Informed Precision Dosing of Tamoxifen. <i>Frontiers in Pharmacology</i> , 2020, 11, 283.	1.6	19
1035	The effects of adjuvant hormonotherapy on tear functions in patients with breast cancer. <i>International Ophthalmology</i> , 2020, 40, 2077-2083.	0.6	5
1036	Effect of Tamoxifen on the Risk of Osteoporosis and Osteoporotic Fracture in Younger Breast Cancer Survivors: A Nationwide Study. <i>Frontiers in Oncology</i> , 2020, 10, 366.	1.3	12
1037	The Role of Circulating Tumor Cells in the Metastatic Cascade: Biology, Technical Challenges, and Clinical Relevance. <i>Cancers</i> , 2020, 12, 867.	1.7	63
1038	The clinical usefulness of the CTS5 in the prediction of late distant recurrence in postmenopausal women with estrogen receptor-positive early breast cancer. <i>Breast Cancer</i> , 2021, 28, 67-74.	1.3	5
1039	Validation of CTS5 on a Retrospective Cohort of Real-Life Pre- and Postmenopausal Patients Diagnosed With Estrogen Receptor-Positive Breast Cancers: Is It Prognostic?. <i>Clinical Breast Cancer</i> , 2021, 21, e53-e62.	1.1	7
1040	Impairment of endoxifen formation in tamoxifen-treated premenopausal breast cancer patients carrying reduced-function CYP2D6 alleles. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1243-1252.	1.1	18
1041	Update on systemic treatment for newly diagnosed inflammatory breast cancer. <i>Journal of Advanced Research</i> , 2021, 29, 1-12.	4.4	20
1042	Low 4-OHtam concentrations are associated with adverse clinical outcome among early stage premenopausal breast cancer patients treated with adjuvant tamoxifen. <i>Molecular Oncology</i> , 2021, 15, 957-967.	2.1	10
1043	Breast cancer endocrine therapy adherence in health professional shortage areas: Unique effects on patients with mental illness. <i>Journal of Psychosomatic Research</i> , 2021, 140, 110294.	1.2	4
1044	Clinical validity of clinical treatment score 5 (CTS5) for estimating risk of late recurrence in unselected, non-trial patients with early oestrogen receptor-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 186, 115-123.	1.1	12
1045	Development of a self-management intervention to improve tamoxifen adherence in breast cancer survivors using an Intervention Mapping framework. <i>Supportive Care in Cancer</i> , 2021, 29, 3329-3338.	1.0	8

#	ARTICLE	IF	CITATIONS
1046	Moving beyond the stage: how characteristics at diagnosis dictate treatment and treatment-related quality of life year losses for women with early stage invasive breast cancer. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, 21, 847-857.	0.7	3
1047	Microvascular breast reconstruction and thromboembolic events in patients on hormone therapy: Audit of practice from a tertiary referral centre. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2021, 74, 957-965.	0.5	4
1048	Breast Cancer Index Predicts Extended Endocrine Benefit to Individualize Selection of Patients with HR+ Early-stage Breast Cancer for 10 Years of Endocrine Therapy. <i>Clinical Cancer Research</i> , 2021, 27, 311-319.	3.2	58
1049	Small-molecule inhibitors of breast cancer-related targets: Potential therapeutic agents for breast cancer. <i>European Journal of Medicinal Chemistry</i> , 2021, 210, 112954.	2.6	41
1050	Pleiotropic Mechanisms Drive Endocrine Resistance in the Three-Dimensional Bone Microenvironment. <i>Cancer Research</i> , 2021, 81, 371-383.	0.4	10
1051	Drug repurposing for breast cancer therapy: Old weapon for new battle. <i>Seminars in Cancer Biology</i> , 2021, 68, 8-20.	4.3	74
1053	Synopsis of the Treatment of Breast Cancer. , 2021, , 53-64.		0
1054	Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients With Surgically Resected Stage I-III <i>EGFR</i> -Mutant Non-Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 325-332.	1.5	7
1055	Body Composition Analysis of 10 Years versus 5 Years of Adjuvant Endocrine Therapy in Patients with Nonmetastatic Breast Cancer. <i>Journal of Oncology</i> , 2021, 2021, 1-8.	0.6	1
1056	Depressive and Anxiety Symptoms and Disorders. , 2021, , 185-197.		0
1057	Breast Cancer Recurrence and Survival. , 2021, , 33-52.		0
1058	Male Breast Cancer. , 2021, , 643-656.		0
1059	Three photoinitiators induce breast tumor growth in mouse xenografts with MCF-7 breast cancer cells. <i>Current Research in Toxicology</i> , 2021, 2, 322-328.	1.3	4
1060	Case Report: Long-Term Response to Pembrolizumab Combined With Endocrine Therapy in Metastatic Breast Cancer Patients With Hormone Receptor Expression. <i>Frontiers in Immunology</i> , 2021, 12, 610149.	2.2	5
1061	Expert consensus on diagnosis, treatment and fertility management of young breast cancer patients. <i>Journal of the National Cancer Center</i> , 2021, 1, 23-23.	3.0	2
1062	Molecular Biomarkers for Contemporary Therapies in Hormone Receptor-Positive Breast Cancer. <i>Genes</i> , 2021, 12, 285.	1.0	18
1063	Microablative Fractional CO2 Laser for Vulvovaginal Atrophy in Women With a History of Breast Cancer: A Pilot Study at 4-week Follow-up. <i>Clinical Breast Cancer</i> , 2021, 21, e539-e546.	1.1	20
1064	Overcoming oncogene addiction in breast and prostate cancers: a comparative mechanistic overview. <i>Endocrine-Related Cancer</i> , 2021, 28, R31-R46.	1.6	3



#	ARTICLE	IF	CITATIONS
1065	The Effect of Subsequent Pregnancy on Prognosis in Young Breast Cancer Patients (â‰¥35 Years Old) According to Hormone Receptor Status. <i>Cancer Management and Research</i> , 2021, Volume 13, 1505-1515.	0.9	2
1066	A follow-up study of a randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-month depot for 2 versus 3 or more years with tamoxifen for 5Âyears as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer. <i>Breast Cancer</i> , 2021, 28, 684-697.	1.3	1
1067	Hsa_circ_0025202 suppresses cell tumorigenesis and tamoxifen resistance via miR-197-3p/HIPK3 axis in breast cancer. <i>World Journal of Surgical Oncology</i> , 2021, 19, 39.	0.8	23
1068	A novel signature predicts recurrence risk and therapeutic response in breast cancer patients. <i>International Journal of Cancer</i> , 2021, 148, 2848-2856.	2.3	1
1069	Therapeutic Advances in Oncology. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2008.	1.8	22
1070	Tackling cancer cell dormancy: Insights from immune models, and transplantation. <i>Seminars in Cancer Biology</i> , 2022, 78, 5-16.	4.3	9
1071	The multigene classifiers 95GC/42GC/155GC for precision medicine in ERâ€positive HER2â€negative early breast cancer. <i>Cancer Science</i> , 2021, 112, 1369-1375.	1.7	7
1072	FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1. <i>Breast Cancer Research</i> , 2021, 23, 21.	2.2	22
1073	Evaluating human epidermal growth factor receptor 2 roles in the efficacy of Tamoxifen treatment in breast cancer, a systematic review. <i>Pharmacological Reports</i> , 2021, 73, 435-442.	1.5	0
1074	Positive estrogen receptor status is a poor prognostic factor in node-negative breast cancer. <i>Medicine (United States)</i> , 2021, 100, e25000.	0.4	2
1075	Generating a Precision Endoxifen Prediction Algorithm to Advance Personalized Tamoxifen Treatment in Patients with Breast Cancer. <i>Journal of Personalized Medicine</i> , 2021, 11, 201.	1.1	13
1076	Tamoksifen Kullanan HastalarÄ±n Jinekolojik YÃ¶nden DeÄŸerlendirilmesi. <i>Arsiv Kaynak Tarama Dergisi</i> , 2021, 30, 45-51.	0.1	0
1077	The Role of Chemotherapy in Patients With HER2-Negative Isolated Locoregional Recurrence of Breast Cancer: A Multicenter Retrospective Cohort Study. <i>Frontiers in Oncology</i> , 2021, 11, 653243.	1.3	1
1078	Estrogen receptor alpha in the brain mediates tamoxifen-induced changes in physiology in mice. <i>ELife</i> , 2021, 10, .	2.8	17
1079	Direct comparison of three different mathematical models in two independent datasets of EUSOMA certified centers to predict recurrence and survival in estrogen receptor-positive breast cancer: impact on clinical practice. <i>Breast Cancer Research and Treatment</i> , 2021, 187, 455-465.	1.1	2
1080	Monitoring serum estradiol levels in breast cancer patients during extended adjuvant letrozole treatment after five years of tamoxifen: a prospective trial. <i>Breast Cancer Research and Treatment</i> , 2021, 187, 769-775.	1.1	5
1081	Emerging strategies for treating metastasis. <i>Nature Cancer</i> , 2021, 2, 258-270.	5.7	71
1083	Endocrine therapy for cancer. <i>Surgery</i> , 2021, 39, 208-214.	0.1	0

#	ARTICLE	IF	CITATIONS
1084	Personalized and targeted therapies. <i>ChemistrySelect</i> , 2023, 8, 2103-2126.	0.7	0
1085	What is behind the fear of cancer during menopausal hormone therapy in China?. <i>Archives of Gynecology and Obstetrics</i> , 2021, 304, 1353-1361.	0.8	1
1086	Locally Advanced Breast Cancer—A Narrative Review of Management in the Indian Scenario. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2021, 42, 137-145.	0.1	0
1087	Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies. <i>Cancer Discovery</i> , 2021, 11, 874-899.	7.7	107
1088	Success and risks of pregnancy after breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 593-600.	1.1	4
1089	Understanding Molecular Process and Chemotherapeutics for the Management of Breast Cancer. <i>Current Chemical Biology</i> , 2021, 15, 69-84.	0.2	1
1090	The risk of menopausal symptoms in premenopausal breast cancer patients and current pharmacological prevention strategies. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 1163-1175.	1.0	3
1091	Patterns of Recurrence after Neoadjuvant Therapy in Early Breast Cancer, according to the Residual Cancer Burden Index and Reductions in Neoadjuvant Treatment Intensity. <i>Cancers</i> , 2021, 13, 2492.	1.7	5
1092	Imaging Androgen Receptors in Breast Cancer with <sup>18</sup> F-Fluoro-5 $\alpha$ -Dihydrotestosterone PET: A Pilot Study. <i>Journal of Nuclear Medicine</i> , 2022, 63, 22-28.	2.8	10
1093	Current Landscape of Targeted Therapy in Hormone Receptor-Positive and HER2-Negative Breast Cancer. <i>Current Oncology</i> , 2021, 28, 1803-1822.	0.9	24
1094	The risk of contralateral breast cancer: a SEER-based analysis. <i>British Journal of Cancer</i> , 2021, 125, 601-610.	2.9	27
1095	Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune Suppression. <i>Molecular Diagnosis and Therapy</i> , 2021, 25, 409-424.	1.6	33
1096	Inhibition of Antiestrogen-Promoted Pro-Survival Autophagy and Tamoxifen Resistance in Breast Cancer through Vitamin D Receptor. <i>Nutrients</i> , 2021, 13, 1715.	1.7	14
1097	Retinal toxicities of systemic anticancer drugs. <i>Survey of Ophthalmology</i> , 2022, 67, 97-148.	1.7	16
1098	Regarding the Addition of CDK4/6 Inhibitor to Postoperative Endocrine Therapy in Patients With HR-Positive HER2-Negative High-Risk Breast Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 1506-1507.	0.8	0
1099	Metabolic comorbidities and the association with risks of recurrent metastatic disease in breast cancer survivors. <i>BMC Cancer</i> , 2021, 21, 590.	1.1	14
1100	Challenges in Adjuvant Therapy for Premenopausal Women Diagnosed With Luminal Breast Cancers. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, e47-e61.	1.8	12
1101	Breast Cancer in Adolescent and Young Adult Women Under the Age of 40 Years. <i>JCO Oncology Practice</i> , 2021, 17, 305-313.	1.4	62

#	ARTICLE	IF	CITATIONS
1102	Risk of Endometrial Cancer and Frequencies of Invasive Endometrial Procedures in Young Breast Cancer Survivors Treated With Tamoxifen: A Nationwide Study. <i>Frontiers in Oncology</i> , 2021, 11, 636378.	1.3	9
1103	Using data mining technology to predict medication-taking behaviour in women with breast cancer: A retrospective study. <i>Nursing Open</i> , 2021, , .	1.1	2
1104	Contemporary Cancer Program Practice Profile Report (CP3R) Compliance Rates for Breast Cancer: A National Cancer Database Analysis. <i>Annals of Surgical Oncology</i> , 2021, 28, 8589-8599.	0.7	1
1105	Selection of Adjuvant Endocrine Therapy for Women with Breast Cancer in Menopausal Transition: Is It Simpler than We Thought?. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1444-1446.	3.0	1
1106	Analysis of tamoxifen and its metabolites in dried blood spot and volumetric absorptive microsampling: comparison and clinical application. <i>Heliyon</i> , 2021, 7, e07275.	1.4	1
1107	Decision aids linked to evidence summaries and clinical practice guidelines: results from user-testing in clinical encounters. <i>BMC Medical Informatics and Decision Making</i> , 2021, 21, 202.	1.5	10
1108	Risk of primary lung cancer after adjuvant radiotherapy in breast cancer—a large population-based study. <i>Npj Breast Cancer</i> , 2021, 7, 71.	2.3	10
1109	Extending Adjuvant Endocrine Therapy for 10 Years: A Mixed-Methods Analysis of Women's Decision Making in an Online Breast Cancer Forum. <i>Healthcare (Switzerland)</i> , 2021, 9, 688.	1.0	4
1110	Validation of the Clinical Treatment Score Post-Five Years in Breast Cancer Patients for Predicting Late Distant Recurrence: A Single-Center Investigation in Korea. <i>Frontiers in Oncology</i> , 2021, 11, 691277.	1.3	4
1112	Volumetric Absorptive Microsampling as a New Biosampling Tool for Monitoring of Tamoxifen, Endoxifen, 4-OH Tamoxifen and N-Desmethyldamoxifen in Breast Cancer Patients. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 2417-2430.	2.0	4
1113	Fertility Preservation and Breast Cancer. <i>Current Breast Cancer Reports</i> , 2021, 13, 197-207.	0.5	0
1114	Role of microbiota-derived short-chain fatty acids in cancer development and prevention. <i>Biomedicine and Pharmacotherapy</i> , 2021, 139, 111619.	2.5	140
1115	Molecular Mechanism and Prevention Strategy of Chemotherapy- and Radiotherapy-Induced Ovarian Damage. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7484.	1.8	34
1116	Downregulation of RPS14 inhibits the proliferation and metastasis of estrogen receptor-positive breast cancer cells. <i>Anti-Cancer Drugs</i> , 2021, 32, 1019-1028.	0.7	9
1117	On Becoming a Mother After Cancer Survival: A Comprehensive Literature Review. <i>OnCOReview</i> , 0, , .	0.1	0
1118	Mechanisms of endocrine therapy resistance in breast cancer. <i>Molecular and Cellular Endocrinology</i> , 2021, 532, 111322.	1.6	40
1119	Does the Time of Day at Which Endocrine Therapy Is Taken Affect Breast Cancer Patient Outcomes?. <i>Current Oncology</i> , 2021, 28, 2523-2528.	0.9	2
1120	Selective Estrogen Receptor Modulators in Gynecology Practice. <i>Clinical Obstetrics and Gynecology</i> , 2021, 64, 803-812.	0.6	6

#	ARTICLE	IF	CITATIONS
1121	Current and emerging estrogen receptor-targeted therapies for the treatment of breast cancer. <i>Essays in Biochemistry</i> , 2021, 65, 985-1001.	2.1	10
1123	Breast Cancer Endocrine Therapy Promotes Weight Gain With Distinct Adipose Tissue Effects in Lean and Obese Female Mice. <i>Endocrinology</i> , 2021, 162, .	1.4	14
1124	Hormonoterapia adyuvante en c�ncer de mama. Revisi3n de la Evidencia y Abordaje Terap�utico en el Instituto Instituto Nacional de Cancerolog�a, Bogot�, Colombia. <i>Revista Colombiana De Cancerolog�a</i> , 0, 25, 130-141.	0.0	0
1125	Bisphosphonates and breast cancer survival: a meta-analysis and trial sequential analysis of 81508 participants from 23 prospective epidemiological studies. <i>Aging</i> , 2021, 13, 19835-19866.	1.4	4
1126	Association of Modifiable Risk Factors With Early Discontinuation of Adjuvant Endocrine Therapy. <i>JAMA Oncology</i> , 2021, 7, 1196.	3.4	13
1127	Endocrine Therapy With or Without CDK4/6 Inhibitors in Women With Hormone-receptor Positive Breast Cancer: What do we Know About the Effects on Cognition?. <i>Clinical Breast Cancer</i> , 2022, 22, 191-199.	1.1	8
1128	18F-fluorodeoxyglucose (FDG) PET or 18F-fluorothymidine (FLT) PET to assess early response to aromatase inhibitors (AI) in women with ER+ operable breast cancer in a window-of-opportunity study. <i>Breast Cancer Research</i> , 2021, 23, 88.	2.2	11
1129	Heterogeneity of estrogen receptor based on 18F-FES PET imaging in breast cancer patients. <i>Clinical and Translational Imaging</i> , 0, , 1.	1.1	2
1130	Turning scientific serendipity into discoveries in breast cancer research and treatment: a tale of PhD students and a 50-year roaming tamoxifen team. <i>Breast Cancer Research and Treatment</i> , 2021, 190, 19-38.	1.1	6
1131	Therapeutic Options in the Management of Aromatase Inhibitor-Associated Bone Loss.. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2021, 21, .	0.6	1
1132	Competing nomogram for late-period breast cancer-specific death in patients with early-stage hormone receptor-positive breast cancer. <i>Clinical Breast Cancer</i> , 2021, , .	1.1	2
1133	Lifestyle and quality of life in patients with early-stage breast cancer receiving adjuvant endocrine therapy. <i>Current Opinion in Oncology</i> , 2021, 33, 553-573.	1.1	11
1134	Mammographic density changes following BC treatment. <i>Clinical Imaging</i> , 2021, 76, 88-97.	0.8	0
1135	Assessing Predictors of Tamoxifen Nonadherence in Patients with Early Breast Cancer. <i>Patient Preference and Adherence</i> , 2021, Volume 15, 2051-2061.	0.8	11
1136	Impact of systemic adjuvant therapy and CYP2D6 activity on mammographic density in a cohort of tamoxifen-treated breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2021, 190, 451-462.	1.1	1
1137	Agrimol B present in <i>Agrimonia pilosa Ledeb</i> impedes cell cycle progression of cancer cells through G0 state arrest. <i>Biomedicine and Pharmacotherapy</i> , 2021, 141, 111795.	2.5	11
1138	MLL3 is a de novo cause of endocrine therapy resistance. <i>Cancer Medicine</i> , 2021, 10, 7692-7711.	1.3	6
1139	Study design and methods for the using exercise to relieve joint pain and improve AI adherence in older breast cancer survivors (REJOIN) trial. <i>Journal of Geriatric Oncology</i> , 2021, 12, 1146-1153.	0.5	3

#	ARTICLE	IF	CITATIONS
1140	The Cost-Effectiveness of Adjuvant Tamoxifen Treatment of Hormone Receptor-Positive Early Breast Cancer Among Premenopausal and Perimenopausal Ghanaian Women. <i>Value in Health Regional Issues</i> , 2021, 25, 196-205.	0.5	4
1141	Evaluation of the Number of Follow-up Surgical Procedures and Time Required for Delayed Breast Reconstruction by Clinical Risk Factors, Type of Oncological Therapy, and Reconstruction Approach. <i>Aesthetic Plastic Surgery</i> , 2022, 46, 71-82.	0.5	3
1142	Who Can Receive the Benefit of a Palbociclib Add-On in Patients With HR+HER2- Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy?. <i>Journal of Clinical Oncology</i> , 2021, 39, 3089-3090.	0.8	1
1143	Longitudinal Trends in Illness Perception and Depression during Adjuvant Breast Cancer Endocrine Therapy: A Prospective Observational Study. <i>Healthcare (Switzerland)</i> , 2021, 9, 1223.	1.0	9
1144	Optimal adjuvant endocrine therapy for breast cancer. <i>Lancet Oncology</i> , The, 2021, 22, 1357-1358.	5.1	6
1145	Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 1458-1467.	5.1	41
1146	Patterns of care of breast cancer patients in Morocco - A study of variations in patient profile, tumour characteristics and standard of care over a decade. <i>Breast</i> , 2021, 59, 193-202.	0.9	7
1147	Endocrine resistance and epigenetic reprogramming in estrogen receptor positive breast cancer. <i>Cancer Letters</i> , 2021, 517, 55-65.	3.2	16
1148	Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy. <i>Annals of Oncology</i> , 2021, 32, 1256-1266.	0.6	16
1149	Fertility and breast cancer: A literature review of counseling, preservation options and outcomes. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 166, 103461.	2.0	10
1150	Breast diseases. , 2022, , 289-322.e3.		1
1151	Cancer screening and prevention: Sex and gender evidence in lung, breast, and colorectal cancer. , 2021, , 75-99.		0
1152	Acquired mutations and transcriptional remodeling in long-term estrogen-deprived locoregional breast cancer recurrences. <i>Breast Cancer Research</i> , 2021, 23, 1.	2.2	43
1153	The role of capecitabine-based neoadjuvant and adjuvant chemotherapy in early-stage triple-negative breast cancer: a systematic review and meta-analysis. <i>BMC Cancer</i> , 2021, 21, 78.	1.1	23
1154	Breast Cancer Clinical Trials: The Landscape at the Uganda Cancer Institute and Lessons Learned. <i>JCO Global Oncology</i> , 2021, 7, 127-132.	0.8	5
1155	Study protocol for a randomised controlled feasibility trial of a virtual intervention (STRIDE) for symptom management, distress and adherence to adjuvant endocrine therapy after breast cancer. <i>BMJ Open</i> , 2021, 11, e041626.	0.8	7
1156	Increasing Mortality in Korean Patients With Breast Cancer: High Mortality Rate in Elderly Breast Cancer Population Due to Suboptimal Treatment and Other Diseases. <i>Cancer Control</i> , 2021, 28, 107327482110379.	0.7	0
1157	Breast Cancer Therapeutics and Biomarkers: Past, Present, and Future Approaches. <i>Breast Cancer: Basic and Clinical Research</i> , 2021, 15, 117822342199585.	0.6	22

#	ARTICLE	IF	CITATIONS
1158	Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. The Cochrane Library, 2021, 2021, CD007245.	1.5	6
1159	Fertility Communication and High-Risk Patients. , 2014, , 61-72.		2
1161	Endocrine Therapy in Clinical Practice. Cancer Drug Discovery and Development, 2019, , 215-240.	0.2	1
1162	Endometrial Cancer Prevention. , 2014, , 593-611.		1
1163	Differential expression of the BCAT isoforms between breast cancer subtypes. Breast Cancer, 2021, 28, 592-607.	1.3	7
1165	Implicit persuasion in medical decision-making. Journal of Argumentation in Context, 2018, 7, 209-227.	0.4	5
1168	Hormone-Targeted Therapy and Resistance. Annual Review of Cancer Biology, 2018, 2, 291-312.	2.3	11
1169	Early Discontinuation of Endocrine Therapy and Recurrence of Breast Cancer among Premenopausal Women. Clinical Cancer Research, 2021, 27, 1421-1428.	3.2	19
1170	Psychologische Optimierung von Erwartungen zur Prävention von Nocebo-Nebenwirkungen bei Brustkrebs - 2 Fallberichte. Verhaltenstherapie, 2015, 25, 219-227.	0.3	8
1171	Fbxo22-mediated KDM4B degradation determines selective estrogen receptor modulator activity in breast cancer. Journal of Clinical Investigation, 2018, 128, 5603-5619.	3.9	39
1172	Do we still need breast cancer screening in the era of targeted therapies and precision medicine?. Insights Into Imaging, 2020, 11, 105.	1.6	31
1173	The Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program "CASCADE". PLoS Medicine, 2016, 13, e1002204.	3.9	119
1174	Extended Adjuvant Tamoxifen for Early Breast Cancer: A Meta-Analysis. PLoS ONE, 2014, 9, e88238.	1.1	51
1175	Breast Cancer "Tailored Follow-up" in Italian Oncology Units: A Web-Based Survey. PLoS ONE, 2014, 9, e94063.	1.1	8
1176	Crossover Effects of Estrogen Receptor Status on Breast Cancer-Specific Hazard Rates by Age and Race. PLoS ONE, 2014, 9, e110281.	1.1	7
1177	National Proficiency Testing Result of CYP2D6*10 Genotyping for Adjuvant Tamoxifen Therapy in China. PLoS ONE, 2016, 11, e0162361.	1.1	5
1178	Neoadjuvant and Adjuvant Therapies for Breast Cancer. Southern Medical Journal, 2017, 110, 638-642.	0.3	30
1179	Optimal Management of the Premenopausal Patient with Estrogen Receptor-Positive Breast Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e12-e15.	1.8	2

#	ARTICLE	IF	CITATIONS
1180	The effects of adjuvant endocrine therapy on bone health in women with breast cancer. <i>Journal of Endocrinology</i> , 2019, 241, R111-R124.	1.2	26
1181	Metformin and cancer: <i>&lt;i&gt;Quo vadis et cui bono?&lt;/i&gt;</i> . <i>Oncotarget</i> , 2016, 7, 54096-54101.	0.8	15
1182	Polymorphisms of <i>&lt;i&gt;ESR1, UGT1A1, HCN1, MAP3K1&lt;/i&gt;</i> and <i>&lt;i&gt;CYP2B6&lt;/i&gt;</i> are associated with the prognosis of hormone receptor-positive early breast cancer. <i>Oncotarget</i> , 2017, 8, 20925-20938.	0.8	39
1183	Impact of persistence on survival of patients with breast cancer treated with endocrine therapy in Northeast China: a prospective study. <i>Oncotarget</i> , 2017, 8, 102499-102510.	0.8	5
1184	Hypomethylation associated enhanced transcription of trefoil factor-3 mediates tamoxifen-stimulated oncogenicity of ER+ endometrial carcinoma cells. <i>Oncotarget</i> , 2017, 8, 77268-77291.	0.8	12
1185	Variations in plasma concentrations of tamoxifen metabolites and the effects of genetic polymorphisms on tamoxifen metabolism in Korean patients with breast cancer. <i>Oncotarget</i> , 2017, 8, 100296-100311.	0.8	25
1186	Prognostic values of the mRNA expression of natural killer receptor ligands and their association with clinicopathological features in breast cancer patients. <i>Oncotarget</i> , 2018, 9, 27171-27196.	0.8	7
1187	Y-box binding protein YBX1 and its correlated genes as biomarkers for poor outcomes in patients with breast cancer. <i>Oncotarget</i> , 2018, 9, 37216-37228.	0.8	24
1188	CpG promoter hypo-methylation and up-regulation of microRNA-190b in hormone receptor-positive breast cancer. <i>Oncotarget</i> , 2019, 10, 4664-4678.	0.8	3
1189	Tamoxifen therapy benefit predictive signature coupled with prognostic signature of post-operative recurrent risk for early stage ER+ breast cancer. <i>Oncotarget</i> , 2015, 6, 44593-44608.	0.8	39
1190	Targeting BET bromodomain proteins in solid tumors. <i>Oncotarget</i> , 2016, 7, 53997-54009.	0.8	86
1191	New insights into acquired endocrine resistance of breast cancer. , 2019, 2, 198-209.		32
1192	The role of exosomal microRNAs; focus on clinical applications in breast cancer. , 2019, 2, 847-861.		3
1193	Tamoxifen side effects: pharmacogenetic and clinical approach in Mexican mestizos. <i>Translational Cancer Research</i> , 2019, 8, 23-34.	0.4	11
1194	State of the art of overcoming efflux transporter mediated multidrug resistance of breast cancer. <i>Translational Cancer Research</i> , 2019, 8, 319-329.	0.4	10
1195	Mechanistic Insight of Drug Resistance with Special Focus on Iron in Estrogen Receptor Positive Breast Cancer. <i>Current Pharmaceutical Biotechnology</i> , 2014, 15, 1141-1157.	0.9	5
1196	Nomogram Model of LNR Predicts Survival in Premenopausal Patients with Node-positive Luminal Breast Cancer. <i>Anticancer Research</i> , 2017, 37, 4575-4586.	0.5	3
1197	Adjuvant Endocrine Therapy for Hormone-positive Breast Cancer, Focusing on Ovarian Suppression and Extended Treatment: An Update. , 2017, 37, 5329-5341.		18

#	ARTICLE	IF	CITATIONS
1198	Gynaecological malignancies after breast cancer diagnosis: A population-based study. <i>Clinical Journal of Obstetrics and Gynecology</i> , 2019, 2, 113-118/.	0.1	3
1199	A systematic review and economic evaluation of intraoperative tests [RD-100i one-step nucleic acid amplification (OSNA) system and Metasin test] for detecting sentinel lymph node metastases in breast cancer. <i>Health Technology Assessment</i> , 2015, 19, 1-216.	1.3	33
1200	Risk Factors Associated with Endometrial Pathology in Premenopausal Breast Cancer Patients Treated with Tamoxifen. <i>Yonsei Medical Journal</i> , 2020, 61, 317.	0.9	22
1201	Prognostic Factors of Local-Regional Recurrence in Patients with Operable Breast Cancer in Asia: A Meta-Analysis. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2019, 7, 690-695.	0.1	5
1202	Progesterone induces cell apoptosis via the CACNA2D3/Ca <sup>2+</sup> /p38 MAPK pathway in endometrial cancer. <i>Oncology Reports</i> , 2020, 43, 121-132.	1.2	20
1203	ERAs for menopause treatment: Welcome the "designer estrogens"™. <i>Cleveland Clinic Journal of Medicine</i> , 2017, 84, 463-470.	0.6	6
1204	Hormonal therapies in young breast cancer patients: when, what and for how long?. <i>Journal of Thoracic Disease</i> , 2013, 5 Suppl 1, S36-46.	0.6	21
1205	Stock identification of neon flying squid (<em>Ommastrephes bartramii</em>) in the North Pacific Ocean on the basis of beak and statolith morphology. <i>Scientia Marina</i> , 2014, 78, 239-248.	0.3	12
1206	Young Patients with Hormone Receptor-Positive Breast Cancer Have a Higher Long-Term Risk of Breast Cancer Specific Death. <i>Journal of Breast Cancer</i> , 2019, 22, 96.	0.8	11
1207	Adjuvant hormonal therapy in premenopausal women with breast cancer. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2015, 36, 195-200.	0.1	4
1208	Younger tamoxifen-treated breast cancer patients also had higher risk of endometrial cancer and the risk could be reduced by sequenced aromatase inhibitor use: A population-based study in Taiwan. <i>Tzu Chi Medical Journal</i> , 2020, 32, 175.	0.4	4
1209	Young Age Is Associated with Increased Locoregional Recurrence in Node-Positive Breast Cancer with Luminal Subtypes. <i>Cancer Research and Treatment</i> , 2017, 49, 484-493.	1.3	12
1210	Understanding the molecular mechanisms of cancer prevention by dietary phytochemicals: From experimental models to clinical trials. <i>World Journal of Biological Chemistry</i> , 2016, 7, 88.	1.7	84
1211	Management of long-term breast cancer survivors in Korea. <i>Journal of the Korean Medical Association</i> , 2016, 59, 266.	0.1	5
1212	Impact of CYP2D6 in the adjuvant treatment of breast cancer patients with tamoxifen. <i>World Journal of Clinical Oncology</i> , 2014, 5, 374.	0.9	6
1213	Caring for the breast cancer survivor's health and well-being. <i>World Journal of Clinical Oncology</i> , 2014, 5, 693.	0.9	17
1214	Emerging gene-based prognostic tools in early breast cancer: First steps to personalised medicine. <i>World Journal of Clinical Oncology</i> , 2014, 5, 795.	0.9	10
1215	Precautions for Patients Taking Tamoxifen. <i>Journal of the Advanced Practitioner in Oncology</i> , 2018, 9, .	0.2	7



#	ARTICLE	IF	CITATIONS
1216	Benefits and Harms of Phytoestrogen Consumption in Breast Cancer Survivors. Asian Pacific Journal of Cancer Prevention, 2015, 16, 3091-3096.	0.5	12
1217	Breast Cancer: Lifestyle, the Human Gut Microbiota/Microbiome, and Survivorship. , 2020, 24, .		29
1218	Neutrophil to Lymphocyte Ratio after Treatment Completion as a Potential Predictor of Survival in Patients with Triple-Negative Breast Cancer. Journal of Breast Cancer, 2021, 24, 443.	0.8	7
1219	Endocrine Therapy of Short Duration Prevents Local and Contralateral Recurrence of Ductal Carcinoma in Situ of the Breast: A Multicenter Real-World Study in China. SSRN Electronic Journal, 0, , .	0.4	0
1220	Locoregional and Locally Advanced Breast Cancer. UNIPA Springer Series, 2021, , 429-466.	0.1	0
1221	High expression of transmembrane P24 trafficking protein 9 predicts poor prognosis in breast carcinoma. Bioengineered, 2021, 12, 8965-8979.	1.4	8
1222	Optimal Endocrine Therapy in Premenopausal Women: A Pragmatic Approach to Unanswered Questions. JCO Oncology Practice, 2022, 18, 211-216.	1.4	10
1223	Endocrine resistance in breast cancer: from molecular mechanisms to therapeutic strategies. Journal of Molecular Medicine, 2021, 99, 1691-1710.	1.7	40
1225	Fatigue and endocrine symptoms among women with early breast cancer randomized to endocrine versus chemoendocrine therapy: Results from the TAILORx patient-reported outcomes substudy. Cancer, 2021, , .	2.0	3
1226	P10s-PADRE vaccine combined with neoadjuvant chemotherapy in ER-positive breast cancer patients induces humoral and cellular immune responses. Oncotarget, 2021, 12, 2252-2265.	0.8	6
1229	Sex Steroids and Breast Cancer: An Overview. Journal of Cancer Therapy, 2013, 04, 851-856.	0.1	2
1231	Systemic Therapy. , 2014, , 381-420.		0
1232	Zalecenia dotyczÄ...ce uzupeÅnijÄ...cego leczenia chorych na wczesnego raka piersi Sprawozdanie z 13. MiÅ™dzynarodowej Konferencji w St. Gallen. Nowotwory, 2013, 63, 432-435.	0.1	0
1234	Breast Surgery. , 2013, , 229-256.		0
1235	Oncocontraception. , 2014, , 255-271.		1
1236	Atypical endometrial hyperplasia arising in an endometrial polyp in a tamoxifen-treated breast cancer patient in whom endometrial cytology was negative for cancer^ ^mdash;A case report^ ^mdash;. The Journal of the Japanese Society of Clinical Cytology, 2014, 53, 318-322.	0.0	0
1237	Epirubicin/Cyclophosphamide followed by Docetaxel as Primary Systemic Therapy in Breast Cancer. Annals of Cancer Research and Therapy, 2014, 22, 19-23.	0.1	0
1238	The Long and Short of Tamoxifen Therapy: A Review of the ATLAS Trial. Journal of the Advanced Practitioner in Oncology, 2014, 5, .	0.2	10

#	ARTICLE	IF	CITATIONS
1239	Randomized Allocation to Treatment Groups and the Importance of Adjusting for Covariates. <i>Journal of the Advanced Practitioner in Oncology</i> , 2014, 5, 61-3.	0.2	0
1240	Response to chemotherapy and association with three tumour markers in breast cancer patients in Ghana. <i>International Journal of Cancer Therapy and Oncology</i> , 2014, 2, 02034.	0.2	0
1241	Adjuvant Therapy for Breast Cancer: Hormonal Therapy. , 2015, , 353-362.		0
1242	Early Breast Cancers. , 2015, , 61-112.		0
1244	Hormonal Therapy in Nonmetastatic Breast Cancer. , 2015, , 339-344.		0
1245	Pharmacogenetics and Antineoplastic Therapies. <i>Advances in Predictive, Preventive and Personalised Medicine</i> , 2015, , 275-305.	0.6	0
1247	Clinical Use of Aromatase Inhibitors in Breast Cancer: History and Present. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2015, , 1-11.	0.1	0
1248	Understanding the New Biology of Estrogen-Induced Apoptosis and Its Application in Patient Care. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2015, , 101-114.	0.1	0
1249	Adjuvant Systemic Therapy for Renal Cell Carcinoma. , 2015, , 229-243.		0
1250	Results of a multi-centre survey concerning the treatment of hormone-dependent breast cancer in Poland in 2009â€“2013. <i>OnCOReview</i> , 2015, 5, 21-26.	0.1	0
1252	Breast Cancer Patients' Experiences and Reflections Regarding Information about Adjuvant Endocrine Therapy and its Side-Effects - A Focus Group Study. <i>SOJ Nursing &amp; Health Care</i> , 2015, 1, 01-08.	0.0	2
1253	MORPHOLOGICAL AND ULTRASOUND CHARACTERISTICS OF ENDOMETRIUM IN PATIENTS WITH BREAST CANCER AND THE RISK OF SECONDARY TUMORS. <i>Journal of Clinical Practice</i> , 2015, 6, 39-47.	0.2	0
1254	Morphological and ultrasound characteristics of endometrium in patients with breast cancer and the risk of secondary tumors. <i>Journal of Clinical Practice</i> , 2015, 6, 39-47.	0.2	0
1255	Chronic Conditions and Cancer in Older Adults. , 2016, , 421-454.		2
1256	Breast Cancer in Young Women (Premenopausal Breast Cancer). , 2016, , 375-387.		0
1257	Adjuvant Systemic Treatment for Breast Cancer: An Overview. , 2016, , 311-321.		0
1259	Effect of Surgery and Adjuvant Therapy in Reproductive and Sexual Dysfunction in Pre-menopausal Women with Breast Cancer. , 2016, 5, .		1
1260	Carcinome canalaire infiltrant d'Ã©butant. , 2016, , 145-149.		0

#	ARTICLE	IF	CITATIONS
1261	Targeting of Steroid Hormone Receptor Function in Breast and Prostate Cancer. Endocrinology, 2016, , 1-21.	0.1	0
1263	Breast cancer in young: Experience at a tertiary care centre in Tirupati, Andhra Pradesh. The Journal of Clinical and Scientific Research, 2016, 5, 93.	0.1	0
1264	Second Primary Neoplasms Following a Diagnosis of Breast Cancer. , 2016, , 213-234.		0
1265	Endocrine Therapy. , 2016, , 323-334.		0
1266	Does the molecular classification of breast cancer point the way for biomarker identification in prostate cancer?. World Journal of Clinical Urology, 2016, 5, 80.	0.0	0
1267	Breast Cancer in Younger Women. , 2016, , 529-564.		0
1268	Ductal Carcinoma In Situ. , 2016, , 221-228.		0
1269	Prognostic and Predictive Gene Expression Signatures in Breast Cancer. , 2016, , 269-281.		0
1270	Endocrine Therapy. , 2016, , 67-82.		0
1271	Disturbances of Lipid Metabolism in a Cancer Cell and How This Knowledge Increases Its Role in Clinical Oncology. , 2016, , 761-789.		0
1272	Lower Breast Cancer Mortality in Patients Aged 70+ Achievable. Deutsches A&#x0308;rzteblatt International, 2016, 113, 287.	0.6	0
1273	Breast cancer survivors. Early diagnosis â€“ successful treatment â€“ quality of life: multidisciplinary approach. Reproductive Endocrinology, 2016, .	0.0	0
1274	Lobular breast cancer. Onkologie (Czech Republic), 2016, 10, 166-169.	0.0	0
1275	Pharmacogenomics of Tamoxifen. , 2016, , 265-277.		0
1277	Understanding Biomarkers in Early-Stage Invasive Breast Cancer: Tools From the ASCO Clinical Guideline. Journal of the Advanced Practitioner in Oncology, 2016, 7, .	0.2	0
1278	Decision Support for a Woman Considering Continuing Extended Endocrine Therapy for Breast Cancer: A Case Study. Canadian Oncology Nursing Journal = Revue Canadienne De Nursing Oncologique, 2016, 26, 297-303.	0.1	1
1279	Challenges of Endocrine Therapy in Breast Cancer. , 2017, , 825-850.		0
1280	Mammatumoren. , 2017, , 419-444.		0

#	ARTICLE	IF	CITATIONS
1281	Follow-Up of Patients with Breast Cancer. , 2017, , 769-778.		0
1282	Cardiotoxicity During and After Breast Cancer Treatment. , 2017, , 117-126.		0
1283	Invasive Breast Cancer Therapy 2017: How Well Are We Hitting the Target?. Resistance To Targeted Anti-cancer Therapeutics, 2017, , 1-34.	0.1	0
1285	Invasive Carcinomas. , 2018, , 191-232.		1
1286	Tamoxifen: An Update. , 2018, , 291-299.		0
1287	News in hormonal therapy for breast cancer. Onkologie (Czech Republic), 2017, 11, 257-262.	0.0	0
1288	Luminal-like HER2-negative stage IA breast cancer: a multicenter retrospective study on long-term outcome with propensity score analysis. Oncotarget, 2017, 8, 112816-112824.	0.8	3
1289	Current Treatment Options for Human Epidermal Growth Factor Receptor 2-Directed Therapy in Metastatic Breast Cancer: An Indian Perspective. Indian Journal of Medical and Paediatric Oncology, 2018, 39, 368-379.	0.1	1
1290	Practical consensus recommendations on ovarian suppression in early breast cancer (adjuvant). South Asian Journal of Cancer, 2018, 07, 151-155.	0.2	1
1291	Adverse effects of adjuvant endocrine therapy. Meditsinskiy Sovet, 2018, , 64-69.	0.1	1
1292	Impact of hormonal therapy and other adjuvant therapies on contralateral breast volume change after implant-based breast reconstruction. Archives of Plastic Surgery, 2018, 45, 432-440.	0.4	3
1293	Adjuvant Endocrine Therapy for Breast Cancer. , 2019, , 413-432.		0
1295	Substantiated approaches to the diagnosis and treatment of tamoxifen-induced endometrial conditions in patients with breast cancer. Journal of Obstetrics and Women's Diseases, 2018, 67, 69-78.	0.0	3
1297	Les modulateurs s�lectifs des r�cepteurs aux �strog�nes : � propos de deux exemples. , 2019, , 197-207.		0
1298	Learning Hormonal Therapy Medication Adherence from an Online Breast Cancer Forum. , 2019, , 233-257.		0
1299	Oncofertility Consults in the�REI Setting. , 2019, , 289-295.		0
1300	Adjuvant Systemic Therapy: Endocrine Therapy. , 2019, , 103-127.		0
1301	Cost-Effectiveness Analysis of Neoadjuvant Chemotherapy with Zoledronic Acid for HER2-Negative Breast Cancer in Japan: The JONIE1 Study. Health, 2019, 11, 1017-1027.	0.1	0

#	ARTICLE	IF	CITATIONS
1302	Adjuvant Hormone Therapy for Breast Cancer. , 2019, , 479-487.		0
1304	Endometrial Cancer Prevention. , 2019, , 653-676.		0
1306	Is Tamoxifen Use a Factor Affecting Continence in Breast Cancer Patients?. Cureus, 2019, 11, e5417.	0.2	1
1308	Ovarian Stimulation in Women with Breast Cancer. , 2020, , 105-115.		0
1309	Safety and Challenges of Pregnancy in Women with a History of Endocrine-Sensitive Breast Cancer. , 2020, , 9-15.		0
1311	Large-scale randomized evidence: Trials and meta-analyses of trials. , 2020, , 51-66.		0
1313	FBXO22, an epigenetic multiplayer coordinating senescence, hormone signaling, and metastasis. Cancer Science, 2020, 111, 2718-2725.	1.7	10
1314	Is the extension of adjuvant hormone therapy for breast cancer justified?. Meditsinskiy Sovet, 2020, , 74-79.	0.1	0
1315	Long-Term Recurrence of Completely Resected NSCLC. JTO Clinical and Research Reports, 2020, 1, 100076.	0.6	1
1316	The role of tumor microenvironment and exosomes in dormancy and relapse. Seminars in Cancer Biology, 2022, 78, 35-44.	4.3	24
1318	Adding ovarian suppression to tamoxifen for pre-menopausal breast cancer. The National Medical Journal of India, 2020, 33, 289.	0.1	0
1319	Clinical Implications of Serum 25-Hydroxyvitamin D Status after 5-Year Adjuvant Endocrine Therapy for Late Recurrence of Hormone Receptor-positive Breast Cancer. Journal of Breast Cancer, 2020, 23, 498.	0.8	3
1320	Personalized Management of Cancers of Various Organs/Systems. , 2021, , 509-602.		0
1322	Breast Cancer Diagnosis and Management. , 2020, , 313-328.		0
1323	The role of interactomic interactions in tamoxifen-resistant breast cancer: new approaches to searching for the mechanisms of pathogenesis. Onkologiya Zhurnal Imeni P A Gertsena, 2020, 9, 80.	0.0	1
1324	Cardio-Oncology: Preventing Broken Hearts in Women with Breast Cancer. , 2020, , 217-236.		0
1325	Endocrine Treatment of Young Patients with EBC. , 2020, , 113-126.		0
1326	Tumors: Breast. , 2020, , 1-8.		0

#	ARTICLE	IF	CITATIONS
1327	Tyrosine-Derived Novel Benzoxazine Active in a Rat Syngenic Mammary Tumor Model of Breast Cancer. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 16293-16316.	2.9	7
1328	Towards Unravelling the Role of ER $\pm$ -Targeting miRNAs in the Exosome-Mediated Transferring of the Hormone Resistance. <i>Molecules</i> , 2021, 26, 6661.	1.7	10
1329	Adjuvant Endocrine Therapy in Early Breast Cancer. , 2021, , 165-177.		0
1331	Comprehensive treatment of early breast cancer. <i>Onkologie (Czech Republic)</i> , 2020, 14, 148-156.	0.0	0
1332	The Long and Short of Tamoxifen Therapy: A Review of the ATLAS Trial. <i>Journal of the Advanced Practitioner in Oncology</i> , 2014, 5, 57-60.	0.2	12
1333	Effect of young age, positive margins, and triple negative status on disease recurrence after breast conserving therapy. <i>Gland Surgery</i> , 2016, 5, 15-23.	0.5	2
1334	Adjuvant endocrine therapy in premenopausal women with breast cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2015, 13, 663-72.	0.3	14
1335	Exosomes-mediate microRNAs transfer in breast cancer chemoresistance regulation. <i>American Journal of Cancer Research</i> , 2016, 6, 2129-2139.	1.4	29
1336	Endocrine Therapy for Early Breast Cancer: Updated Review. <i>Ochsner Journal</i> , 2017, 17, 405-411.	0.5	44
1337	Understanding Biomarkers in Early-Stage Invasive Breast Cancer: Tools From the ASCO Clinical Guideline. <i>Journal of the Advanced Practitioner in Oncology</i> , 2016, 7, 666-671.	0.2	0
1338	Talking About My Care: Detecting Mentions of Hormonal Therapy Adherence Behavior in an Online Breast Cancer Community. <i>AMIA ... Annual Symposium proceedings</i> , 2017, 2017, 1868-1877.	0.2	6
1339	Physical and Emotional Experiences of Chemotherapy: a Qualitative Study among Women with Breast Cancer in Southern Thailand. <i>Asian Pacific Journal of Cancer Prevention</i> , 2018, 19, 521-528.	0.5	7
1340	Genomic Testing in the Management of Early-Stage Breast Cancer. <i>Journal of Clinical Outcomes Management</i> , 2017, 24, 229-238.	1.7	1
1341	Precautions for Patients Taking Tamoxifen. <i>Journal of the Advanced Practitioner in Oncology</i> , 2018, 9, 78-83.	0.2	9
1342	A combination of the PI3K pathway inhibitor plus cell cycle pathway inhibitor to combat endocrine resistance in hormone receptor-positive breast cancer: a genomic algorithm-based treatment approach. <i>American Journal of Cancer Research</i> , 2018, 8, 2359-2376.	1.4	24
1343	Managerial Self-Efficacy for Chemotherapy-Related Symptoms and Related Risk Factors in Women with Breast Cancer. <i>Asian Pacific Journal of Cancer Prevention</i> , 2017, 18, 1549-1553.	0.5	3
1344	Renalase overexpression in ER-positive breast cancer. <i>International Journal of Clinical and Experimental Pathology</i> , 2018, 11, 1297-1307.	0.5	4
1345	Patient Messaging Content Associated with Initiating Hormonal Therapy after a Breast Cancer Diagnosis. <i>AMIA ... Annual Symposium proceedings</i> , 2019, 2019, 962-971.	0.2	0

#	ARTICLE	IF	CITATIONS
1347	Treatment of Premenopausal Women: Finding the Right-Sized Endocrine Therapy. JCO Oncology Practice, 2021, , OP2100720.	1.4	0
1348	Importance of medication reconciliation in cancer patients. Journal of Pharmaceutical Policy and Practice, 2021, 14, 98.	1.1	6
1349	Endocrine Treatment for Breast Cancer Patients Revisited—History, Standard of Care, and Possibilities of Improvement. Cancers, 2021, 13, 5643.	1.7	16
1350	Evaluating the Risk of Breast Cancer Recurrence and Metastasis After Adjuvant Tamoxifen Therapy by Integrating Polymorphisms in Cytochrome P450 Genes and Clinicopathological Characteristics. Frontiers in Oncology, 2021, 11, 738222.	1.3	0
1351	Endometrial Surveillance in Tamoxifen and Letrozole Treated Breast Cancer Patients. Cureus, 2021, 13, e20030.	0.2	0
1352	Immunohistochemistry for Thymidine Kinase-1 (TK1): A Potential Tool for the Prognostic Stratification of Breast Cancer Patients. Journal of Clinical Medicine, 2021, 10, 5416.	1.0	10
1355	Breast Health. , 2022, , 347-403.		0
1356	Tumors: Breast. , 2021, , 5215-5222.		0
1358	Evaluation of Optic Nerve Head Parameters and Electro-Physiology Among Breast Cancer Patients on Tamoxifen. Cureus, 2022, 14, e21042.	0.2	0
1359	Mammakarzinom: Update 2019. , 0, , .		0
1360	Long-term control of recurrent disease in a patient with hormones receptor-positive breast cancer. , 2021, 1, 56.		0
1361	Endocrine Treatment of Breast Cancer. , 2022, , 1783-1789.		0
1362	Clinical Treatment Score post-5 years as a predictor of late distant recurrence in hormone receptor-positive breast cancer: systematic review and meta-analysis. British Journal of Surgery, 2022, 109, 411-417.	0.1	4
1363	Current challenges in metastasis research and future innovation for clinical translation. Clinical and Experimental Metastasis, 2022, 39, 263-277.	1.7	11
1364	A new strategy: long-term adjuvant tamoxifen treatment and other discoveries at the University of Leeds. , 2022, , 47-65.		0
1365	Hormonal and Targeted Treatments in Breast Cancer. , 2022, , 443-463.		3
1366	DREAM, a possible answer to the estrogen paradox of the Women's Health Initiative Trial. Heliyon, 2022, 8, e08666.	1.4	1
1367	How we treat HR-positive, HER2-negative early breast cancer. Future Oncology, 2022, 18, 1003-1022.	1.1	11

#	ARTICLE	IF	CITATIONS
1368	Machine Learning to Discern Interactive Clusters of Risk Factors for Late Recurrence of Metastatic Breast Cancer. <i>Cancers</i> , 2022, 14, 253.	1.7	3
1369	Development and Validation of a Predictive Model of Severe Fatigue After Breast Cancer Diagnosis: Toward a Personalized Framework in Survivorship Care. <i>Journal of Clinical Oncology</i> , 2022, 40, 1111-1123.	0.8	23
1370	Arabidaea chica chloroform extract modulates estrogen and androgen receptors on luminal breast cancer cells. <i>BMC Complementary Medicine and Therapies</i> , 2022, 22, 18.	1.2	1
1371	Lipid Changes During Endocrine Therapy in Breast Cancer Patients: The Results of a 5-Year Real-World Retrospective Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 670897.	1.3	4
1372	Assessment of compliance with hormonal therapy in early breast cancer patients with positive hormone receptor phenotype: A single institution study. <i>Breast</i> , 2022, 62, 69-74.	0.9	0
1373	Conjugated polymer nanoparticles and their nanohybrids as smart photoluminescent and photoresponsive material for biosensing, imaging, and theranostics. <i>Mikrochimica Acta</i> , 2022, 189, 83.	2.5	25
1374	Rationale and usability findings of an e-health intervention to improve oral anticancer adherence among breast cancer survivors: The My Journey mindfulness study. <i>Contemporary Clinical Trials Communications</i> , 2022, 26, 100898.	0.5	6
1375	Vasomotor symptoms in early breast cancer—a “real world” exploration of the patient experience. <i>Supportive Care in Cancer</i> , 2022, 30, 4437-4446.	1.0	5
1376	Assessing Estrogenic Activity of Classical -Binding Compounds. <i>Methods in Molecular Biology</i> , 2022, 2418, 187-201.	0.4	1
1377	Breast Cancer Index Is a Predictive Biomarker of Treatment Benefit and Outcome from Extended Tamoxifen Therapy: Final Analysis of the Trans-aTTom Study. <i>Clinical Cancer Research</i> , 2022, 28, 1871-1880.	3.2	11
1378	Abemaciclib: The First FDA-Approved CDK4/6 Inhibitor for the Adjuvant Treatment of HR+ HER2 <sup>+</sup> Early Breast Cancer. <i>Annals of Pharmacotherapy</i> , 2022, 56, 1258-1266.	0.9	4
1379	Adjuvant treatment for breast cancer. <i>Surgery</i> , 2022, 40, 132-138.	0.1	0
1380	Breast cancer management in 2021: A primer for the obstetrics and gynecology. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2022, 82, 30-45.	1.4	18
1381	Comparative analysis of the CYP2D6 metabolic activity and its effect on its effect on the treatment results of primary breast cancer. <i>Sarkomy Kosteji, MÅçgkih Tkanej l Opuholi KoÅ¾i</i> , 2022, 13, 39-47.	0.0	0
1382	Abbreviated endocrine therapy duration for low estrogen receptor-positive breast cancer: The counter to extended endocrine therapy. <i>Cancer</i> , 2022, , .	2.0	1
1384	Tumor Dormancy: Biologic and Therapeutic Implications. <i>World Journal of Oncology</i> , 2022, 13, 8-19.	0.6	9
1385	Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapy. <i>European Journal of Cancer</i> , 2022, 164, 52-61.	1.3	0
1386	Effect of letrozole on follicular fluid steroids concentrations in cancer patients undergoing oocyte cryopreservation. <i>Journal of Assisted Reproduction and Genetics</i> , 2022, 39, 1169-1176.	1.2	2



#	ARTICLE	IF	CITATIONS
1387	Gene expression trend changes in breast cancer populations over two decades: insights from The Cancer Genome Atlas database. <i>Hereditas</i> , 2022, 159, 18.	0.5	4
1388	Androgen receptor expression and its prognostic value in T1N0 luminal/HER2- breast cancer. <i>Future Oncology</i> , 2022, , .	1.1	0
1389	Development of a Prognostic App (iCanPredict) to Predict Survival for Chinese Women With Breast Cancer: Retrospective Study. <i>Journal of Medical Internet Research</i> , 2022, 24, e35768.	2.1	0
1390	Endocrine therapy initiation among women with stage Iâ€“III invasive, hormone receptor-positive breast cancer from 2001â€“2016. <i>Breast Cancer Research and Treatment</i> , 2022, 193, 203-216.	1.1	5
1391	Selective pressure of endocrine therapy activates the integrated stress response through NFÎ²B signaling in a subpopulation of ER positive breast cancer cells. <i>Breast Cancer Research</i> , 2022, 24, 19.	2.2	6
1392	Very Late Recurrence in Breast Cancer: Is Breast Cancer a Chronic Disease?. <i>Cureus</i> , 2022, 14, e22804.	0.2	0
1393	The Futility of Futility Analyses in Adjuvant Trials in Hormone Receptor Positive Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2022, , .	3.0	0
1394	Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality. <i>Cancer Treatment Reviews</i> , 2022, 105, 102375.	3.4	82
1395	Anti-estrogen Therapy and Fertility Preservation in Premenopausal Breast Cancer Patients: a Review. <i>Current Breast Cancer Reports</i> , 0, , 1.	0.5	0
1396	RMAC study: A randomized study for evaluation of metronomic adjuvant chemotherapy in recurrent head and neck cancers post salvage surgical resection in those who are ineligible for re-irradiation. <i>Oral Oncology</i> , 2022, 128, 105816.	0.8	2
1397	Identificaci3n de rizobios en n3dulos de <i>Lupinus alopecuroides</i> Desr. desarrolladas en las chacras de Castrovirreyna, Huancavelica. , 2021, 1, 36-45.		0
1398	Simulation modeling of breast cancer endocrine therapy duration by patient and tumor characteristics. <i>Cancer Medicine</i> , 2022, 11, 297-307.	1.3	2
1400	Caseâ€“based survey: The impact of breastâ€“cancer treatment on fertility in Japan. <i>Journal of Obstetrics and Gynaecology Research</i> , 2022, 48, 553-562.	0.6	0
1401	Breast Cancer Treatment and Recent Trends. <i>Journal of the Nihon University Medical Association</i> , 2021, 80, 281-284.	0.0	0
1402	Current status of AYA-generation breast cancer: trends worldwide and in Japan. <i>International Journal of Clinical Oncology</i> , 2022, 27, 16-24.	1.0	3
1404	Association of treatment-emergent symptoms identified by patient-reported outcomes with adjuvant endocrine therapy discontinuation. <i>Npj Breast Cancer</i> , 2022, 8, 53.	2.3	11
1411	Dynamics of Long-Term Patient-Reported Quality of Life and Health Behaviors After Adjuvant Breast Cancer Chemotherapy. <i>Journal of Clinical Oncology</i> , 2022, 40, 3190-3204.	0.8	23
1415	Commentary on "aTTom": long-term effects of continuing adjuvant Tamoxifen to 10 years. <i>Chinese Clinical Oncology</i> , 2014, 3, 7.	0.4	6

#	ARTICLE	IF	CITATIONS
1416	Epidemiological and anatomopathological profile of breast cancer in the region of North-West of Tunisia.. Tunisie Medicale, 2021, 99, 441-448.	0.2	1
1417	Endometrial atrophy or hyperplasia? Patient management tactics against the background of antiestrogen therapy. Onkologiya Zhurnal Imeni P A Gertsena, 2022, 11, 13.	0.0	1
1418	Adherence to Hormonal Therapy in Breast Cancer Patients in Saudi Arabia: A Single-Center Study. Cureus, 2022, , .	0.2	2
1420	Treatment of Breast Cancer in Young Adults. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, 42, 795-806.	1.8	8
1421	Evolution of Medical Approaches and Prominent Therapies in Breast Cancer. Cancers, 2022, 14, 2450.	1.7	4
1422	Field carcinogenesis and biological significance of the potential of the bystander effect: carcinogenesis, therapeutic response, and tissue regeneration. Surgery Today, 2022, , .	0.7	1
1423	Use of a convolutional neural network-based mammographic evaluation to predict breast cancer recurrence among women with hormone receptor-positive operable breast cancer. Breast Cancer Research and Treatment, 2022, , .	1.1	2
1424	Limiting systemic endocrine overtreatment in postmenopausal breast cancer patients with an ultralow classification of the 70-gene signature. Breast Cancer Research and Treatment, 2022, , .	1.1	2
1425	The applications of plasma cell-free DNA in cancer detection: Implications in the management of breast cancer patients. Critical Reviews in Oncology/Hematology, 2022, 175, 103725.	2.0	1
1426	Experts' opinions progress and trends in the surgical management of breast cancer in Taiwan. Journal of Cancer Research and Practice, 2022, 9, 45.	0.2	0
1427	Personalizing Adjuvant Endocrine Therapy for Early-Stage Hormone Receptorâ€“Positive Breast Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, , 60-72.	1.8	15
1428	The History of Early Breast Cancer Treatment. Genes, 2022, 13, 960.	1.0	16
1429	Using machine learning to predict individual patient toxicities from cancer treatments. Supportive Care in Cancer, 2022, 30, 7397-7406.	1.0	2
1430	The inhibition of tamoxifen on UGT2B gene expression and enzyme activity in rat liver contribute to the estrogen homeostasis dysregulation. BMC Pharmacology & Toxicology, 2022, 23, .	1.0	4
1431	Tamoxifen: The Past, Present, and Future of a Previous Orphan Drug. European Journal of Medical and Health Sciences, 2022, 4, 1-10.	0.1	1
1432	The relationship of endometrial pathologies with endometrial thickness and inflammatory markers in breast cancers using tamoxifen. Archives of Gynecology and Obstetrics, 2023, 307, 565-571.	0.8	5
1433	Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptorâ€“Positive, Human Epidermal Growth Factor Receptor 2â€“Negative Breast Cancer. Journal of Clinical Oncology, 2022, 40, 2408-2419.	0.8	42
1434	Oncocontraception. , 2014, , 255-271.		0

#	ARTICLE	IF	CITATIONS
1435	Long-term complications of chemotherapy. , 2023, , 234-240.		0
1436	Adapting an Evidence-Based Exercise and Education Program for Older Breast Cancer Survivors for the REJOIN Trial. <i>Journal of Aging and Physical Activity</i> , 2022, , 1-9.	0.5	0
1437	Real-world assessment of quality-of-life in patients with breast cancer treated with adjuvant endocrine therapy. <i>Future Oncology</i> , 0, , .	1.1	0
1438	Improving Adherence to Adjuvant Endocrine Therapy in Sub-Saharan Africa: Challenges and Innovative Nurse-Driven Solutions. <i>Oncologist</i> , 0, , .	1.9	1
1439	Breast Cancer Epidemiology and Contemporary Breast Cancer Care: A Review of the Literature and Clinical Applications. <i>Clinical Obstetrics and Gynecology</i> , 2022, 65, 461-481.	0.6	6
1441	Extended endocrine therapy in breast cancer: A basket of length-constraint feature selection metaheuristics to balance Type I against Type II errors. <i>Journal of Biomedical Informatics</i> , 2022, 131, 104112.	2.5	0
1442	Preventing late recurrence in hormone receptor-positive early breast cancer: a review. <i>European Journal of Cancer</i> , 2022, 172, 53-64.	1.3	3
1443	Systemic Treatment of Breast Cancer. 1st Central-Eastern European Professional Consensus Statement on Breast Cancer. <i>Pathology and Oncology Research</i> , 0, 28, .	0.9	12
1446	Clinical and Biological Aspects of Disseminated Tumor Cells and Dormancy in Breast Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	12
1447	Tamoxifen use and potential effects on liver parenchyma: A long-term prospective transient elastographic evaluation. <i>Hepatology Communications</i> , 2022, 6, 2565-2568.	2.0	1
1448	Rewiring of the Endocrine Network in Triple-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
1449	The implementation of a noninvasive lymph node staging (NILS) preoperative prediction model is cost effective in primary breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 194, 577-586.	1.1	7
1450	Perceptions and attitudes of medical oncologists regarding fertility preservation and pregnancy in high-risk cancer patients: A survey among Canadian medical oncologists. <i>Cancer Medicine</i> , 2023, 12, 1912-1921.	1.3	5
1451	Appraising Adjuvant Endocrine Therapy in Hormone Receptor Positive HER2-Negative Breast Cancer – A Literature Review. <i>Current Oncology</i> , 2022, 29, 4956-4969.	0.9	3
1452	Association between tamoxifen and tooth loss in women with breast cancer. <i>Supportive Care in Cancer</i> , 0, , .	1.0	1
1453	Factors affecting inter-individual variability in endoxifen concentrations in patients with breast cancer: results from the prospective TOTAM trial. <i>Breast Cancer Research and Treatment</i> , 2022, 195, 65-74.	1.1	6
1454	Perioperative Care of the Cancer Patient: Breast Procedures. , 2023, , 262-281.		2
1455	Copy number heterogeneity identifies ER+ breast cancer patients that do not benefit from adjuvant endocrine therapy. <i>British Journal of Cancer</i> , 0, , .	2.9	0

#	ARTICLE	IF	CITATIONS
1456	Clinical Outcomes of Adjuvant Hormone Therapy in a Cohort of Patients With Infiltrating Non-metastatic Breast Cancer in a Latin American Cancer Center. <i>Cureus</i> , 2022, , .	0.2	0
1457	Tamoxifen improves homeostasis in the peri-implant bone remodeling of osseointegrated titanium implants. <i>Journal of Periodontal Research</i> , 2022, 57, 880-890.	1.4	2
1458	Prognostic significance of programmed death-1 and programmed death ligand-1 proteins in breast cancer. <i>Human Antibodies</i> , 2022, , 1-20.	0.6	0
1461	Hot flushes and sweating, sleep problems, joint and muscular discomfort, and physical and mental exhaustion in breast cancer survivors during the first 24 months of tamoxifen therapy: a prospective observational study. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
1462	ESO-ESMO fifth international consensus guidelines for breast cancer in young women (BCY5). <i>Annals of Oncology</i> , 2022, 33, 1097-1118.	0.6	46
1463	The Utility of Breast Cancer Index (BCI) Over Clinical Prognostic Tools for Predicting the Need for Extended Endocrine Therapy: A Safety Net Hospital Experience. <i>Clinical Breast Cancer</i> , 2022, 22, 823-827.	1.1	2
1464	In It for the Long Haul: Long-Term Benefit With Adjuvant Endocrine Therapy for Premenopausal Women With Early-Stage Steroid Receptor-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 0, , .	0.8	1
1465	Determinants and Effectiveness of Extending the Duration of Adjuvant Hormone Therapy beyond 5 Years in Patients with Breast Cancer. <i>Cancer Research</i> , 2022, 82, 3614-3621.	0.4	1
1466	Tumor cell dormancy: Molecular mechanisms, and pharmacological approaches to target dormant cells for countering tumor. <i>Journal of Drug Delivery Science and Technology</i> , 2022, 75, 103645.	1.4	1
1467	Tailoring adjuvant endocrine therapy in early breast cancer: When, how, and how long?. <i>Cancer Treatment Reviews</i> , 2022, 110, 102445.	3.4	8
1468	Leveraging Electronic Health Records to Address Breast Cancer Disparities. <i>Current Breast Cancer Reports</i> , 2022, 14, 199-204.	0.5	0
1469	Breast Cancer Subtypes and Prognosis: Answers to Subgroup Classification Questions, Identifying the Worst Subgroup in Our Single-Center Series. <i>Breast Cancer: Targets and Therapy</i> , 0, Volume 14, 259-280.	1.0	3
1471	Omission of Radiation. , 2022, , 347-358.		1
1472	Interdisciplinary Approach in Breast Cancer. , 2022, , .		0
1473	Endocrine therapy resistance: what we know and future directions. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , 480-496.	0.5	5
1474	Genome-wide analysis of the FOXA1 transcriptional regulatory network identifies super enhancer associated LncRNAs in tamoxifen resistance. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	3
1475	Persistence with tamoxifen and aromatase inhibitors in Germany: a retrospective cohort study with 284,383 patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	3
1476	Current Molecular Combination Therapies Used for the Treatment of Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11046.	1.8	19

#	ARTICLE	IF	CITATIONS
1477	Recent Progress in Detection of Breast Cancer Biomarkers by Clinical and Imprinting Polymer-Based Sensors. , 2022, , 303-330.		0
1478	Extended adjuvant endocrine treatment for premenopausal women: A Delphi approach to guide clinical practice. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
1479	14-3-3 $\beta$ , drives estrogen receptor loss via ER $\alpha$ 36 induction and GATA3 inhibition in breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	2
1480	Extended adjuvant endocrine therapy for women with hormone receptor-positive early breast cancer: A meta-analysis with trial sequential analysis of randomized controlled trials. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
1482	Breast diseases. , 2023, , 311-344.e7.		0
1484	Adherence to endocrine therapy in patients with hormone receptor-positive early-stage breast cancer: a retrospective study. <i>International Journal of Clinical Pharmacy</i> , 2023, 45, 184-190.	1.0	1
1485	Protocol for the postoperative radiotherapy in N1 breast cancer patients (PORT-N1) trial, a prospective multicenter, randomized, controlled, non-inferiority trial of patients receiving breast-conserving surgery or mastectomy. <i>BMC Cancer</i> , 2022, 22, .	1.1	3
1486	Regulation of Metastatic Tumor Dormancy and Emerging Opportunities for Therapeutic Intervention. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13931.	1.8	6
1487	Extended Adjuvant Endocrine Treatment in Luminal Breast Cancers in the Era of Genomic Tests. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13604.	1.8	1
1488	Impact of organic anion transporting polypeptide, P-glycoprotein, and breast cancer resistance protein transporters on observed tamoxifen and endoxifen concentration and adverse effects. <i>Pharmacogenetics and Genomics</i> , 0, Publish Ahead of Print, .	0.7	0
1489	Breast Cancer Subtypes in Northern Thailand and Barriers to satisfactory survival outcomes. <i>BMC Cancer</i> , 2022, 22, .	1.1	0
1490	Polypharmacy and medication fill nonadherence in a population-based sample of adolescent and young adult cancer survivors, 2008â€“2017. <i>Journal of Cancer Survivorship</i> , 0, , .	1.5	1
1491	Ceramide kinase confers tamoxifen resistance in estrogen receptor-positive breast cancer by altering sphingolipid metabolism. <i>Pharmacological Research</i> , 2023, 187, 106558.	3.1	3
1492	Pregnancy After Breast Cancer â€“ Prognostic Safety and Pregnancy Outcomes According to Oestrogen Receptor Status: A Systematic Review. <i>Journal of Breast Cancer</i> , 0, 25, .	0.8	0
1493	Hormonal therapy for cancer. <i>Medicine</i> , 2023, 51, 28-31.	0.2	3
1494	Study of potential inhibition of the estrogen receptor $\alpha$ by cannabinoids using an in silico approach: Agonist vs antagonist mechanism. <i>Computers in Biology and Medicine</i> , 2023, 152, 106403.	3.9	0
1495	Saikosaponin A enhances Docetaxel efficacy by selectively inducing death of dormant prostate cancer cells through excessive autophagy. <i>Cancer Letters</i> , 2023, 554, 216011.	3.2	7
1496	In Vitro Anticancer Activity of Methanolic Extract of <i>Justicia adhatoda</i> Leaves with Special Emphasis on Human Breast Cancer Cell Line. <i>Molecules</i> , 2022, 27, 8222.	1.7	7

#	ARTICLE	IF	CITATIONS
1497	Breast cancer: emerging principles of metastasis, adjuvant and neoadjuvant treatment from cancer registry data. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 721-735.	1.2	5
1498	Effects of chronic tamoxifen treatment in female rat sexual behaviour. <i>Heliyon</i> , 2022, 8, e12362.	1.4	1
1500	Injectable Nano Drug Delivery Systems for the Treatment of Breast Cancer. <i>Pharmaceutics</i> , 2022, 14, 2783.	2.0	12
1501	Predictors of adherence and the role of primary non-adherence in antihormonal treatment of breast cancer. <i>BMC Cancer</i> , 2022, 22, .	1.1	2
1503	Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom study. <i>Breast Cancer Research</i> , 2022, 24, .	2.2	1
1504	Borderline indications for ovarian suppression: addressing uncertainties with patients. <i>Future Oncology</i> , 0, , .	1.1	0
1505	The impact of HIV on non-adherence for tamoxifen among women with breast cancer in South Africa. <i>Breast Cancer Research and Treatment</i> , 2023, 197, 647-659.	1.1	4
1506	Prognostic effect of subsequent childbirth after the diagnosis of breast cancer using propensity score matching analysis. <i>Breast Cancer</i> , 0, , .	1.3	0
1507	Liquid biopsy for monitoring of tumor dormancy and early detection of disease recurrence in solid tumors. <i>Cancer and Metastasis Reviews</i> , 2023, 42, 161-182.	2.7	10
1509	Impact of clinicopathological factors on extended endocrine therapy decision making in estrogen receptor-“positive breast cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
1510	Targeted Endocrine Agents should be the Dominant Systemic Therapies Prescribed in Luminal A Breast Cancer. <i>Breast Cancer: Basic and Clinical Research</i> , 2023, 17, 117822342211454.	0.6	0
1511	Breast cancer cells interact with tumor-derived extracellular matrix in a molecular subtype-specific manner. , 2023, 146, 213301.		2
1512	Ten-Year Probabilities of Death Due to Cancer and Cardiovascular Disease among Breast Cancer Patients Diagnosed in North-Eastern Spain. <i>International Journal of Environmental Research and Public Health</i> , 2023, 20, 405.	1.2	4
1513	Survival in male breast cancer over the past 3 decades. <i>Journal of the National Cancer Institute</i> , 2023, 115, 421-428.	3.0	2
1514	Adherence to Adjuvant Endocrine Therapy in Breast Cancer Patients. <i>Current Oncology</i> , 2023, 30, 1461-1472.	0.9	12
1515	Adjuvant Therapy for High-Risk Localized Renal Cell Carcinoma: Current Landscape and Future Direction. <i>OncoTargets and Therapy</i> , 0, Volume 16, 49-64.	1.0	1
1516	Side Effects and Its Management in Adjuvant Endocrine Therapy for Breast Cancer: A Matter of Communication and Counseling. <i>Breast Cancer: Basic and Clinical Research</i> , 2023, 17, 117822342211454.	0.6	4
1517	Use of endocrine therapy for estrogen receptor-positive breast cancer among American Indians and Alaska natives. <i>Breast Cancer Research and Treatment</i> , 0, , .	1.1	0

#	ARTICLE	IF	CITATIONS
1518	New tamoxifen analogs for breast cancer therapy: synthesis, aromatase inhibition and <i>in silico</i> studies. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 12798-12807.	2.0	1
1519	Tailoring Treatment for Patients with Inflammatory Breast Cancer. <i>Current Treatment Options in Oncology</i> , 2023, 24, 580-593.	1.3	8
1520	Progranulin and Breast Cancer Mortality: 13-Year Follow-Up of a Cohort Study. <i>Breast Cancer: Targets and Therapy</i> , 0, Volume 15, 251-261.	1.0	0
1521	Tailoring the optimal duration of the extended adjuvant endocrine therapy in patients with early-stage breast cancer. A systematic review and meta-analysis of randomized clinical trials. <i>Breast</i> , 2023, 69, 258-264.	0.9	1
1522	Long-Term Adherence to Adjuvant Endocrine Therapy Following Various Radiotherapy Modalities in Early Stage Hormone Receptor Positive Breast Cancer. <i>Clinical Breast Cancer</i> , 2023, , .	1.1	1
1523	Prolonged endocrine therapy in the management of hormone receptor-positive early-stage breast cancer: What is the appropriate duration?. <i>Journal of Obstetrics and Gynaecology Research</i> , 2023, 49, 1079-1082.	0.6	0
1524	Tamoxifen evolution. <i>British Journal of Cancer</i> , 2023, 128, 421-425.	2.9	14
1525	The Polish Society of Gynecological Oncology Guidelines for the Diagnosis and Treatment of Endometrial Carcinoma (2023). <i>Journal of Clinical Medicine</i> , 2023, 12, 1480.	1.0	0
1526	Lessons from other fields of medicine, Part 1: Breast cancer. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2023, , 101-118.	1.0	2
1527	Risk of Secondary Cancer after Adjuvant Tamoxifen Treatment for Ductal Carcinoma In Situ: A Nationwide Cohort Study in South Korea. <i>Diagnostics</i> , 2023, 13, 792.	1.3	0
1528	Ten-Year Oncologic Outcomes in T1-3N1 Breast Cancer After Targeted Axillary Sampling: A Retrospective Study. <i>Annals of Surgical Oncology</i> , 2023, 30, 4669-4677.	0.7	3
1529	A Review of Endocrine Therapy in Early-stage Breast Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 0, Publish Ahead of Print, .	0.6	0
1530	Host-Related Factors in the Interplay among Inflammation, Immunity and Dormancy in Breast Cancer Recurrence and Prognosis: An Overview for Clinicians. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4974.	1.8	2
1531	Bilateral Breast Cancer: Clinical Profile and Management. <i>Indian Journal of Surgical Oncology</i> , 0, , .	0.3	0
1532	Severe hyperlipidemia pancreatitis induced by taking tamoxifen after breast cancer surgery—Case report. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1
1533	How Does Dietary Intake Relate to Dispositional Optimism and Health-Related Quality of Life in Germline BRCA1/2 Mutation Carriers?. <i>Nutrients</i> , 2023, 15, 1396.	1.7	1
1534	Enhancing Targeted Therapy in Breast Cancer by Ultrasound-Responsive Nanocarriers. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5474.	1.8	4
1535	Tamoxifen use and risk of endometrial cancer in breast cancer patients: A systematic review and dose-response meta-analysis. <i>Cancer Reports</i> , 2023, 6, .	0.6	5

#	ARTICLE	IF	CITATIONS
1536	Extended adjuvant aromatase inhibition after sequential endocrine therapy in postmenopausal women with breast cancer: follow-up analysis of the randomised phase 3 DATA trial. <i>EClinicalMedicine</i> , 2023, 58, 101901.	3.2	2
1538	Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with/without adjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 0, , .	1.1	0
1539	What Is Known about Breast Cancer in Young Women?. <i>Cancers</i> , 2023, 15, 1917.	1.7	18
1540	Acute myocarditis during adjuvant therapies for breast cancer: a case report. <i>Surgical Case Reports</i> , 2023, 9, .	0.2	0
1541	Relationship between tumor microbiota transcriptional activity and gene expression in breast cancer. <i>BMC Cancer</i> , 2023, 23, .	1.1	2
1542	Compliance to adjuvant endocrine therapy and survival in breast cancer patients.. <i>Cancer Treatment and Research Communications</i> , 2023, 35, 100704.	0.7	1
1543	An emerging generation of endocrine therapies in breast cancer: a clinical perspective. <i>Npj Breast Cancer</i> , 2023, 9, .	2.3	18
1544	The prognostic value and biological functions of <i>HFM1</i> in breast cancer. <i>Epigenomics</i> , 0, , .	1.0	0
1545	Dormancy in Breast Cancer. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2023, 13, a041331.	2.9	7
1546	Importance of Gut Microbiome-Based Therapeutics in Cancer Treatment. <i>Biological and Medical Physics Series</i> , 2023, , 831-885.	0.3	0
1547	GRACE-trial: a randomised active-controlled trial for vulvovaginal atrophy in patients with breast cancer on endocrine therapy – study protocol. <i>BMJ Open</i> , 2023, 13, e068053.	0.8	1
1548	PRR15 deficiency facilitates malignant progression by mediating PI3K/Akt signaling and predicts clinical prognosis in triple-negative rather than non-triple-negative breast cancer. <i>Cell Death and Disease</i> , 2023, 14, .	2.7	1
1549	Optimum duration of extended adjuvant endocrine therapy in patients with hormone receptor-positive breast cancer: protocol for a network meta-analysis of randomised controlled trials. <i>BMJ Open</i> , 2023, 13, e070972.	0.8	0
1550	Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor-Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial. <i>Journal of Clinical Oncology</i> , 2023, 41, 3329-3338.	0.8	7
1551	Encapsulation for breast cancer treatment. , 2023, , 661-720.		0
1590	A cell cycle centric view of tumour dormancy. <i>British Journal of Cancer</i> , 2023, 129, 1535-1545.	2.9	4
1591	Diabetes mellitus in breast cancer survivors: metabolic effects of endocrine therapy. <i>Nature Reviews Endocrinology</i> , 2024, 20, 16-26.	4.3	2
1592	Comparative efficacy and safety of extended adjuvant endocrine therapy for hormone receptor-positive early breast cancer: a Bayesian network meta-analysis. <i>Breast Cancer Research and Treatment</i> , 0, , .	1.1	0



#	ARTICLE	IF	CITATIONS
1616	Biomarkers predictive of a response to extended endocrine therapy in breast cancer: a systematic review and meta-analysis. <i>Breast Cancer Research and Treatment</i> , 0, , .	1.1	0
1635	The CDK4/6 inhibitor revolution â€” a game-changing era for breast cancer treatment. <i>Nature Reviews Clinical Oncology</i> , 2024, 21, 89-105.	12.5	4
1644	Interventions to improve oral endocrine therapy adherence in breast cancer patients. <i>Journal of Cancer Survivorship</i> , 0, , .	1.5	0